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PREFACE 
This thesis is divided into seven chapters, including this one:  
Chapter 1: 
The preliminary chapter of this thesis provides a coherent background and rationale, the aim and 
objectives of this study, as well as the  subject’s novelty and relevance. Chapter 1 presents the structure 
of the thesis, according to UKZN’s  guidelines, and is concluded with the outline of the thesis.  
Chapter 2: 
This subsequent chapter is a literature review on what is known about the rampant Zika virus (ZIKV), 
as well as what is not known. Included in this chapter are information regarding ZIKV epidemiology 
and transmission, life cycle, pathogenesis and clinical manifestation, diagnosis of ZIKV, and 
therapeutic targets of the virus and host. Additionally, an overview of the up-to-date research and 
advancements on drug design and development against ZIKV is provided.  
Chapter 3: 
This chapter introduces computer-aided drug design and includes an in-depth description into the 
computational methodologies that were applied to carry out analyses, as well as the conceptual 
understanding behind molecular dynamics, modelling and drug design.  
Chapter 4: (Published article) 
This chapter features an article titled, “Brain Grants Permission of Access to Zika Virus but Denies 
Entry to Drugs: A Molecular Modeling Perspective to Infiltrate the Boundary.”, which integrates a 
review, proposed strategies for drug design and the application of computational tools. This material 
will assist researchers in designing and developing effective and potent drugs to treat ZIKV. This 
article has been published in the journal of RSC Advances and is the final version of the published 
manuscript. This chapter is presented in the required format of the journal. 
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Chapter 5: (Published article) 
This chapter includes  an  article  titled,  “A Panoptic Uncovering of the Dynamical Evolution of the 
Zika Virus NS5 Methyltransferase Binding Site Loops–Zeroing in on the Molecular Landscape.”,  
which addresses another objective of this thesis, covering the molecular dynamics of the ZIKV NS5 
methyltransferase enzyme, particularly upon binding to two potential inhibitors, sinefungin and 
compound 5. This is a comparative study showing the interactions that occur between the two 
inhibitors and the methyltransferase, respectively, to demonstrate which inhibitor is a more potent 
inhibitor in terms of binding to the viral enzyme. This information is key in the drug development 
process toward finding anti-ZIKV drugs. This article has been published in the journal of Chemical 
Biology and Drug Design and is the final version of the published manuscript. This chapter is 
presented in the required format of the journal. 
Chapter 6: (Published article) 
This chapter comprises   an   article   titled,   “Molecular Mechanism of Resveratrol Inhibition of Zika 
Virus NS3 Helicase - Behind the Scenes”,  which  examines  the  structural dynamics of the ZIKV NS3 
helicase enzyme upon binding of resveratrol, an ATPase inhibitor. Molecular dynamics were carried 
out on bound and unbound enzymes to determine the binding mechanism and binding interactions, 
which is key in determining the efficiency of this potential ZIKV inhibitor in drug development. This 
article has been published in the journal of Future Virology and is the final version of the published 
manuscript. This chapter is presented in the required format of the journal. 
Chapter 7: 
This chapter concludes the thesis and recommends future work. 
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ABSTRACT 
The rampant Zika virus has received worldwide attention after becoming a global crisis following the 
Brazilian epidemic in 2015. From an obscure and neglected pathogen, Zika virus is now a notorious 
virus associated with neurological disorders in infants and adults. Since 2016, the rapid research 
response from the global scientific community have led to the discovery of numerous potential small 
molecule inhibitors and vaccines against the Zika virus. Although, in spite of this massive research 
initiative, there is still no effective antiviral nor vaccine that has made it out of clinical trials.  
The design and development of new chemical entities demands excessive cost, time and resources. 
Therefore, this study applies computer-aided drug design techniques, which accelerates the rational 
drug design process. Computational approaches including molecular docking, virtual screening, 
molecular modeling and molecular dynamics facilitate the filtration of large databases of compounds 
to sift out potential lead compounds. 
Furthermore, research has dedicated several resources toward FDA-approved drug repurposing. 
Generally, drugs have similar effects on viruses of the same family; hence drugs that have previously 
been effective in treating other flaviviruses, such as Dengue virus and West Nile virus, are being 
tested for its potential inhibition of Zika virus. However, the ability of these drugs to pass the blood-
brain barrier to treat infected neurons poses a challenge to anti-Zika virus drug discovery. This study 
proposes innovative strategies to design drugs that are capable of passing the blood-brain barrier, and 
to be able to use drugs that are impermeable via drug delivery mechanisms. This study also assesses 
the bioavailability and blood-brain barrier permeability of screened drugs to scrutinize the list of 
potential Zika virus inhibitors. 
Apart from identifying potential inhibitors, understanding the structural dynamics of viral targets and 
molecular mechanisms underlying potential inhibition of the virus is imperative. This study explores 
the structural and molecular dynamics of key targets of the Zika virus, the NS3 helicase and the NS5 
methyltransferase enzymes, using computational approaches mentioned above and several others 
elaborated in this thesis. These computational methods also allowed the identification of precise 
interactions, amino acid residues, inhibitory mechanisms and pharmacophoric features involved in 
binding of lead compounds to these enzymes. 
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Chapter 4 represents the first study of this thesis, which presents a concise literature background of 
Zika virus and identifies blood-brain barrier permeability as a core challenge in anti-Zika virus drug 
development. This study also provides approaches that may enable researchers to create effective 
anti-Zika virus drugs. 
Chapter 5 is the subsequent study of this thesis, which applies molecular dynamics to comparatively 
investigate the mechanism of inhibition and binding mode of two potential inhibitors, sinefungin and 
compound 5, to the NS5 methyltransferase. The specific pharmacophoric moieties of the most stable 
inhibitor are also identified in this study. 
Chapter 6 is the final study of this thesis, which examines the structural dynamics of the Zika virus 
NS3 helicase enzyme upon binding of ATPase inhibitor and flavivirus lead compound, resveratrol, 
and reports the key interactions and amino acid residues of the NS3 helicase that contribute highly to 
binding of resveratrol.  
This thesis presents an all-inclusive in silico assessment to advance research in drug design and 
development of Zika virus inhibitors, thus providing a greater understanding of the structural 
dynamics that occur in unbound and inhibitor-bound Zika virus target enzymes. Therefore, the 
constituents of this thesis are considered an essential platform in the progression of research toward 
anti-ZIKV drug design, discovery and delivery against Zika virus. 
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CHAPTER 1: INTRODUCTION 
1 Background & Rationale 
Zika virus is an arthropod-borne flavivirus that belongs to the Flaviviridae family (White et al., 2016). 
Despite the reduced rate of ZIKV infections since early 2017, ZIKV remains a universal problem 
(Depoux et al., 2018). Some of the underlying concerns include the possibility of re-emergence and 
distribution of ZIKV in parts of the world with high prevalence of Aedes mosquitoes, the gap in 
literature surrounding modes of transmission not yet determined, the enduring risk for women that 
want to have children and other susceptible women residing or traveling in endemic countries, and 
the devastating congenital anomalies associated with ZIKV (Hajra, Bandyopadhyay and Hajra, 2016). 
Over and above these concerns, the biggest problem is the current lack of an approved, effective 
antiviral treatment that will also pass the blood-brain barrier (BBB) (Munjal et al., 2017). 
Over the last few years, there have been many endeavors to assess potential anti-ZIKV drugs targeting 
viral and host proteins (Pascoalino et al., 2016; Munjal et al., 2017; Yuan et al., 2017; Zhang et al., 
2017; Xia et al., 2018). Directing drugs toward key viral proteins in the ZIKV life cycle may inhibit 
replication of the virus with minimal harm to the host (Saiz and Martín-Acebes, 2017). A typical 
ZIKV particle consists of structural proteins (capsid, precursor membrane, membrane and envelope) 
and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) (Weaver et al., 2016). All 
proteins are important in the ZIKV life cycle, but the NS3 and NS5 are the most fundamental proteins 
in ZIKV maturation and replication (Saw et al., 2017). The NS3 protein is composed of the C-terminal 
helicase involved in ATP hydrolysis and RNA binding, and the N-terminal protease associated with 
maturation of ZIKV NS proteins (Jain et al., 2016; Y. Li et al., 2018). The NS5 protein constitutes an 
N-terminal methyltransferase (MTase) involved in RNA capping and a C-terminal RNA-dependent 
RNA-polymerase (RdRp) responsible for RNA synthesis (Duan et al., 2017; Zhang et al., 2017). 
The usual symptoms of ZIKV infection include mild fever, rash, conjunctivitis and arthralgia (Beaver 
et al., 2018). Although, since 2016, ZIKV infection was discovered to be associated with secondary 
complications including neurological disorder Guillain–Barré syndrome and congenital brain 
aberrations such as microcephaly, ventriculomegaly, cerebral atrophy, diffuse calcifications, ocular 
anomalies and cortical development (Baud et al., 2017; Krauer et al., 2017; Agrawal et al., 2018; Lee 
et al., 2018; Mier-Y-Teran-Romero et al., 2018).  
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A great deal of research effort has been put into preventative measures such as vaccines, and 
therapeutic approaches such as antivirals, however, effective treatment regimens are yet to pass 
clinical trials (Pascoalino et al., 2016; Xu et al., 2016; Xie et al., 2017; Garg, Mehmetoglu-Gurbuz 
and Joshi, 2018). Considerable factors that pose as challenges in the drug design and discovery 
process of ZIKV inhibitors include BBB permeation, target-specificity, drug efficacy and minimal 
host toxicity (Saiz and Martín-Acebes, 2017; Alimonti et al., 2018). Developing a new chemical 
entity that agrees with all these factors, also taking into consideration progressing viral mutations and 
unknown ZIKV pathogenicity, requires extensive time, effort and money. A more rapid and 
economical approach involves computer-aided drug design (CADD) (Goldbeck, 2012; Das, Saha and 
Abdul, 2017), which applies molecular dynamics simulations, molecular docking, virtual screening 
and pharmacophore modelling to filter out lead compounds from large databases to be experimentally 
tested (Trott and Olson, 2010; Lionta et al., 2014; Munir, Azam and Mehmood, 2016; Raabe, 2017). 
So instead of starting from scratch, computational methods allow for certain steps in the rational drug 
design process to be avoided. 
As a result of a lack of effective inhibitors of ZIKV infection, the study herein applies fundamental 
computational approaches for research into anti-ZIKV therapy, thus providing an improved 
understanding of drug targets and potential inhibitors of ZIKV. 
 
2 Aims & Objectives 
The main goals of this thesis are: 
a) To identify challenges associated with drug design and discovery of potent ZIKV inhibitors 
and provide computational approaches to overcome those challenges,  
b) To classify the ZIKV NS3 and NS5 major target proteins, and apply computational methods 
to identify potential small molecules that inhibit them, and 
c) To analyze the intra- and intermolecular interactions between those potential inhibitors and 
target proteins. 
 
3 
 
Objectives: 
1. To generate systematic strategies describing the steps taken toward designing compounds and 
identifying potential inhibitors of drug targets with improved BBB permeability by: 
1.1. Providing a coherent introduction to ZIKV and identifying core challenges in ZIKV therapy. 
1.2. Assessing bioavailability of screened drugs as potential ZIKV inhibitors. 
1.3. Presenting strategies to assist with the design of compounds with improved BBB 
permeability profile and to deliver those that are impermeable. 
 
2. To explore the structural dynamics and mechanism of inhibition of the ZIKV NS5 MTase enzyme 
when bound to competitive inhibitors of the natural substrate, S-adenosyl-L-methionine (SAM), 
namely, sinefungin and compound 5. This imparts knowledge of the binding mode at the SAM-
binding site, thus contributing to effective anti-ZIKV drug design and discovery. This will also 
give us a better understanding of which inhibitor binds with greater affinity to the MTase by: 
2.1. Incorporating molecular docking with 200 ns of molecular dynamic simulations for the apo 
enzyme and inhibitor-bound complexes. 
2.2. Implementing various post-dynamic analyses to describe the binding landscape of the 
MTase and to reveal structural modifications in ZIKV NS5 MTase following inhibitor 
binding. 
 
3. To study the binding landscape of the ATPase pocket in the ZIKV NS3 helicase by presenting 
the chemical features of flavivirus lead drug, resveratrol, at the ATP-binding pocket by: 
3.1. Applying molecular docking to obtain conformations of resveratrol that bind with highest 
affinity to the helicase pocket. 
3.2. Employing 200 ns of molecular dynamics simulations of the unbound and resveratrol-bound 
enzymes, identifying the precise residues and interactions involved in binding of resveratrol 
to the helicase. 
4 
 
3 Novelty & Significance 
Before the Brazilian outbreak in 2015, ZIKV was much-neglected in terms of research and very little 
was understood about the virus or the mechanism of infection (Campos, Bandeira and Sardi, 2015; 
Saiz and Martín-Acebes, 2017). Since then, there have been numerous attempts to discover effective 
drugs that can cure the virus, as well as preventative vaccines and antibodies (Barrows et al., 2016; 
Byler, Ogungbe and Setzer, 2016; Larocca et al., 2016; Xu et al., 2016; Richner et al., 2017; Shan, 
Muruato, et al., 2017; Xie et al., 2017; Garg, Mehmetoglu-Gurbuz and Joshi, 2018), however, none 
have been successful in providing an effective, approved anti-ZIKV treatment till date. 
The urge for a cure is driven by a number of factors, particularly the devastating effects of ZIKV on 
pregnant women and their infants as ZIKV has been associated with neurological complications in 
babies as well as adults (Brasil et al., 2016; Chan et al., 2016; Krauer et al., 2017; Agrawal et al., 
2018; Mier-Y-Teran-Romero et al., 2018). The danger associated with ZIKV infection persists also 
because of the increasing mutation rate, modes of ZIKV transmission that are still unknown and 
travelers from countries where ZIKV is still rife. 
We decided to identify challenges associated with the design and discovery of ZIKV inhibitors. A 
major requirement for an effective drug is its ability to pass the BBB, so we created novel approaches 
to design BBB-permeable drugs as well as transport BBB-impermeable drugs to the brain. A potent 
antiviral drug must also have minimal adverse effects toward its host, therefore, we undertook studies 
to investigate mechanisms of inhibition of compounds on viral targets instead of host targets. Using 
CADD, we investigated the structural dynamics and binding mechanisms of the two major viral 
targets that are key role players in ZIKV infection, the NS3 and NS5 proteins. This was the first study 
to investigate the binding landscapes of the potential inhibitors Sinefungin, Compound 5 and 
Resveratrol to ZIKV enzymes. Characterization of the structural and functional nature of the binding 
pockets within these enzymes will favor the development of potential unique and selective small 
molecule inhibitors of ZIKV. Understanding the interactions that occur between the inhibitors and 
enzymes, as well as the amino acid residues that highly contribute to binding and enzyme activity, 
will assist in improving inhibition by modification of those residues and in treating possible mutations 
that may occur in future.  
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Therefore, the composition of this thesis is regarded as an essential platform in the progression of 
research toward anti-ZIKV drug design, discovery and delivery.  
The structure of the thesis is according to UKZN guidelines. 
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CHAPTER 2: LITERATURE REVIEW 
1 Introduction to Zika Virus 
The ZIKV is a mosquito-borne virus at the center of the continuing pandemic and public health crisis 
(Plourde and Bloch, 2016). In 1947, ZIKV was originally isolated from a sentinel rhesus macaque 
monkey and afterwards in Aedes africanus mosquitoes. The virus was named after the place where it 
had been first isolated, i.e. within the Ugandan Zika forest (Dick, Kitchen and Haddow, 1952a). The 
ZIKV belongs to the flavivirus genus and is akin to other flaviviruses, including Dengue virus 
(DENV), West Nile virus (WNV), Yellow Fever virus (YFV) and Japanese Encephalitis virus (JEV) 
(Devnarain, Ramharack and Soliman, 2017). The similarity of the flaviviruses also give reason to 
them having the same vector, which is the Aedes aegypti mosquito (Muktar, Tamerat and Shewafera, 
2016). Infection by ZIKV seems to show mild illness, however, persistent infection can lead to severe 
manifestations that include congenital brain abnormalities and Guillain-Barré syndrome (Lazear and 
Diamond, 2016).  
The chapter herein has pertinent and up-to-date literature that is relevant to the aims and objectives 
of this study, and brings into context the known facts about ZIKV, as well as what has not yet been 
established. The viral structure itself will be elaborated to provide insight into the pharmacological 
targets of ZIKV that will advance the drug design and development of anti-ZIKV drugs. 
 
2 Epidemiology & Distribution 
The primary mode of transmission of ZIKV is through the bite of an infected Aedes mosquito 
(Stegomyia subgenus) (Muktar, Tamerat and Shewafera, 2016). Other known methods include sexual 
transmission, perinatal, blood transfusion, intrauterine, and laboratory exposure (Filipe, Martins and 
Rocha, 1973; Besnard et al., 2014; Musso et al., 2014; Musso, Roche, Robin, et al., 2015; Tabata et 
al., 2016; Turmel et al., 2016; Sharma and Lal, 2017; Winkler et al., 2017).  
Only occasional ZIKV cases had been documented prior to 2007, after the initial outbreak in 1947 
(MacNamara, 1954; Filipe, Martins and Rocha, 1973; Olson et al., 1981; Petersen et al., 2016). After 
these sporadic cases, in 2007, the Micronesian Yap state had reported the first ZIKV outbreak 
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(Lanciotti et al., 2008; Duffy et al., 2009). The ZIKV was later massively identified in October 2013 
in French Polynesia and other islands of the Pacific (Cao-Lormeau and Musso, 2014; Cao-Lormeau 
et al., 2014). The virus then moved to South America in May 2015 when infections were reported in 
Brazil, which were found to be associated with Guillain-Barré syndrome and later with microcephaly 
(Campos, Bandeira and Sardi, 2015). From 2015 till 2017, over 20 countries in Europe documented 
2133 cases of ZIKV infection (Spiteri et al., 2017). The World Health Organization (WHO) has 
declared three areas in Europe as high risk, which include Georgia, south of the Russian Federation 
and the Madeira island in Portugal (Gulland, 2016). Up till now, mosquito-borne ZIKV has infected 
86 countries and lands worldwide (Figure 2.1) (Hills, Fischer and Petersen, 2017). 
 
Figure 2.1 Global distribution of Zika virus in humans and animals since 1947. Autochthonous 
vector-borne human cases were documented in colored countries, while countered labeled with using 
animal profiles and years have documented Zika virus in naturally infected animals (Bueno et al., 
2016). 
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The most effective way to prevent ZIKV infection is to avoid been bitten by mosquitoes. This is 
accomplished by using mosquito repellent that is EPA-registered, being protected by door and 
window screens, removing standing water surrounding residences and using long-sleeved clothing 
(Hennessey, Fischer and Staples, 2016). In Africa, ZIKV was detected in Aedes aegypti, Aedes 
africanus, Aedes apicoargenteus, Aedes luteocephalus, Aedes albopictus, Aedes vitattus, Aedes 
dalzieli, Aedes taylori, Aedes hirsutus, Aedes unilinaetus, Aedes metallicus, Aedes furcifer and Aedes 
opok. The ZIKV has also been isolated from Anopheles coustani, Culex perfuscus and Mansonia 
uniformis mosquitoes (Shehu et al., 2018).  
  
3 The Zika Virus Life Cycle 
The ZIKV particle enters an animal cell via clathrin-dependent endocytosis through cellular receptors 
on the cell surface. Upon fusion of the cell membrane and the viral particle, viral components are 
released into the cell, the viral RNA strand is translated for polyprotein formation. The new 
polyproteins are cleaved, forming NS and structural proteins, and assemble in the endoplasmic 
reticulum (ER) to form new virions. Viral replication via the polymerase occurs on the surface of the 
ER to produce double-stranded (ds) RNA, which is transcribed and replicated. The assembled virions 
enter the Golgi apparatus to mature into viral particles via cleavage by Furin-like protease and dock 
onto the inner cell membrane to exit the cell through exocytosis where they set off to infectious life 
cycles (Sreedharan, 2015; Lee et al., 2018). Replicated viral particles in the blood of monkeys infected 
with ZIKV are transmitted to other monkeys through mosquito bites. Mosquitoes carrying infected 
blood also transmit the virus to people, and their infected blood are passed on to other people through 
mosquito bites, sexual transmission and other modes of distribution. Finally, when the virus is 
transmitted to a pregnant mother, it is passed on to her baby perinatally (Figure 2.2) (Besnard et al., 
2014). 
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Figure 2.2 The life cycle of Zika virus in blood and in organisms. A key role player in the viral life 
cycle is the vector, which in this case is the Aedes mosquito (Adapted from (Sreedharan, 2015)). 
 
4 Clinical Manifestation of Zika Virus 
Since 2015, the distribution of ZIKV throughout the Western Hemisphere has been associated with 
congenital abnormalities, microcephaly and Guillain-Barré syndrome (Lazear and Diamond, 2016). 
Surprisingly, there is a broad range of cell types and body fluids in which ZIKV manifests. This is 
consistent with the incidences, modes of transmission and clinical manifestations that were 
documented during the current epidemic (Calvet et al., 2018).  
The general symptoms of ZIKV infection include mild flu-like symptoms, such as cutaneous rashes, 
arthralgia, low-grade fever, conjunctivitis and myalgia, which typically clear up within a week (A. 
Wang et al., 2017). Although lately severe disease has affected people who have been infected with 
ZIKV. Associated diseases include thrombocytopenic purpura, thrombocytopenia and multiple organ 
failure (Brent et al., 2016; Sharp et al., 2016; Boyer Chammard et al., 2017; Hersh, Gundacker and 
Boltax, 2017). It may be noted that infection of ZIKV has a preference to neural progenitor cells as 
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opposed adult neural cells, as seen by the rare occurrence of encephalitis and meningitis. This is also 
consistent with the ability of the virus to cause damage to the neonatal brain, resulting in impaired 
neurodevelopment and microcephaly in babies (Miner and Diamond, 2017). ZIKV infection has also 
manifested in eye tissue, leading to uveitis and conjunctivitis in adults (Furtado et al., 2016; Agrawal 
et al., 2018).  
The most pressing concerns of the American ZIKV outbreak are the associated congenital 
abnormalities and number of stillborn babies. These inconsistent  abnormalities include corpus 
callosum abnormalities, microcephaly, brainstem and cerebellum hypoplasia, cerebral calcifications, 
cortical deformities, intrauterine growth limitation, ventriculomegaly, enlarged cisterna magna and 
impeded myelination (Miner and Diamond, 2017). ZIKV infection of infants may also cause loss of 
hearing and vision, and more consequently optic neuritis, dislocation of the lens and mottling of 
retinal pigment epithelium (Vinhaes et al., 2016; Singh et al., 2017; Manangeeswaran et al., 2018; 
Zaidi et al., 2018).  
A few cases of ZIKV infection are associated with autoimmunity, however, the mechanism of 
induction is unknown (Anaya et al., 2016; Monsalve et al., 2017; Acosta-Ampudia et al., 2018). 
Guillain-Barré syndrome was associated with ZIKV infection during the French Polynesian, Brazilian 
and Colombian outbreaks, which presents as peripheral nerve degeneration and ascending paralysis 
(Brasil et al., 2016). It either occurs simultaneously with ZIKV infection or as a repercussion, which 
implies that polyneuropathy occurs as a result of either direct infection, and/or autoimmunity (Mier-
Y-Teran-Romero et al., 2018).  
 
5 Diagnosis of Zika Virus 
The early symptoms of ZIKV infection present itself rather ambiguously, as they are indicative of 
several other illnesses and diseases. Therefore, verification of ZIKV infection requires laboratory 
evidence, such as tissue or fluid samples with detected ZIKV antigen or RNA (Baud et al., 2017). 
Generally, diagnostic strategies used to detect other arboviruses are used to diagnose ZIKV infection. 
Acute-phase samples are tested for the ZIKV genome using quantitative reverse transcription PCR 
(RT-qPCR) and to detect specific anti-ZIKV IgG and IgM antibodies, serology assays such as 
enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are used (Calvet, Dos Santos 
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and Sequeira, 2016). Clinical specimens such as amniotic fluid, placenta, saliva, cerebrospinal fluid 
(CSF), blood (serum and plasma) including cord blood, urine, semen, breast milk, tissues and vaginal 
secretion can be used to detect ZIKV (Gourinat et al., 2015; Calvet et al., 2016a, 2018; Calvet, Dos 
Santos and Sequeira, 2016; Mansuy et al., 2016; Carod-Artal, 2018). Should a doctor detect 
microcephalic features of a fetus after an ultrasound, RT-qPCR and viral metagenomics can be used 
to identify ZIKV in the amniotic fluid of the pregnant woman and sequence the ZIKV genome 
(Khandia, Munjal and Dhama, 2017). Due to the transient nature of viremia, molecular techniques 
used, like RT-qPCR ought to be implemented soon after the onset of the infection, typically within a 
week, when ZIKV nucleic acids are present (Lanciotti et al., 2008). 
The plaque-reduction neutralization test (PRNT) is used to verify test results that are negative ZIKV 
nucleic acid tests, non-negative serology tests or presumed equivocal, positive or inconclusive. 
However, PRNT is labor intensive, strenuous, time consuming, cost-ineffective, demands specialized 
infrastructure and produces low yield (Shan, Ortiz, et al., 2017). An improved diagnostic assay, called 
the multiplex microsphere immunoassay (MIA) is used to detect antibodies against ZIKV envelope 
(E) protein and NS proteins NS1 and NS5 (Wong et al., 2017). Antigens of ZIKV may also be 
detected in tissue samples via immunohistochemistry. It is recommended that both serological and 
molecular tests be performed for a reliable and accurate diagnosis (Calvet, Dos Santos and Sequeira, 
2016). 
Despite having the knowledge of how to diagnose ZIKV, routine lab diagnosis is still lacking in 
resource-limited countries, such as Nigeria. Well-equipped labs for thorough diagnosis of ZIKV is 
still scarce, therefore, the reinforcement of health systems and workforce is crucial (Shehu et al., 
2018).  
 
6 Components of Zika Virus 
The enveloped ZIKV encloses an 11 kilobase viral genome made up of positive-sense, single stranded 
RNA, or (+)ssRNA. The genome of an individual ZIKV particle constitutes 3,419 amino acid residues 
and 10,794 nucleotide base pairs. Included is the open reading frame (ORF) comprising a 106 
nucleotide long 5’-untranslated region (UTR) containing an m7gpppAmpN2 and a 428 nucleotide long 
3’-UTR that lacks a poly-A tail.  A  strand  not  too  far  from  the  3’  end  that  is  crucial  for  viral  replication  
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is a 90-120 nucleotide long strand that translates into a hairpin loop. Host cell furin-like proteases and 
viral serine proteases cleave the genome to produce segments that translate into functional domains 
of the virus. The polyprotein encoded by the ORF is cleaved into three structural proteins, Precursor 
of Membrane (PrM), Envelope (E) and Capsid (C). The rest of the genome encodes seven NS proteins, 
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (van Hemert and Berkhout, 2016). The NS1, NS3 
and NS5 proteins are highly conserved while the NS2a, NS2b, NS4a and NS4b are not. The 
arrangement of the genomic protein is as follows: 5’-C-PrM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-
NS5-3’. A vital step for virion maturation is the cleavage of PrM to form Pr and M by proteases 
located in the Golgi apparatus during particle release (Figure 2.3) (Li et al., 2008; Nambala and Su, 
2018).  
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Figure 2.3 The Zika virion above segments of Zika virus genome with corresponding available 
crystal structures of encoded proteins (PDB: 4I31, 5GJB, 5H4I, 5IY3, 5U4W and 5YGH) (Prepared 
by Author). 
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7 Zika Virus Pathogenesis 
In the mosquito vector, the virus replicates in salivary cells and the epithelial cell layer of central 
alimentary canal and small intestine (Guedes et al., 2017; Lim et al., 2018). The infectious ZIKV 
appears in the saliva of the mosquito after approximately five days. Upon biting, the mosquito 
cutaneously inoculates ZIKV into the host (Dudley et al., 2017). Thereafter, fibroblasts, Langerhans 
cells and epidermal keratinocytes become infected (Olagnier et al., 2016). It has been observed in 
African and Asian strains that when ZIKV enters the bloodstream, it mainly targets monocytes (Foo 
et al., 2017). Monocytes have the ability to permeate the placenta, testes and brain, which are immune 
privileged sites (Benhar, London and Schwartz, 2012). Once the viral is transmitted, the ZIKV E 
protein contains the main epitope that mediates viral attachment to the host cell receptor, which is 
followed by endocytosis of the virus particles, nucleocapsid uncoating, and release of viral RNA into 
the host cell. The E protein has also been observed to enter the nucleus of the host cell upon ZIKV 
infection (Shehu et al., 2018). This could justify the range of developmental complications that arise 
from ZIKV infection. 
There is more than one way that ZIKV can be transmitted perinatally. It can occur via trophoblastic 
plug leakage, through the placenta, vertical transmission of the virus during delivery, or viral diffusion 
into the amniotic sac during its development (Boeuf et al., 2016; Tabata et al., 2016; Sarwar and 
Saqib, 2017; Winkler et al., 2017). Infection of ZIKV through the placenta may compromise its ability 
to supply enough oxygen and nutrients to the growing foetus, contributing to microcephaly (Miner et 
al., 2016). In 2016, a hypothesis was proposed that liver injury due to ZIKV infection leads to 
metabolite accumulation, including vitamin A, which may lead to the pathogenesis of microcephaly 
(Mawson, 2016). Buildup of vitamin A is toxic and has previously caused embryopathies such as 
microcephaly (Dibley and Jeacocke, 2001). 
The virus is transmitted sexually during acute viral infection. Due to the potential neurological 
complications that may occur, this has special significance when the subjected partner is pregnant. 
The ZIKV tends to attack the nervous system by permeating the foetal blood‑brain  barrier. Upon 
attachment to neuronal cells, ZIKV RNA is released and induces apoptosis, which ultimately causes 
impediment of neuronal growth, proliferation and differentiation (Musso, Roche, Robin, et al., 2015; 
Mansuy et al., 2016; Turmel et al., 2016; Devhare et al., 2017; Winkler et al., 2017).  
18 
 
In 2017, Simonin et al. found genetic pathogenic differences between the Asian and African ZIKV 
strains (Figure 2.4) in vivo and ex vivo, where African strains are more virulent. Asian strains of ZIKV 
may contribute to the ability to initiate persistent infections within foetal nervous systems, but African 
strains can cause more acute infections (Simonin et al., 2017). Should the African strain infect a 
pregnant mother in her early stages of pregnancy, it could lead to natural abortion, but infection of 
the same woman by the Asian strain may only cause chronic effects without foetal demise (Shehu et 
al., 2018).  
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Figure 2.4 Phylogenetic analysis of Zika virus genomes based on region. Phylogenetic analysis of 
existing genomes was categorized by lineage and then continent of isolation. Asian strains (America) 
were grouped in blue, African strains in red, and strains from Asia and Oceania in green (Beaver et 
al., 2018). 
Upon onset of ZIKV infection, the immune system reacts by developing IgM, which persists in the 
blood stream for approximately three months. This is followed by the development of IgG, which 
persists in the blood stream for years (Calvet et al., 2018). Upon viral attack, a cell releases interferon 
(IFN) to warn other cells to enhance their defenses. The NS5 protein of ZIKV antagonizes the IFN-I 
response to stimulate E3 ubiquitin ligase UBR4-independent degradation of STAT2 in humans (Grant 
et al., 2016; Miner and Diamond, 2017). 
 
8 Pharmacological Targets of Zika Virus 
Identifying and understanding viral targets are important in the drug design and discovery process. 
Among the NS proteins of ZIKV, the NS3 and NS5 proteins are lead targets for the design of anti-
ZIKV drugs, while the NS1, E and PrM proteins can be used for prophylactic antibody and vaccine 
development (Barzon et al., 2016).  
The ZIKV C protein is a symmetric, icosahedral homodimer that is essential for enclosure of viral 
RNA during assembly of the ZIKV particle. The C protein has a sphere-shaped lipid bilayer 
membrane that stems from the host cell (A. Wang et al., 2017). It constitutes a hydrophobic region 
involved in interaction and dimerization with the membrane, and an RNA-binding region (Fontaine 
et al., 2018). 
The ZIKV PrM protein constitutes a C-terminal transmembrane domain, a central ectodomain and 
the Pr N-terminal domain. For assembly and release of virions that are capable of fusion, furin-like 
proteases of the host cell cleave the Pr domain (Nambala and Su, 2018).  
The E protein is the key target for neutralizing antibodies as it comprises of immunogenic epitopes – 
ectodomains E-DI, E-DII and E-DIII. It functions in the recognition of entry cofactors and host cell 
receptors (Barzon et al., 2016). The DII domain has a fusion loop in its apex, which is hydrophobic 
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in nature and responsible for penetration into the cellular membrane (Bressanelli et al., 2004). This 
domain is identified by cross-reactive antibodies with low neutralizing efficiency, while the DIII 
domain is identified by protective neutralizing antibodies. The DIII domain resembles an 
immunoglobulin and comprises of the receptor-binding site (J. Wang et al., 2017). The ZIKV E 
protein contains a glycosylation site at Asparagine residue 154 and a five-residue insertion, as 
compared to DENV E protein, which is glycosylated at Asparagine residues 67 and 153. Alteration 
of these glycosylation sites will influence neurovirulence and transmission of ZIKV (Fontes-Garfias 
et al., 2017; Wen et al., 2018).  
The glycosylated NS1 protein plays a major role in immune evasion and ZIKV maturation and 
replication (Muller and Young, 2013). The NS1 interacts with the E and PrM proteins and forms 
intracellular homodimers and extracellular hexameric lipoproteins (Edeling, Diamond and Fremont, 
2014). It also exhibits various electrostatic characteristics involved in host interactions that may 
influence immunogenicity and pathogenesis (Song et al., 2016). The NS1 gene of the Asian ZIKV 
strain that causes majority of the recent epidemics contains a mutation that augments mosquito 
infection and is responsible for the inhibition of IFN-β induction (Xia et al., 2018). 
Information regarding the NS2A protein lacking in literature. It is a hydrophobic constituent of the 
replication complex and regulates host cellular defenses against viruses (Leung et al., 2008). Yoon et 
al. (2017) have shown that the ZIKV NS2A protein expression decreases proliferation, causes radial 
glial cells to differentiate early and leads to abnormal neuronal positioning in infants (Yoon et al., 
2017). A mutation of amino acid residue 175 (AV) in the NS2A protein impairs synthesis of ZIKV 
RNA in vivo (Márquez-Jurado et al., 2018). There is a current lack of an experimentally-derived 
crystal structure of the NS2A protein.  
Like the NS2A protein, the ZIKV NS2B cofactor is a small protein situated within the membrane. It 
interacts with and chaperones the NS3 protease by means of a central hydrophilic region, whereas the 
hydrophobic regions secure the NS2B–NS3 complex to the membrane of the ER (Barzon et al., 2016). 
the NS2B cofactor region from Zika virus protease is essential for recognition of host cell substrates 
(Hill et al., 2018). 
The ZIKV NS3 protein is made up of two connected domains that are globular in shape (Jain et al., 
2016). The helicase occupies the C-terminal end, while the protease is situated at the N-terminal end. 
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The helicase is a monomer associated with viral RNA unwinding for replication, while the protease 
binds to the NS2B cofactor and is involved in polyprotein cleavage (Saw et al., 2017). 
Like the NS2A, the ZIKV NS4A and NS4B are integral membrane proteins and components of the 
replication complex, also associated with the NS3 protein. The NS4A and NS4B proteins are 
responsible for inhibiting the Akt-mTOR pathway and cellular dysregulation during ZIKV infection, 
causing defective productions of neurons from neural stem cells (NSCs) and abnormal stimulation of 
autophagy in NSCs of foetuses (Liang et al., 2016). The ZIKV NS4A protein also inhibits the 
interaction of the RLR-mitochondrial antiviral-signaling protein that induces immune responses upon 
viral attack. Therefore, the NS4A plays a role in immune evasion (Ma et al., 2018).  Till date, there 
has been no experimentally-determined crystal structure of the ZIKV NS4B enzyme. 
The ZIKV NS5 protein represents the largest protein that is conserved among flaviviruses (Duan et 
al., 2017). The C-terminal RdRp is responsible for viral RNA synthesis, while the N-terminal MTase 
is responsible for methylation  and  capping  the  5’  end  of  the  viral  RNA (Coutard et al., 2017; Zhang 
et al., 2017). 
 
8.1 The NS3 Helicase 
The ZIKV NS3 helicase belongs to the SF2 superfamily of helicases (Singleton, Dillingham and 
Wigley, 2007). The helicase domain occupies amino acid residues 168-617 of the entire NS3 enzyme 
and contains three domains that are similar to each other based on size (Figure 2.5). Residues 182–
327 that make up Domain 1 and residues 328-480 that form Domain 2 constitute α/β  RecA-like folds 
arranged one behind the other, which are conserved in Superfamily 1 and 2 helicases (Jain et al., 
2016). Domain 1 comprises motifs I (Walker A or P loop), Ia, II (Walker B) and III, which are divided 
from motifs IV, IVa, V and VI of domain 2. Motifs I, II and VI are fundamental in ATP binding and 
hydrolysis, while motifs Ia, IV and V are involved in interdomain communication and RNA binding. 
The helicase of ZIKV and DENV4 bind ATP at the lower end of the fissure at the border of domains 
1 and 2, while the RNA-binding pocket separates domains 1 and 2 from domain 3. Domains 2 
connects with Domain 3 through a  β-hairpin strand of domain 2, which serves to enable unwinding 
of ds RNA. Domain 3 mainly contain α-helical structures that interact with RNA in addition to the 
NS5 RdRp (Saw et al., 2017).  
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Figure 2.5 The NS3 helicase of Zika virus. The three domains of comparable size are demonstrated 
in orange (Domain 1), blue (Domain 2) and green (Domain 3). The P-loop of Domain 1 is represented 
in yellow, which surrounds the binding site of ATP. The RNA-binding loop whose flexibility 
influences RNA replication is shown in pink (Prepared by Author). 
 
8.2 The NS5 Methyltransferase 
The first 260 amino acid residues of the ZIKV NS5 protein makes up the MTase enzyme. The 33kDa 
enzyme has three binding sites that bind ssRNA, SAM (a methyl donor and natural substrate) and 
guanosine triphosphate (GTP) (Coloma et al., 2016). The MTase consists of four α-helices in the 
center of seven β-sheets. The MTase consists of a K-D-K-E catalytic tetrad that is conserved among 
flaviviruses The N-terminal end, especially residue (D146) of the MTase is the functional end that 
serves  to  methylate  the  5’  cap  at  positions N-7  and  ribose  2’-OH, which is essential for viral RNA 
replication. (Stephen et al., 2016). Capping includes four stages (Figure 2.6) (Chatrin et al., 2018). 
Apart from methylation, the MTase is also involved in the initiation and elongation of RNA 
polymerization by the RdRp (Coutard et al., 2017). 
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Figure 2.6 Diagram represents the methyltransferase enzyme of the Zika virus NS5 protein on the 
left, showing the three different binding-pockets, and the four-step process of capping by the 
methyltransferase on the right (Prepared by Author). 
 
9 Therapeutic targets of Host 
Apart from the viral targets, identifying the host factors associated with viral inhibition and activation 
of immune response against viral attack are especially important aspects of research. Host proteins 
that are established as promoters of ZIKV infection include AXL, Tyro-3, DC-SIGN, TIM-1 and 
TIM-4 (Barzon et al., 2016).  
In cells of the human placenta, the most expressed ZIKV entry factor is TIM-1 (Tabata et al., 2016). 
In radial glia of the developing human cortex, AXL is expressed abundantly during neurogenesis 
(Nowakowski et al., 2016; Retallack et al., 2016). In mammalian cells, ZIKV infects foetal 
endothelial cells via AXL tyrosine kinase receptors, allowing passage of the virus into the foetal 
bloodstream and tissues (Olagnier et al., 2016; Meertens et al., 2017; Richard et al., 2017). 
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Both innate and inflammatory immune responses are activated when ZIKV infects a host cell, 
inducing cellular expression of IFN-α, IFN-β, CCL5, IFN regulatory factor 7 (IRF7), MDA5, RIG-I 
and TLR3 (Barzon et al., 2016). Increased expression and activation of TLR3 due to ZIKV infection 
caused shrinkage of organelles, erratic neuron production and apoptosis (Dang et al., 2016), while 
TLR3 inhibition via small interfering RNA (siRNA) augmented ZIKV replication (Hamel et al., 
2015). Therefore, TLR3 is a major factor in the activation of host antiviral response against ZIKV. 
Replication of ZIKV can be reduced via regulating the innate immune response of the host through 
treatment with IFN-I and IFN-II (Lazear et al., 2016; Chaudhary et al., 2017; Lee and Ng, 2018). 
Other host restriction proteins in ZIKV inhibition include IFN-induced transmembrane proteins, 
which may be promising therapeutic targets for drug design (Saiz et al., 2018). The SPCS1 gene is 
essential for selective cleavage of flavivirus proteins (Zhang et al., 2016).  
 
10 Advances in Design & Development of Anti-Zika Virus Drugs & Therapies 
There is no effective antiviral treatment currently available for ZIKV. Although recently, much effort 
has been put into the hunt for potential antivirals using various approaches, from drug-based to target-
based. The identified potential antiviral compounds include those that target the host as well as the 
virus (Saiz and Martín-Acebes, 2017). The following up-to-date information will promote design and 
development of more potent drugs to curb ZIKV. 
10.1 Small Molecule Inhibitors 
Specific anti-ZIKV drugs are currently lacking. Patients infected with ZIKV are treated for their 
symptoms, such as anti-histamines to treat itchy rashes, fluids for dehydration and acetaminophen for 
pain and fever (Centers for Disease Control and Prevention, 2018). Several compounds have been 
shown to inhibit different stages of the ZIKV life cycle (Figure 2.7).  
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Figure 2.7 Drugs that target different stages of the Zika virus life cycle (Saiz et al., 2018). 
Two main classes of small molecule inhibitors of ZIKV are nucleoside/nucleotide inhibitors and non-
nucleoside inhibitors. In the nucleoside/nucleotide group, NITD008, sofosbuvir, BCX4430 and MK-
0608 have presented moderate in vitro and in vivo potency, although none of them totally prevent 
demise of mice infected with ZIKV (Xie et al., 2017). Sofosbuvir is an FDA-approved treatment for 
Hepatitis C virus (HCV) with low efficacy against ZIKV (Reznik and Ashby, 2017). 
Nucleoside/nucleotide inhibitors are the basis of antiviral drugs due to its broad-spectrum inhibition 
of viruses from a single lineage.  
Non-nucleoside inhibitors have been identified through cell-based screening in an effort to repurpose 
drugs, which concentrated on pharmacologically active compounds, FDA-approved compounds and 
compounds already in clinical trial. This led to the identification of daptomycin, palonosetron, 
emricasan, brequinar, mefloquine, ivermectin, mycophenolate mofetil, niclosamide, and antimalarial 
compounds. Of these, drugs approved for pregnancy B category include palonosetron, niclosamide 
and daptomycin. However, these drugs have presented low potency in vitro and no potency in vivo 
(Barrows et al., 2016; Kmietowicz, 2016; Pascoalino et al., 2016; Xu et al., 2016; Adcock et al., 
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2017). Table 2.1 represents compounds that have demonstrated anti-ZIKV activity in different cell 
types.  
Table 2.1 Compounds that represent potential antiviral compounds against the Zika virus (Devnarain, 
Ramharack and Soliman, 2017; Munjal et al., 2017; Saiz and Martín-Acebes, 2017; da Silva, Martins 
and Jardim, 2018). 
Compound Description Tested cell/assay Reference 
Emricasan Pan-caspase inhibitor 
Glioblastoma SBN-
19, hNPCS and 
human astrocytes 
cells 
(Xu et al., 2016) 
Palonosetron* Nausea/vomiting drug In silico (Barrows et al., 2016) 
Bortezomib 20S proteasome inhibitor 
C6/36, vero cells, 
C57BL/6 mice (Xin et al., 2017) 
Bromocriptine Ergoline derivative and dopamine agonist Vero cells (Chan et al., 2017) 
Brequinar Pyrimidine synthesis inhibitor In silico (Adcock et al., 2017) 
Chloroquine# Antimalarial agent Vero, hNSC and hBMEC cells 
(Shiryaev et al., 
2017) 
Niclosamide*, PHA-
690509 Antiparasitic drugs 
Glioblastoma SBN-
19, hNPCS and 
human astrocytes 
(Xu et al., 2016) 
Ivermectin# Antiparasitic drugs HuH7 cells (Kmietowicz, 2016) 
Daptomycin* Lipopeptide antibiotic HuH7 cells (Barrows et al., 2016) 
Mycophenolic acid Immune-suppressant drug HuH7 cells 
(Barrows et al., 
2016) 
Sertraline# Antidepressant HuH7 cells (Barrows et al., 2016) 
Pyrimethamine Antimalarial agent HuH7 cells (Barrows et al., 2016) 
Cyclosporine A Immunosuppressant HuH7 cells (Barrows et al., 2016) 
Azathioprine* Immunosuppressant HuH7 cells (Barrows et al., 2016) 
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Mefloquine* Antimalaria drug HuH7 cells (Barrows et al., 2016) 
Sofosbuvir* Adenosine analog 
HNPCs, Huh-7, SH-
5YSY, Vero cells, 
neurosphere, in 
silico 
(Reznik and Ashby, 
2017) 
Curcumin Antioxidant and anti-inflammatory agent HeLa cells 
(Mounce et al., 
2017) 
25-Hydroxycholesterol Regulates cholesterol and immunity BHKK-21 (Li et al., 2017) 
Epigallocatechin 
gallate Phenolic antioxidant Vero cells 
(Carneiro et al., 
2016) 
Saliphenylhalamide Immuno-modulatory agent 
Human telomerase 
reverse transcriptase 
(hTERT)-
immortalized retinal 
pigment (RPE) 
(Kuivanen et al., 
2017) 
GSK126 EZH2 MTase inhibitor 
TERT-immortalized 
HFF cells 
(Arbuckle et al., 
2017) 
Pentagalloylglucose Phenolic antioxidant Vero B4 (Behrendt et al., 2017) 
Heparin Anticoagulant Human neural progenitor cells (Ghezzi et al., 2017) 
Suramin Anti-parasitic drug Vero cells (Tan et al., 2017) 
Obatoclax Pro-apoptotic protein hTERT-RPE (Kuivanen et al., 2017) 
Nanchangmycin Antibiotic U2OS cells (Rausch et al., 2017) 
Novobiocin, lopinavir-
ritonavir 
Antibiotic, HIV 
antiviral Vero/Huh-7/in silico (Yuan et al., 2017) 
Aprotinin Competitive serine protease inhibitor In silico (Chen et al., 2016) 
N-(4-hydroxyphenyl) 
retinamide Pro-apoptotic agent Vero cells 
(C. Wang et al., 
2017) 
Merimepodib Antiproliferative agent Huh7 (Tong et al., 2018) 
Gemcitabine Cytidine analog hTERT-RPE (Kuivanen et al., 2017) 
Cimiracemate B, 
Rosemarinic acid 
Phenylpropanoid, 
antioxidant. In silico 
(Byler, Ogungbe and 
Setzer, 2016) 
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6-
methylmercaptopurine 
riboside 
Thiopurine nucleoside 
analogue 
Vero and SII—
SY5Y neuronal cells 
(de Carvalho et al., 
2017) 
4’,7-digalloylcatechin, 
prenylated chalcone, 
2’,4,4’-trihydroxy-3,3’-
diprenylchalcone, bis-
indole alkaloid 
flinderole, lignan di-O-
demethylisoguaiacin 
ZIKV NS5 RdRp 
inhibitors In silico 
(Byler, Ogungbe and 
Setzer, 2016)  
Nordihydroguaiaretic 
Acid Hypolipidemic drug Vero cells 
(Merino-Ramos et 
al., 2017) 
7-deaza-2’-C-
methyladenosine 
(CMA),  2’-CMA,  2’-C-
methylcytidine,  2’-C-
methylguanosine,  2’-C-
methyluridine 
Nucleoside analogues Vero, Human nUKF-NB-4 and PS cells 
(Zmurko et al., 
2016) 
 
10.2 Prophylactic Antibodies and Vaccines 
The overwhelming effects of ZIKV have called on the urgency of effective therapeutic agents and a 
vaccine. Developmental stage vaccines against ZIKV include nucleic acid-based vaccines, inactivated 
virus, subunit vaccines, live vector vaccines, recombinant ZIKV, and virus-like particles (Alam et al., 
2017; Ali et al., 2017).  
Epitopes of B and T cells have been identified, which are crucial in the development of vaccines. 
These include HLA-B7 (B cells), QTLTPVGRL (T cells) and IRCIGVSNRDFV (T cells) (Ali et al., 
2017). In 2016, researchers published work of DNA vaccines that express ZIKV E and PrM, and a 
sequence of deletion mutants, which prevented viraemia in mice (Larocca et al., 2016). In 2017, a 
live-attenuated   vaccine   containing   a   3’-UTR deletion of 10 nucleotides prevented viraemia and 
induced protective immunity and a strong T cell response (Shan, Muruato, et al., 2017). An RNA 
vaccine encoding ZIKV PrM-E and modified using 1-methylpseudouridine, also known as mRNA-
LNP, showed safe and effective moderate immunization in mice and macaques (Pardi et al., 2017). 
Two immunizations using this vaccine decreased foetal mice infection and totally rescued a viability 
defect (Richner et al., 2017). This vaccine entered combined phase I/II clinical trial. In 2018, an 
attenuated vaccine based on recombinant vesicular stomatitis virus was developed, which expressed 
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PrM-E-NS1 ZIKV polyprotein. It stimulated T cell immune response, ZIKV antibodies (Abs) and 
conferred protection against ZIKV in mice (A. Li et al., 2018). Potential vaccines that are currently 
in clinical trials are listed in Table 2.2 below. 
Table 2.2 Stages of Zika virus vaccines that entered clinical trials (Adapted from Garg, Mehmetoglu-
Gurbuz and Joshi, 2018). 
Vaccine Name Antigen Platform Phase Clinical Trial 
No. 
Anticipated 
End Date 
VRC 319 PrM-E DNA vaccine I NCT02840487 Dec 2018 
VRC 320 PrM-E DNA vaccine I NCT02996461 Dec 2018 
VRC 705 PrM-E DNA vaccine II NCT03110770 Jan 2020 
GLS 5700 PrM-E DNA vaccine I NCT02887482 Jun 2018 
GLS 5700 PrM-E DNA vaccine I NCT02809443 Nov 2017 
ZPIV Whole 
virus 
Purified inactivated 
virus 
I NCT02963909 Feb 2019 
ZPIV Whole 
virus 
Purified inactivated 
virus 
I NCT02952833 Jun 2019 
ZPIV Whole 
virus 
Purified inactivated 
virus 
I NCT02937233 Jun 2018 
ZPIV Whole 
virus 
Purified inactivated 
virus 
I NCT03008122 Jan 2020 
VLA1601 Whole 
virus 
Purified inactivated 
virus 
I NCT03425149 Nov 2018 
MV-ZIKA PrM-E in 
measles 
vector 
Live attenuated 
recombinant 
vaccine 
I NCT02996890 Apr 2018 
mRNA-1325 PrM-E mRNA vaccine I/II NCT03014089 Sep 2018 
TAK-426 Whole 
virus 
Purified inactivated 
virus 
I NCT03343626 Sep 2020 
rZIKV/D4D30-
713 
Whole 
genome 
Live attenuated 
virus 
I NCT03611946 Sep 2019 
MR 766 Whole 
virus 
Purified inactivated 
virus 
I N/A N/A 
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The third domain of ZIKV E protein was inhibited by ZKA64 human monoclonal Ab, and prevented 
death in mice (Stettler et al., 2016). However, they do not support Ab-dependent enhancement and 
certain mutations must be engineered, flaviviruses often develop resistance to Abs and the dost of 
development still limits its use especially in third-world countries (Xie et al., 2017). The development 
of EDE1 class of Abs have shown to regulate fatal ZIKV infection (Ali et al., 2017). An effective 
human monoclonal Ab ZIKV-117 inhibited E protein from different Asian-American and African 
strains in vitro and in vivo, by significantly decreasing foetal and placental infection, tissue pathology 
and demise (Hasan et al., 2017).  
The considerable development that has been made regarding discovery of anti-ZIKV therapeutics 
remains at an initial phase of discovery. It will be several years until ZIKV therapy is approved by 
the FDA. 
 
11 References 
Acosta-Ampudia, Y. et al. (2018)   ‘Autoimmune   Neurological   Conditions   Associated  With   Zika  
Virus   Infection.’,   Frontiers in molecular neuroscience. Frontiers Media SA, 11, p. 116. doi: 
10.3389/fnmol.2018.00116. 
Adcock, R. S. et al. (2017)  ‘Evaluation  of  anti-Zika virus activities of broad-spectrum antivirals and 
NIH clinical collection compounds using a cell-based, high-throughput   screen   assay’,   Antiviral 
Research, 138, pp. 47–56. doi: 10.1016/j.antiviral.2016.11.018. 
Agrawal, R. et al. (2018)  ‘Zika  Virus  and  the  Eye’,  Ocular Immunology and Inflammation, 26(5), pp. 
654–659. doi: 10.1080/09273948.2017.1294184. 
Alam, A. et al. (2017)   ‘Recent   trends   in  ZikV  research:  A  step  away   from  cure’,  Biomedicine & 
Pharmacotherapy, 91(1), pp. 1152–1159. doi: 10.1016/j.biopha.2017.05.045. 
Ali, A. et al. (2017)  ‘Advances  in  research  on  Zika  virus’,  Asian Pacific Journal of Tropical Medicine. 
No longer published by Elsevier, 10(4), pp. 321–331. doi: 10.1016/J.APJTM.2017.03.020. 
Anaya, J.-M. et al. (2016)   ‘Zika   virus   and   neurologic   autoimmunity:   the   putative   role   of  
gangliosides.’,  BMC medicine. BioMed Central, 14, p. 49. doi: 10.1186/s12916-016-0601-y. 
Arbuckle, J. H. et al. (2017)  ‘Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent 
31 
 
Antiviral  State  and  Suppress   Infection  by  Diverse  Viral  Pathogens.’,  mBio. American Society for 
Microbiology (ASM), 8(4), pp. 01141-17. doi: 10.1128/mBio.01141-17. 
Barrows, N. J. et al. (2016) ‘A  Screen  of  FDA-Approved Drugs for Inhibitors of  Zika  Virus  Infection’,  
Cell Host and Microbe, 20(2), pp. 259–270. doi: 10.1016/j.chom.2016.07.004. 
Barzon, L. et al. (2016)   ‘Zika   virus:   from   pathogenesis   to   disease   control’,  FEMS Microbiology 
Letters. Edited by A. van Vliet. Oxford University Press, 363(18), p. fnw202. doi: 
10.1093/femsle/fnw202. 
Baud, D. et al. (2017)  ‘An  update  on  Zika  virus  infection’,  The Lancet. Elsevier, 390(10107), pp. 
2099–2109. doi: 10.1016/S0140-6736(17)31450-2. 
Beaver, J. T. et al. (2018)  ‘Evolution  of  Two Major Zika Virus Lineages: Implications for Pathology, 
Immune  Response,  and  Vaccine  Development’,  Frontiers in Immunology. Frontiers, 9, p. 1640. doi: 
10.3389/fimmu.2018.01640. 
Behrendt, P. et al. (2017)  ‘Pentagalloylglucose,  a highly bioavailable polyphenolic compound present 
in  Cortex  moutan,  efficiently  blocks  hepatitis  C  virus  entry’,  Antiviral Research, 147, pp. 19–28. doi: 
10.1016/j.antiviral.2017.09.006. 
Benhar,   I.,  London,  A.  and  Schwartz,  M.   (2012)   ‘The  privileged   immunity of immune privileged 
organs:   the   case   of   the   eye.’,   Frontiers in immunology. Frontiers Media SA, 3, p. 296. doi: 
10.3389/fimmu.2012.00296. 
Besnard, M. et al. (2014)   ‘Evidence   of   perinatal   transmission   of   zika   virus,   French   Polynesia,  
December 2013 and February   2014’,   Eurosurveillance, 19(13), pp. 8–11. doi: 10.2807/1560-
7917.ES2014.19.13.20751. 
Boeuf, P. et al. (2016)   ‘The   global   threat   of   Zika   virus   to   pregnancy:   epidemiology,   clinical  
perspectives,  mechanisms,  and  impact.’,  BMC medicine. BioMed Central, 14(1), pp. 112–120. doi: 
10.1186/s12916-016-0660-0. 
Boyer Chammard, T. et al. (2017)  ‘Severe  Thrombocytopenia  after  Zika  Virus  Infection,  Guadeloupe,  
2016.’,  Emerging infectious diseases. Centers for Disease Control and Prevention, 23(4), pp. 696–
698. doi: 10.3201/eid2304.161967. 
Brasil, P. et al. (2016)  ‘Guillain-Barre  syndrome  associated  with  Zika  virus  infection’,  Lancet, 387(1), 
p. 1482. doi: 10.1016/S0140-6736(16)30058-7. 
Brent, C. et al. (2016)  ‘Preliminary  Findings  from  an  Investigation  of  Zika  Virus Infection in a Patient 
with No Known Risk Factors — Utah,   2016’,  MMWR. Morbidity and Mortality Weekly Report, 
32 
 
65(36), pp. 981–982. doi: 10.15585/mmwr.mm6536e4. 
Bressanelli, S. et al. (2004)  ‘Structure  of  a  flavivirus  envelope  glycoprotein  in  its  low-pH-induced 
membrane fusion conformation.’,  The EMBO journal. European Molecular Biology Organization, 
23(4), pp. 728–38. doi: 10.1038/sj.emboj.7600064. 
Bueno, M. G. et al. (2016)  ‘Animals  in  the  Zika  Virus  Life  Cycle:  What  to  Expect  from  Megadiverse  
Latin American  Countries’,  PLOS Neglected Tropical Diseases. Edited by A. C. A. Clements. Public 
Library of Science, 10(12), p. e0005073. doi: 10.1371/journal.pntd.0005073. 
Byler,   K.   G.,   Ogungbe,   I.   V.   and   Setzer,   W.   N.   (2016)   ‘In-silico screening for anti-Zika virus 
phytochemicals’,   Journal of Molecular Graphics and Modelling, 69, pp. 78–91. doi: 
10.1016/j.jmgm.2016.08.011. 
Calvet, G. et al. (2016)  ‘Detection  and  sequencing  of  Zika  virus  from  amniotic  fluid  of  fetuses  with  
microcephaly  in  Brazil:  a  case  study’,  The Lancet Infectious Diseases. Elsevier, 16(6), pp. 653–660. 
doi: 10.1016/S1473-3099(16)00095-5. 
Calvet, G. A. et al. (2018)  ‘Study  on  the  persistence  of  Zika  virus  (ZIKV)  in  body  fluids  of  patients  
with   ZIKV   infection   in   Brazil.’,   BMC infectious diseases. BioMed Central, 18(1), p. 49. doi: 
10.1186/s12879-018-2965-4. 
Calvet,  G.  A.,  Dos  Santos,  F.  B.  and  Sequeira,  P.  C.   (2016)   ‘Zika  virus   infection:  Epidemiology,  
clinical  manifestations  and  diagnosis’,  Current Opinion in Infectious Diseases, 29(5), pp. 459–466. 
doi: 10.1097/QCO.0000000000000301. 
Campos,  G.  S.,  Bandeira,  A.  C.  and  Sardi,  S.  I.  (2015)  ‘Zika  Virus  Outbreak,  Bahia  Brazil’,  Emerging 
Infectious Diseases, 21(10), pp. 1885–1886. doi: 10.32301/eid2110.150847. 
Cao-Lormeau, V.-M. et al. (2014)  ‘Zika  virus, French  polynesia,  South  pacific,  2013.’,  Emerging 
infectious diseases. Centers for Disease Control and Prevention, 20(6), pp. 1085–6. doi: 
10.3201/eid2006.140138. 
Cao-Lormeau, V.-M.  and  Musso,  D.  (2014)  ‘Emerging  arboviruses  in  the  Pacific.’,  Lancet. Elsevier, 
384(9954), pp. 1571–2. doi: 10.1016/S0140-6736(14)61977-2. 
Carneiro, B. M. et al. (2016)  ‘The  green  tea  molecule  EGCG  inhibits  Zika  virus  entry’,  Virology. 
Academic Press, 496(1), pp. 215–218. doi: 10.1016/J.VIROL.2016.06.012. 
Carod-Artal, F. J. (2018)  ‘Neurological  complications  of  Zika  viru  infection’,  Expert Review of Anti-
Infective Therapy, 16(5), pp. 399–410. doi: 10.1080/14787210.2018.1466702. 
33 
 
de Carvalho, O. V. et al. (2017)   ‘The   thiopurine   nucleoside   analogue   6-methylmercaptopurine 
riboside (6MMPr)  effectively  blocks  Zika  virus  replication’,  International Journal of Antimicrobial 
Agents, 50(6), pp. 718–725. doi: 10.1016/j.ijantimicag.2017.08.016. 
Centers for Disease Control and Prevention (2018). Available at: 
https://www.cdc.gov/zika/symptoms/treatment.html (Accessed: 15 January 2019). 
Chan, J. F.-W. et al. (2017)  ‘Novel  antiviral  activity  and  mechanism  of  bromocriptine  as  a  Zika  virus  
NS2B-NS3   protease   inhibitor’,   Antiviral Research. Elsevier, 141(1), pp. 29–37. doi: 
10.1016/J.ANTIVIRAL.2017.02.002. 
Chatrin, C. et al. (2018)  ‘The  structure  of  the  binary  methyltransferase-SAH complex from Zika virus 
reveals  a  novel  conformation  for  the  mechanism  of  mRNA  capping’,  Oncotarget. Impact Journals, 
9(3), pp. 3160–3171. doi: 10.18632/oncotarget.23223. 
Chaudhary, V. et al. (2017)  ‘Selective  Activation  of  Type  II  Interferon  Signaling  by  Zika  Virus  NS5  
Protein’,   Journal of Virology. Edited by B. R. G. Williams, 91(14), pp. e00163-17. doi: 
10.1128/JVI.00163-17. 
Chen, X. et al. (2016)  ‘Mechanisms of activation and inhibition of Zika virus NS2B-NS3  protease.’,  
Cell research. Nature Publishing Group, 26(11), pp. 1260–1263. doi: 10.1038/cr.2016.116. 
Coloma, J. et al. (2016)  ‘Structures  of  NS5  Methyltransferase  from  Zika  Virus’,  Cell Rep, 16(12), pp. 
3097–3102. doi: 10.1016/j.celrep.2016.08.091. 
Coutard, B. et al. (2017)  ‘Zika  Virus  Methyltransferase:  Structure  and  Functions  for  Drug  Design  
Perspectives’,  Journal of Virology, 91(5), pp. e02202-16. doi: 10.1128/JVI.02202-16. 
Dang, J. et al. (2016)  ‘Zika  Virus  Depletes Neural Progenitors in Human Cerebral Organoids through 
Activation  of  the  Innate  Immune  Receptor  TLR3.’,  Cell stem cell. NIH Public Access, 19(2), pp. 258–
265. doi: 10.1016/j.stem.2016.04.014. 
Devhare, P. et al. (2017)   ‘Zika   virus   infection dysregulates human neural stem cell growth and 
inhibits  differentiation  into  neuroprogenitor  cells’,  Cell Death and Disease. Nature Publishing Group, 
8(10), p. e3106. doi: 10.1038/cddis.2017.517. 
Devnarain, N., Ramharack, P. and Soliman, M. E. (2017)  ‘Brain  grants  permission of access to Zika 
virus  but  denies  entry  to  drugs:  a  molecular  modeling  perspective  to  infiltrate  the  boundary’,  RSC 
Advances. Royal Society of Chemistry, 7(75), pp. 47416–47424. doi: 10.1039/C7RA05918C. 
Dibley,   M.   J.   and   Jeacocke,   D.   A.   (2001)   ‘Safety and Toxicity of Vitamin A Supplements in 
Pregnancy’,  Food and Nutrition Bulletin. SAGE PublicationsSage CA: Los Angeles, CA, 22(3), pp. 
34 
 
248–266. doi: 10.1177/156482650102200304. 
Dick, G. W. A., Kitchen, S. F.  and  Haddow,  A.  J.  (1952)  ‘Zika  Virus  (I). Isolations and serological 
specificity’,  Transactions of the Royal Society of Tropical Medicine and Hygiene, 46(5), pp. 509–
520. doi: 10.1016/0035-9203(52)90042-4. 
Duan, W. et al. (2017)  ‘The  crystal  structure  of Zika virus NS5 reveals conserved drug targets’,  The 
EMBO Journal, 36(7), pp. 919–933. doi: 10.15252/embj.201696241. 
Dudley, D. M. et al. (2017)  ‘Infection  via  mosquito  bite  alters  Zika  virus  tissue  tropism  and  replication  
kinetics  in  rhesus  macaques’,  Nature Communications. Nature Publishing Group, 8(1), p. 2096. doi: 
10.1038/s41467-017-02222-8. 
Duffy, M. R. et al. (2009)  ‘Zika  virus  outbreak  on  Yap  Island,  Federated  States  of  Micronesia’,  The 
New England Journal of Medicine, 360(1), pp. 2536–2543. 
Edeling, M. A., Diamond, M. S. and Fremont, D. H. (2014)   ‘Structural   basis   of   Flavivirus  NS1  
assembly  and  antibody  recognition.’,  Proceedings of the National Academy of Sciences of the United 
States of America. National Academy of Sciences, 111(11), pp. 4285–90. doi: 
10.1073/pnas.1322036111. 
Filipe, A. R.,  Martins,  C.  M.  V.  and  Rocha,  H.  (1973)  ‘Laboratory  infection  with  Zika  virus  after  
vaccination  against  yellow  fever’,  Archiv für die gesamte Virusforschung, 43(4), pp. 315–319. doi: 
10.1007/BF01556147. 
Fontaine, K. A. et al. (2018)   ‘The  Cellular  NMD  Pathway Restricts Zika Virus Infection and Is 
Targeted  by  the  Viral  Capsid  Protein.’,  mBio. American Society for Microbiology, 9(6), pp. e02126-
18. doi: 10.1128/mBio.02126-18. 
Fontes-Garfias, C. R. et al. (2017)  ‘Functional Analysis of Glycosylation of Zika Virus Envelope 
Protein.’,  Cell reports. NIH Public Access, 21(5), pp. 1180–1190. doi: 10.1016/j.celrep.2017.10.016. 
Foo, S.-S. et al. (2017)  ‘Asian  Zika  virus  strains   target  CD14+  blood  monocytes  and   induce  M2-
skewed  immunosuppression  during  pregnancy.’,  Nature microbiology. NIH Public Access, 2(11), pp. 
1558–1570. doi: 10.1038/s41564-017-0016-3. 
Furtado, J. M. et al. (2016)  ‘Uveitis  Associated  with  Zika  Virus  Infection’,  New England Journal of 
Medicine, 375(4), pp. 394–396. doi: 10.1056/NEJMc1603618. 
Garg, H., Mehmetoglu-Gurbuz,  T.  and  Joshi,  A.  (2018)  ‘Recent  Advances  in  Zika  Virus  Vaccines’,  
Viruses, 10(11), p. E631. doi: 10.3390/v10110631. 
35 
 
Ghezzi, S. et al. (2017)   ‘Heparin  prevents  Zika  virus   induced-cytopathic effects in human neural 
progenitor  cells’,  Antiviral Research, 140, pp. 13–17. doi: 10.1016/j.antiviral.2016.12.023. 
Gourinat, A. C. et al. (2015)  ‘Detection  of  zika  virus  in  urine’,  Emerging Infectious Diseases, 21(1), 
pp. 84–86. doi: 10.3201/eid2101.140894. 
Grant, A. et al. (2016)  ‘Zika  Virus  Targets  Human  STAT2  to  Inhibit  Type  I  Interferon  Signaling’,  
Cell Host & Microbe. Cell Press, 19(6), pp. 882–890. doi: 10.1016/J.CHOM.2016.05.009. 
Guedes, D. R. et al. (2017)  ‘Zika  virus  replication  in  the  mosquito  Culex  quinquefasciatus  in  Brazil.’,  
Emerging microbes & infections. Nature Publishing Group, 6(8), p. e69. doi: 10.1038/emi.2017.59. 
Gulland,  A.  (2016)  ‘WHO  warns  of  risk  of  Zika  virus  in  Europe.’,  BMJ (Clinical research ed.). British 
Medical Journal Publishing Group, 353, p. i2887. doi: 10.1136/bmj.i2887. 
Hamel, R. et al. (2015)  ‘Biology  of  Zika  Virus  Infection  in  Human  Skin  Cells’,  Journal of Virology, 
89(17), pp. 8880–8896. doi: 10.1128/jvi.00354-15. 
Hasan, S. S. et al. (2017)  ‘A  human  antibody  against  Zika  virus  crosslinks  the  E  protein  to  prevent 
infection’,   Nature Communications. Nature Publishing Group, 8(14722), pp. 1–6. doi: 
10.1038/ncomms14722. 
van  Hemert,  F.  and  Berkhout,  B.  (2016)  ‘Nucleotide  composition  of  the  Zika  virus  RNA  genome  and  
its  codon  usage.’,  Virology journal. BioMed Central, 13(1), pp. 95–103. doi: 10.1186/s12985-016-
0551-1. 
Hennessey, M., Fischer, M. and Staples,  J.  E.  (2016)  ‘Zika  Virus  Spreads  to  New  Areas  - Region of 
the Americas, May 2015-January  2016’,  American Journal of Transplantation. John Wiley & Sons, 
Ltd, 16(3), pp. 1031–1034. doi: 10.1111/ajt.13743. 
Hersh, A. M., Gundacker, N. D. and Boltax, J. (2017)   ‘Zika-associated Shock and Multi-Organ 
Dysfunction’,  Annals of the American Thoracic Society. American Thoracic Society, 14(11), pp. 
1706–1708. doi: 10.1513/AnnalsATS.201612-988CC. 
Hill, M. E. et al. (2018)  ‘The  Unique  Cofactor  Region  of  Zika  Virus  NS2B–NS3 Protease Facilitates 
Cleavage   of   Key   Host   Proteins’,   ACS Chemical Biology, 13(9), pp. 2398–2405. doi: 
10.1021/acschembio.8b00508. 
Hills, S. L., Fischer, M. and Petersen,  L.  R.   (2017)   ‘Epidemiology  of  Zika  Virus   Infection’,  The 
Journal of Infectious Diseases, 216(suppl_10), pp. S868–S874. doi: 10.1093/infdis/jix434. 
Jain, R. et al. (2016)  ‘Structure  of  the  NS3  helicase  from  Zika  virus’,  Nature Structural and Molecular 
36 
 
Biology. Nature Publishing Group, 23(8), pp. 752–754. doi: 10.1038/nsmb.3258. 
Khandia, R.,  Munjal,  A.  and  Dhama,  K.  (2017)  ‘Consequences  of  Zika  Virus  Infection  During  Fetal  
Stage  and  Pregnancy  Safe  Drugs:  An  Update’,   International Journal of Pharmacology, 13(4), pp. 
370–377. doi: 10.3923/ijp.2017.370.377. 
Kmietowicz,   Z.   (2016)   ‘Questions   your   patients  may   have   about   Zika   virus’,  BMJ, p. i649. doi: 
10.1136/bmj.i649. 
Kuivanen, S. et al. (2017)   ‘Obatoclax,   saliphenylhalamide   and   gemcitabine   inhibit   Zika   virus 
infection in vitro and differentially affect cellular signaling, transcription and metabolism’,  Antiviral 
Research, 139, pp. 117–128. doi: 10.1016/j.antiviral.2016.12.022. 
Lanciotti, R. S. et al. (2008)   ‘Genetic   and   serologic   properties   of   Zika   virus   associated with an 
epidemic,  Yap  State,  Micronesia,  2007.’,  Emerging infectious diseases. Centers for Disease Control 
and Prevention, 14(8), pp. 1232–9. doi: 10.3201/eid1408.080287. 
Larocca, R. A. et al. (2016)  ‘Vaccine  protection  against  Zika  virus  from  Brazil.’,  Nature. NIH Public 
Access, 536(7617), pp. 474–8. doi: 10.1038/nature18952. 
Lazear, H.  and  Diamond,  M.  (2016)  ‘Zika  Virus  :  New  Clinical  Syndromes  and  Its  Emergence  in  the  
Western   Hemisphere’,   Journal of Virology, 90(10), pp. 4864–4875. doi: 10.1128/JVI.00252-
16.Editor. 
Lazear, H. M. et al. (2016)  ‘A  Mouse  Model  of  Zika  Virus  Pathogenesis’,  Cell Host & Microbe, 
19(5), pp. 720–730. doi: 10.1016/j.chom.2016.03.010. 
Lee, C. Y.-P.  and  Ng,  L.  F.  P.   (2018)  ‘Zika  virus:   from  an  obscurity   to  a  priority’,  Microbes and 
Infection. Elsevier Masson, 20(11–12), pp. 635–645. doi: 10.1016/J.MICINF.2018.02.009. 
Lee, I. et al. (2018)   ‘Probing   Molecular   Insights   into   Zika   Virus−Host   Interactions.’,   Viruses. 
Multidisciplinary Digital Publishing Institute  (MDPI), 10(5). doi: 10.3390/v10050233. 
Leung, J. Y. et al. (2008)  ‘Role  of  Nonstructural  Protein  NS2A  in  Flavivirus  Assembly’,  Journal of 
virology. American Society for Microbiology Journals, 82(10), pp. 4731–4741. doi: 
10.1128/jvi.00002-08. 
Li, A. et al. (2018)   ‘A   Zika   virus   vaccine   expressing   premembrane-envelope-NS1   polyprotein.’,  
Nature communications. Nature Publishing Group, 9(1), p. 3067. doi: 10.1038/s41467-018-05276-4. 
Li, C. et al. (2017)   ‘25-Hydroxycholesterol Protects Host against Zika Virus Infection and Its 
Associated   Microcephaly   in   a   Mouse   Model.’, Immunity. Elsevier, 46(3), pp. 446–456. doi: 
37 
 
10.1016/j.immuni.2017.02.012. 
Li, L. et al. (2008)  ‘The  Flavivirus  Precursor Membrane-Envelope Protein Complex: Structure and 
Maturation’,  Science, 319(5871), pp. 1830–1834. doi: 10.1126/science.1153263. 
Liang, Q. et al. (2016)  ‘Zika  Virus  NS4A  and  NS4B  Proteins  Deregulate  Akt-mTOR Signaling in 
Human Fetal Neural Stem Cells to Inhibit  Neurogenesis   and   Induce  Autophagy’,  Cell Stem Cell, 
19(5), pp. 663–671. doi: 10.1016/j.stem.2016.07.019. 
Lim, E. X. Y. et al. (2018)   ‘Mosquitoes   as   Suitable   Vectors   for   Alphaviruses.’,   Viruses. 
Multidisciplinary Digital Publishing Institute  (MDPI), 10(2), pp. 84–100. doi: 10.3390/v10020084. 
Ma, J. et al. (2018)   ‘Zika   Virus   Non-structural Protein 4A Blocks the RLR-MAVS   Signaling’,  
Frontiers in Microbiology. Frontiers, 9(1350), pp. 1–10. doi: 10.3389/fmicb.2018.01350. 
MacNamara,  F.  .  (1954)  ‘Zika  virus  :  A  report  on  three  cases  of  human  infection  during  an  epidemic  
of  jaundice   in  Nigeria’,  Transactions of the Royal Society of Tropical Medicine and Hygiene. No 
longer published by Elsevier, 48(2), pp. 139–145. doi: 10.1016/0035-9203(54)90006-1. 
Manangeeswaran, M. et al. (2018)   ‘ZIKA  virus   infection  causes   persistent   chorioretinal   lesions’,  
Emerging Microbes & Infections. Nature Publishing Group, 7(1), p. 96. doi: 10.1038/s41426-018-
0096-z. 
Mansuy, J. M. et al. (2016)  ‘Zika virus: high infectious viral load in semen, a new sexually transmitted 
pathogen?’,   The Lancet Infectious Diseases. Elsevier Ltd, 16(4), p. 405. doi: 10.1016/S1473-
3099(16)00122-5. 
Márquez-Jurado, S. et al. (2018)  ‘An  Alanine-to-Valine Substitution in the Residue 175 of Zika Virus 
NS2A Protein   Affects   Viral   RNA   Synthesis   and   Attenuates   the   Virus   In   Vivo’,   Viruses. 
Multidisciplinary Digital Publishing Institute, 10(10), p. 547. doi: 10.3390/v10100547. 
Mawson,  A.  R.  (2016)  ‘Pathogenesis  of  Zika  Virus-Associated  Embryopathy.’,  BioResearch open 
access. Mary Ann Liebert, Inc., 5(1), pp. 171–6. doi: 10.1089/biores.2016.0004. 
Meertens, L. et al. (2017)  ‘Axl  Mediates  ZIKA  Virus  Entry   in  Human  Glial  Cells  and  Modulates  
Innate  Immune  Responses’,  Cell Reports, 18(2), pp. 324–333. doi: 10.1016/j.celrep.2016.12.045. 
Merino-Ramos, T. et al. (2017)  ‘Antiviral  Activity  of  Nordihydroguaiaretic  Acid  and  Its  Derivative  
Tetra-O-Methyl  Nordihydroguaiaretic  Acid  against  West  Nile  Virus  and  Zika  Virus.’,  Antimicrobial 
agents and chemotherapy. American Society for Microbiology (ASM), 61(8), pp. e00376-17. doi: 
10.1128/AAC.00376-17. 
38 
 
Mier-Y-Teran-Romero, L. et al. (2018)  ‘Guillain-Barré syndrome risk among individuals infected 
with Zika virus: a multi-country  assessment.’,  BMC medicine. BioMed Central, 16(1), p. 67. doi: 
10.1186/s12916-018-1052-4. 
Miner, J. J. et al. (2016)  ‘Zika  Virus  Infection  during  Pregnancy  in  Mice  Causes  Placental  Damage  
and  Fetal  Demise’,  Cell, 165(5), pp. 1081–1091. doi: 10.1016/j.cell.2016.05.008. 
Miner,  J.  J.  and  Diamond,  M.  S.  (2017)  ‘Zika  Virus  Pathogenesis  and  Tissue  Tropism’,  Cell Host & 
Microbe, 21(2), pp. 134–142. doi: 10.1016/j.chom.2017.01.004. 
Monsalve, D. M. et al. (2017)   ‘Zika   virus   and   autoimmunity.   One-step   forward’,  Autoimmunity 
Reviews, 16(12), pp. 1237–1245. doi: 10.1016/j.autrev.2017.10.008. 
Mounce, B. C. et al. (2017)  ‘Curcumin  inhibits  Zika  and  chikungunya  virus  infection  by  inhibiting  
cell  binding’,  Antiviral Research, 142(1), pp. 148–157. doi: 10.1016/j.antiviral.2017.03.014. 
Muktar, Y., Tamerat, N. and Shewafera, A. (2016)  ‘Aedes  aegypti  as  a  Vector  of  Flavivirus’,  Journal 
of Tropical Diseases. OMICS International, 04(05), pp. 1–7. doi: 10.4172/2329-891X.1000223. 
Muller,  D.  A.  and  Young,  P.  R.  (2013)  ‘The  flavivirus  NS1  protein:  Molecular and structural biology, 
immunology,   role  in  pathogenesis  and  application  as  a  diagnostic  biomarker’,  Antiviral Research. 
Elsevier, 98(2), pp. 192–208. doi: 10.1016/J.ANTIVIRAL.2013.03.008. 
Munjal, A. et al. (2017)   ‘Advances   in   Developing   Therapies   to Combat Zika Virus: Current 
Knowledge and   Future   Perspectives’,   Frontiers in Microbiology, 8(1469), pp. 1–19. doi: 
10.3389/fmicb.2017.01469. 
Musso, D. et al. (2014)  ‘Potential  for  Zika  virus  transmission  through  blood  transfusion  demonstrated  
during an outbreak in French Polynesia, November 2013 to   February   2014’,   Eurosurveillance, 
19(14), pp. 14–16. doi: 10.2807/1560-7917.ES2014.19.14.20761. 
Musso, D. et al. (2015)  ‘Potential  sexual  transmission  of  zika  virus’,  Emerging Infectious Diseases, 
21(2), pp. 359–361. doi: 10.3201/eid2102.141363. 
Nambala, P. and Su, W.-C.  (2018)  ‘Role  of  Zika  Virus  prM  Protein  in  Viral  Pathogenicity  and  Use  
in   Vaccine   Development.’,   Frontiers in microbiology. Frontiers Media SA, 9, p. 1797. doi: 
10.3389/fmicb.2018.01797. 
Nowakowski, T. J. et al. (2016)  ‘Expression  analysis highlights AXL as a candidate zika virus entry 
receptor   in   neural   stem   cells’,   Cell Stem Cell. Elsevier Inc., 18(5), pp. 591–596. doi: 
10.1016/j.stem.2016.03.012. 
39 
 
Olagnier, D. et al. (2016)  ‘Mechanisms  of  Zika  Virus  Infection  and  Neuropathogenesis.’,  DNA and 
cell biology. Mary Ann Liebert, Inc., 35(8), pp. 367–72. doi: 10.1089/dna.2016.3404. 
Olson, J. G. et al. (1981)  ‘Zika  virus,  a  cause  of  fever  in  Central  Java,  Indonesia’,  Transactions of the 
Royal Society of Tropical Medicine and Hygiene. No longer published by Elsevier, 75(3), pp. 389–
393. doi: 10.1016/0035-9203(81)90100-0. 
Pardi, N. et al. (2017)   ‘Zika   virus   protection   by   a   single   low-dose nucleoside-modified mRNA 
vaccination.’,  Nature. NIH Public Access, 543(7644), pp. 248–251. doi: 10.1038/nature21428. 
Pascoalino, B. S. et al. (2016)  ‘Zika  antiviral  chemotherapy:  identification  of  drugs  and  promising  
starting points for drug discovery from an FDA-approved  library.’,  F1000Research. Faculty of 1000 
Ltd, 5, p. 2523. doi: 10.12688/f1000research.9648.1. 
Petersen, L. R. et al. (2016)  ‘Zika  Virus’,  New England Journal of Medicine. Edited by L. R. Baden, 
374(16), pp. 1552–1563. doi: 10.1056/NEJMra1602113. 
Plourde,  A.  R.  and  Bloch,  E.  M.  (2016)  ‘A  Literature  Review  of  Zika  Virus’,  Emerging Infectious 
Diseases, 22(7), pp. 1185–1192. doi: 10.3201/eid2207.151990. 
Rausch, K. et al. (2017)   ‘Screening   Bioactives   Reveals   Nanchangmycin   as   a   Broad   Spectrum  
Antiviral  Active   against  Zika  Virus.’,  Cell reports. NIH Public Access, 18(3), pp. 804–815. doi: 
10.1016/j.celrep.2016.12.068. 
Retallack, H. et al. (2016)  ‘Zika  virus  cell  tropism  in  the  developing  human  brain  and  inhibition  by  
azithromycin’,  Proceedings of the National Academy of Sciences, 113(50), pp. 14408–14413. doi: 
10.1073/pnas.1618029113. 
Reznik, S. E. and Ashby,  J.  C.  R.  (2017)  ‘Sofosbuvir:  an  antiviral  drug  with  potential  efficacy  against  
Zika   infection.’,   International journal of infectious diseases. The Author(s), 55, pp. 29–30. doi: 
10.1016/j.ijid.2016.12.011. 
Richard, A. S. et al. (2017)  ‘AXL-dependent infection of human fetal endothelial cells distinguishes 
Zika  virus  from  other  pathogenic  flaviviruses.’,  Proceedings of the National Academy of Sciences of 
the United States of America. National Academy of Sciences, 114(8), pp. 2024–2029. doi: 
10.1073/pnas.1620558114. 
Richner, J. M. et al. (2017)  ‘Vaccine  Mediated  Protection  Against  Zika  Virus-Induced Congenital 
Disease.’,  Cell. NIH Public Access, 170(2), p. 273–283.e12. doi: 10.1016/j.cell.2017.06.040. 
Saiz, J.-C. et al. (2018)   ‘Host-Directed Antivirals: A Realistic  Alternative   to   Fight   Zika  Virus.’,  
Viruses. Multidisciplinary Digital Publishing Institute  (MDPI), 10(9), p. E453. doi: 
40 
 
10.3390/v10090453. 
Saiz, J.-C. and Martín-Acebes,   M.   A.   (2017)   ‘The   Race   To   Find   Antivirals   for   Zika   Virus’,  
Antimicrobial Agents and Chemotherapy. American Society for Microbiology Journals, 61(6), pp. 
e00411-17. doi: 10.1128/AAC.00411-17. 
Sarwar,  M.  R.  and  Saqib,  A.  (2017)  ‘Zika  Virus  Infection  during  Pregnancy  and  its  Management’,  
Journal of MPE Molecular Pathological Epidemiology. iMedPub, 2(S1), pp. 1–6. Available at: 
http://molecular-pathological-epidemiology.imedpub.com/zika-virus-infection-during-pregnancy-
and-its-management.php?aid=17709 (Accessed: 9 January 2019). 
Saw, W. G. et al. (2017)  ‘Structural features of Zika virus non-structural proteins 3 and -5 and its 
individual  domains  in  solution  as  well  as  insights  into  NS3  inhibition’,  Antiviral Research. Elsevier, 
141(1), pp. 73–90. doi: 10.1016/J.ANTIVIRAL.2017.02.005. 
Shan, C., Muruato, A. E., et al. (2017)   ‘A   live-attenuated Zika virus vaccine candidate induces 
sterilizing  immunity  in  mouse  models.’,  Nature medicine. NIH Public Access, 23(6), pp. 763–767. 
doi: 10.1038/nm.4322. 
Shan, C., Ortiz, D. A., et al. (2017)  ‘Evaluation  of  a  Novel  Reporter  Virus Neutralization Test for 
Serological   Diagnosis   of   Zika   and   Dengue   Virus   Infection.’,   Journal of clinical microbiology. 
American Society for Microbiology Journals, 55(10), pp. 3028–3036. doi: 10.1128/JCM.00975-17. 
Sharma,  A.  and  Lal,  S.  K.  (2017)  ‘Zika  Virus: Transmission, Detection,  Control,  and  Prevention.’,  
Frontiers in microbiology. Frontiers Media SA, 8, p. 110. doi: 10.3389/fmicb.2017.00110. 
Sharp, T. M. et al. (2016)   ‘Zika   Virus   Infection   Associated   With   Severe   Thrombocytopenia.’,  
Clinical infectious  diseases  :  an  official publication of the Infectious Diseases Society of America. 
NIH Public Access, 63(9), pp. 1198–1201. doi: 10.1093/cid/ciw476. 
Shehu, N. Y. et al. (2018)  ‘Pathogenesis,  Diagnostic  Challenges  and  Treatment  of  Zika  Virus  Disease 
in   Resource‑limited   Settings’,   Nigerian Postgraduate Medical Journal, 25(2), pp. 67–72. doi: 
10.4103/npmj.npmj_36_18. 
Shiryaev, S. A. et al. (2017)   ‘Repurposing   of   the   anti-malaria drug chloroquine for Zika Virus 
treatment   and   prophylaxis’,   Scientific Reports. Nature Publishing Group, 7(15771), pp. 1–9. doi: 
10.1038/s41598-017-15467-6. 
da  Silva,  S.,  Martins,  D.  O.  S.  and  Jardim,  A.  C.  G.  (2018)  ‘A  Review  of  the  Ongoing  Research  on  
Zika  Virus  Treatment.’,  Viruses. Multidisciplinary Digital Publishing Institute (MDPI), 10(255), pp. 
1–18. doi: 10.3390/v10050255. 
41 
 
Simonin, Y. et al. (2017)  ‘Differential  virulence  between  Asian  and  African  lineages  of  Zika  virus’,  
PLOS Neglected Tropical Diseases. Edited by R. Rico-Hesse. Public Library of Science, 11(9), p. 
e0005821. doi: 10.1371/journal.pntd.0005821. 
Singh, P. K. et al. (2017)   ‘Zika   virus   infects   cells   lining   the   blood-retinal barrier and causes 
chorioretinal  atrophy  in  mouse  eyes’,  2(4).  doi:  10.1172/jci.insight.92340. 
Singleton, M. R., Dillingham, M. S. and Wigley,  D.  B.  (2007)  ‘Structure and Mechanism of Helicases 
and   Nucleic   Acid   Translocases’,   Annual Review of Biochemistry, 76(1), pp. 23–50. doi: 
10.1146/annurev.biochem.76.052305.115300. 
Song, H. et al. (2016)   ‘Zika  virus  NS1  structure   reveals  diversity  of electrostatic surfaces among 
flaviviruses’,  Nature Structural and Molecular Biology, 23(5), pp. 456–458. doi: 10.1038/nsmb.3213. 
Spiteri, G. et al. (2017)  ‘Surveillance  of  Zika  virus  infection  in  the  EU/EEA,  June  2015  to  January  
2017.’,   Euro   surveillance  : bulletin Europeen sur les maladies transmissibles = European 
communicable disease bulletin. European Centre for Disease Prevention and Control, 22(41). doi: 
10.2807/1560-7917.ES.2017.22.41.17-00254. 
Sreedharan,   J.   (2015)   ‘The  Zika  Virus:  A  new  Threat   from  mosquito’,  Scientia, 11(1), pp. 9–17. 
Available at: 
https://www.researchgate.net/publication/304058803_The_Zika_Virus_A_new_Threat_from_mosq
uito (Accessed: 4 January 2019). 
Stephen, P. et al. (2016)  ‘Structural  Insight  into  NS5  of  Zika  Virus  Leading  to  the Discovery of MTase 
Inhibitors’,   Journal of the American Chemical Society, 138(50), pp. 16212–16215. doi: 
10.1021/jacs.6b10399. 
Stettler, K. et al. (2016)  ‘Specificity,  cross-reactivity, and function of antibodies elicited by Zika virus 
infection.’,  Science (New York, N.Y.), 353(6301), pp. 823–6. doi: 10.1126/science.aaf8505. 
Tabata, T. et al. (2016)  ‘Zika  Virus  Targets  Different  Primary  Human  Placental  Cells,  Suggesting  
Two  Routes  for  Vertical  Transmission’,  Cell Host and Microbe. Elsevier Inc, 20(10), pp. 155–166. 
doi: 10.1016/j.chom.2016.07.002. 
Tan, C. W. et al. (2017)  ‘Polysulfonate  suramin  inhibits  Zika  virus  infection’,  Antiviral Research, 
143, pp. 186–194. doi: 10.1016/j.antiviral.2017.04.017. 
Tong, X. et al. (2018)  ‘Merimepodib,  an  IMPDH  inhibitor, suppresses replication of Zika virus and 
other   emerging   viral   pathogens’,   Antiviral Research, 149, pp. 34–40. doi: 
10.1016/j.antiviral.2017.11.004. 
42 
 
Turmel, J. M. et al. (2016)  ‘Late  sexual  transmission  of  Zika  virus  related  to  persistence  in  the  semen’,  
The Lancet, 387(10037), p. 2501. doi: 10.1016/S0140-6736(16)30775-9. 
Vinhaes, E. S. et al. (2016)  ‘Transient  Hearing  Loss  in  Adults  Associated  with  Zika  Virus  Infection’,  
Clinical Infectious Diseases. Oxford University Press, 64(5), p. ciw770. doi: 10.1093/cid/ciw770. 
Wang, A. et al. (2017)  ‘Zika  virus  genome  biology  and  molecular  pathogenesis’,  Emerging Microbes 
& Infections. Nature Publishing Group, 6(3), p. e13. doi: 10.1038/emi.2016.141. 
Wang, C. et al. (2017)  ‘Nuclear  import  inhibitor  N  -(4-hydroxyphenyl) retinamide targets Zika virus 
(ZIKV)  nonstructural  protein  5  to  inhibit  ZIKV  infection’,  Biochemical and Biophysical Research 
Communications, 493(4), pp. 1555–1559. doi: 10.1016/j.bbrc.2017.10.016. 
Wang, J. et al. (2017)  ‘A  Human  Bi-specific Antibody against Zika Virus with High Therapeutic 
Potential.’,  Cell. NIH Public Access, 171(1), p. 229–241.e15. doi: 10.1016/j.cell.2017.09.002. 
Wen, D. et al. (2018)   ‘N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut 
Invasion  by  Flaviviruses.’,  mBio. American Society for Microbiology (ASM), 9(1), pp. e00046-18. 
doi: 10.1128/mBio.00046-18. 
Winkler, C. W. et al. (2017)   ‘Sexual   and  Vertical   Transmission   of   Zika  Virus   in   anti-interferon 
receptor-treated Rag1-deficient  mice’,  Scientific reports, 7(7176), pp. 1–13. doi: 10.1038/s41598-
017-07099-7. 
Wong, S. J. et al. (2017)   ‘A   Multiplex   Microsphere   Immunoassay   for   Zika   Virus   Diagnosis’,  
EBioMedicine. Elsevier, 16(1), pp. 136–140. doi: 10.1016/J.EBIOM.2017.01.008. 
Xia, H. et al. (2018)  ‘An  evolutionary  NS1  mutation  enhances  Zika  virus evasion of host interferon 
induction.’,  Nature communications. Nature Publishing Group, 9(1), p. 414. doi: 10.1038/s41467-
017-02816-2. 
Xie, X. et al. (2017)  ‘Small  Molecules  and  Antibodies  for  Zika  Therapy’,  The Journal of Infectious 
Diseases. Oxford University Press, 216(suppl_10), pp. S945–S950. doi: 10.1093/infdis/jix406. 
Xin, Q.-L. et al. (2017)   ‘Quantitative  Proteomic  Analysis  of  Mosquito  C6/36  Cells  Reveals  Host  
Proteins  Involved  in  Zika  Virus  Infection.’,  Journal of virology. American Society for Microbiology 
Journals, 91(12), pp. e00554-17. doi: 10.1128/JVI.00554-17. 
Xu, M. et al. (2016)  ‘Identification  of  small-molecule inhibitors of Zika virus infection and induced 
neural  cell  death  via  a  drug  repurposing  screen.’,  Nature medicine. NIH Public Access, 22(10), pp. 
1101–1107. doi: 10.1038/nm.4184. 
43 
 
Yoon, K.-J. et al. (2017)  ‘Zika-Virus-Encoded NS2A Disrupts Mammalian Cortical Neurogenesis by 
Degrading Adherens Junction Proteins’,   Cell Stem Cell, 21(3), p. 349–358.e6. doi: 
10.1016/j.stem.2017.07.014. 
Yuan, S. et al. (2017)  ‘Structure-based discovery of clinically approved drugs as Zika virus NS2B-
NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo’,   Antiviral 
Research. Elsevier B.V., 145, pp. 33–43. doi: 10.1016/j.antiviral.2017.07.007. 
Zaidi, M. B. et al. (2018)  ‘Non-congenital  severe  ocular  complications  of  Zika  virus  infection.’,  JMM 
case reports. Microbiology Society, 5(6), p. e005152. doi: 10.1099/jmmcr.0.005152. 
Zhang, C. et al. (2017)  ‘Structure  of  the  NS5  methyltransferase from Zika virus and implications in 
inhibitor  design’,  Biochemical and Biophysical Research Communications. Academic Press, 492(4), 
pp. 624–630. doi: 10.1016/J.BBRC.2016.11.098. 
Zhang, R. et al. (2016)  ‘A  CRISPR  screen  defines  a  signal  peptide processing pathway required by 
flaviviruses.’,  Nature. NIH Public Access, 535(7610), pp. 164–8. doi: 10.1038/nature18625. 
Zmurko, J. et al. (2016)  ‘The  Viral  Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent 
Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse 
Infection  Model.’,  PLoS neglected tropical diseases. Public Library of Science, 10(5), p. e0004695. 
doi: 10.1371/journal.pntd.0004695. 
 
  
44 
 
CHAPTER 3: COMPUTATIONAL METHODOLOGY 
1 Introduction 
Molecular modelling is the science that explores chemical and biological phenomena in terms of the 
properties of the constituent atoms and molecules (Schmidt, Bergner and Schwede, 2014). It connects 
the living world of biology with the inanimate world of chemistry and physics by analyzing the 
structure and properties of atoms and molecules based on universal laws of physics (Hinsen, 2000). 
Molecular modelling has immense practical use particularly in the fields of materials research, drug 
design and discovery, computational chemistry and computational biology by studying biological and 
chemical systems of various sizes (Redhu and Jindal, 2013).  
Experimentation can appropriately provide the biochemical interactions through which a drug 
substance triggers its pharmacological effect in a biological system, however, an afternoon on the 
computer can save six months in the lab and labor costs. At present, molecular modelling is an integral 
component of pharmaceutical lead discovery (Goldbeck, 2012).  
Rational drug design is a multidisciplinary approach pertaining to the process of using knowledge of 
a biological target to discover novel pharmaceutical compounds (Y. Wang et al., 2015). Usually, the 
compound is a small molecule that influences the biomolecule it binds to, either via activation or 
inhibition, causing a therapeutic effect. These small molecules are designed to be complimentary in 
charge and shape to the pocket of the biological target it binds to, to ensure it binds with high affinity 
(Yu and MacKerell, 2017). The rational drug design approach comprises of three main disciplines: 
computational chemistry, information technology and structural biology; and may be split into two 
main categories, namely, the lead discovery and optimization method, and the compounds’  
druggability prediction method (Y. Wang et al., 2015). Computational methods that correspond to 
these approaches include virtual screening, drug target prediction, molecular docking, three-
dimensional quantitative structure-activity relationship (3D-QSAR) analyses, active vs allosteric site 
modification and scaffold hopping (Zheng et al., 2013). 
Molecular modelling may be described as a three-step process. The first step involves the selection 
of  a  model  to  define  a  system’s   inter- and intra- molecular interactions (Redhu and Jindal, 2013). 
Molecular modelling techniques can broadly be divided into two groups, namely, classical and 
quantum mechanics (QM) (Sutcliffe and Woolley, 2012). Classical mechanics, or Newtonian 
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mechanics, consider molecules rather crudely, like atoms as balls and bonds as springs, and describes 
the motions of macroscopic objects (Chow, 2013). Conversely, QM considers the probability of an 
electron being at a location without having a precise position of atoms or bonds (Quesne, Borowski 
and De Visser, 2016). Quantum mechanical techniques can be broadly divided into two categories, 
namely, semi-empirical and ab initio methods (Ballentine, 2014). Semi-empirical methods involve a 
significant amount of parameterization using parameters extracted from experimental data 
(Christensen et al., 2016).  Ab  initio  methods  on  the  other  hand  are  considered  theoretically  “pure”  in  
the sense that they do not depend solely on experimental measurements (Pokluda et al., 2015).   
The second step involves the application of molecular dynamics to calculate the energies of atoms 
and molecules within the system. The final step involves the analysis of the calculation, as well as the 
verification of the calculation (Redhu and Jindal, 2013). 
The chapter herein appropriately expands on the techniques of molecular modelling/computational 
chemistry utilized in this study. 
 
2 Quantum Mechanics 
In the 1920s, QM was pioneered by physics experts Werner Karl Heisenberg, Max Born and 
Wolfgang Ernst Pauli at a German university (Born, Elsasser and Anderson, 1981). Quantum 
mechanics is a basic physical theory that defines the electrons, atoms and photons of nature at a 
microscale. It also expresses the behavior of these minute units much differently from that seen at 
greater scales (Aerts, 2014).   
Theoretical chemistry and QM can be applied to biological entities and challenges, to provide new 
understandings into the electronic nature of biological systems (Merz, 2014). Various biological 
processes involve energy conversion that are naturally quantum mechanical, including proton and 
electron transfer, light absorption, excitation energy transfer and chemical reactions (McConnell, Li 
and Brudvig, 2010;;  Sjulstok,  Olsen  and  Solov’Yov,  2015;;  Brookes,  2017).  
Analysis of biological systems using QM involves mapping the electrons that constitute molecules in 
a 3D space (Sjulstok,  Olsen  and  Solov’Yov, 2015; Shen, Wu and Yang, 2016). The Schrödinger 
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equation is a fundamental mathematical model in QM, as is the Born-Oppenheimer approximation 
theory in molecular systems (Schrödinger, 1926; Nelson, 1966; Brambilla et al., 2018). 
2.1  The Schrödinger Equation 
In 1913, the Danish physicist Niels Bohr proposed that the electron can circle the nucleus only in 
permitted circular paths, called orbitals (Bohr, 1913). A photon is emitted when an electron falls to a 
lower energy level (closer to the nucleus) and a photon is absorbed when an electron jumps to a higher 
energy level (Figure 3.1). However, his model could not explain the thousands of atoms existing with 
more than one electron, nor did it explain the chemical behaviors of atoms (Kragh, 2012).  
 
Figure 3.1 The Niels Bohr Model (1913) demonstrating the absorption and emission of photons as 
electron move to higher/lower energy levels (n) (Prepared by Author). 
In 1926, Austrian expert in physics, Erwin Schrödinger, built   on  Bohr’s  model  by  presenting   the 
quantum theory that describes the model in a mathematical sense based on probability, as it is 
impossible to know the exact position and momentum of an electron simultaneously (Figure 3.2) 
(Schrödinger, 1926).  
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Figure 3.2 Schrödinger’s  Quantum  Mechanical  Model  (1926)  demonstrating  orbitals  as  differently 
shaped  “lobes”  where  electrons  are  probably  found  (Prepared  by  Author). 
Schrödinger’s   wave   equation considers all matter, including electrons, as waves and contains 
quantum numbers that specify the properties of atomic orbitals and properties of electrons in orbitals.  
The Schrödinger equation is as follows: 
𝐇𝛙 = 𝐄𝛙        (1) 
Where,  
H Hamiltonian operator (includes derivatives regarding atom location) 
E System’s  energy  “eigenvalues” 
Ψ Wave function (normalized, continuous, anti-symmetric and single valued) 
 
𝐇 = 𝐓+ 𝐕       (2) 
Where, 
 H = ൤− ୦
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T Kinetic energy of atom 
V Total potential energy of atom 
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The height of complexity of the Schrödinger equation is simplified by the Born-Oppenheimer 
approximation theory due to the immense number of atoms in molecular systems (Sherrill, 2005; 
Barde et al., 2015). 
2.2 The Born-Oppenheimer Approximation Theory  
A year after Schrödinger proposed the quantum theory, the physicists, Julius Robert Oppenheimer 
and Max Born presented the Born-Oppenheimer approximation that assumes that the motion of 
electrons and atomic nuclei in a molecule can be separated (Born and Oppenheimer, 1927). The theory 
considers a constant kinetic energy of the nucleus while solving for that of electrons. Nuclei weigh 
more than electrons, thus the difference in their velocities make them applicable for using the Born-
Oppenheimer approximation theory (Brambilla et al., 2018). 
The wave function is as follows: 
𝛙(𝐫𝐞𝐥𝐞𝐜) =   𝛙(𝐫𝐞𝐥𝐞𝐜)  (𝛙(𝐫𝐧𝐮𝐜𝐥)        (4) 
Eq 3.2.1 is converted:  
𝑯𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜) =   𝑬𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜)       (5) 
Where, 
HEN Difference between terms based activity to fixed nuclear positions (VNN) or their 
activity to the non-fixed electron positions. 
 
(𝐇𝐞𝐥 + 𝐕𝐍𝐍)  𝛙(𝐫𝐞𝐥) =   𝐄𝐄𝐍𝛙(𝐫𝐞𝐥)       (6) 
Where, 
 EEN Fixed nuclear and fluctuating electron co-ordinates. 
 
The electronic movements within a molecule is explained by the Schrödinger equation, while ground 
electronic states are more accurate using the Born-Oppenheimer approximation. Fixed positions of 
electrons can be analyzed once the equation is solved to construct a potential energy surface (PES) 
and curve (Lewars, 2011). 
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2.3 Potential Energy Surface 
The PES can be calculated using clamped-nuclei electronic structure calculations that arise from the 
Schrödinger equation and Born-Oppenheimer approximation. Since an electrons position varies 
according to that of the nucleus, the PES is considered as the probability of collision of an atom’s 
motion within a molecule. Nuclear clusters of high energy are indicated by high potential energy 
regions, while nuclear arrangements of low energy are shown by low energy regions. This becomes 
useful in the applications of computational chemistry when classifying conformations of the lowest 
energy state (Sutcliffe and Woolley, 2013).  
 
3 Molecular Mechanics 
Molecular mechanics (MM), also known as force field methods, are used for modelling of molecular 
systems by assuming the validity of the Born-Oppenheimer approximation theory. Force fields are 
applied  to  analyze  a  system’s  potential  energy  as  a  function  of  nuclear arrangements (Cornell, Howard 
and Kollman, 1991). Molecular mechanics, which applies classical Newtonian mechanics, is 
applicable for the analysis of complex and large biological systems containing more than thousands 
of atoms (Kostal, 2016). Protein-ligand complexes that are simulated using MM techniques yield free 
energy estimates, which are efficient, precise, consider solvation effects, as well as ligand and protein 
flexibility (Huang et al., 2006). 
Computer aided drug design is makes use of 3D models of biological targets, such as proteins. Even 
though QM is suitable for restrained studies on straightforward models of binding sites within proteins 
and for analyzing the properties of isolated drug-like molecules, it is generally required to likewise 
run simulations on the entire protein solvated in water when utilizing CADD (Vanommeslaeghe et 
al., 2014). Despite innovative attempts to apply semi-empirical methods to achieve this (Liu et al., 
2001), there are weaknesses of semi-empirical energy functions that place strict constraints on the 
timescale of the simulation.  
For these reasons, MM force fields are the preferred approaches for protein dynamics, which resemble 
the QM energy surface with a model of classical mechanics, thus making it inexpensive with respect 
to molecular systems that have thousands of atoms. Moreover, a fairly precise description of 
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dispersion forces is provided by MM potential energy functions, which present QM approaches only 
begin improving at higher theoretical levels (Lu et al., 2016). 
3.1 Potential Energy Function 
The potential energy of a system is calculated using the potential energy function (PEF) of MM. The 
PEF is described as the energy of a force field used to parameterize a molecular system, which is 
governed by a set of equations that also provide constituent atom types of a molecule (Golden and 
Olsen, 2008). 
The total potential energy consists of the extended sum of each potential intra- and inter- molecular 
constituents, which include: 
1. Bond stretching (between directly bonded atoms) 
  𝐄𝐫 =   ∑𝐊𝐫(𝐫 − 𝐫𝟎)𝟐     (7) 
2. Angle bending (atoms bounded to same central atoms) 
𝐄𝛉 =   ∑𝐊𝛉(𝛉 − 𝛉𝟎)𝟐     (8) 
3. Bond torsion 
 𝐄𝛟 =   ∑𝐊𝛟[𝟏 + 𝐜𝐨𝐬(𝐧𝛟 −𝛟𝟎)]   (9) 
4. Non-bonded interactions (van der Waals and electrostatic) 
𝐄𝐧𝐛 = ൤∑∑൬
𝐀𝐢𝐣
  𝐫𝐢𝐣𝟏𝟐
− 𝐁𝐢𝐣
𝐫𝐢𝐣𝟔
  ൰൨ +   ൤∑∑൬𝐪𝐢𝐪𝐣
𝐃𝐫𝐢𝐣
  ൰൨    (10) 
 
Where,  
Kr Bond force constant 
Kθ Angle force constant 
Kϕ Dihedral angle force constant 
ro Equilibrium distance 
51 
 
θo Equilibrium angle 
ϕo Equilibrium phase angle 
rij Distance 
Aij, Bij van der Waal parameters 
D Molecular dielectric constant 
qi, qj:  Charge points 
 
According  to  the  “ball  and  spring”  model,  atoms  are  considered balls or spheres with radii and bonds 
are considered springs (Figure 3.3). Therefore, the final potential energy function equation is: 
𝐄𝐭𝐨𝐭𝐚𝐥 =   𝐄𝐫 + 𝐄𝛉 + 𝐄𝛟 + 𝐄𝐧𝐛   (11) 
 
 
Figure 3.3 Graphical  representation  of  “ball and spring” model describing potential energy function 
and corresponding potential energy diagram (Prepared by Author). 
Force fields are mathematical equations that  explain   the   reliance  of  a  system’s  energy  on   the  co-
ordinates if its particles. It contains a set of parameters achieved from QM calculations or 
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experimental data and an analytical form of potential energy between atoms. Various force fields of 
different complexities for different systems exist in literature (González, 2011).  
Some of the most popular force fields include Chemistry at HARvard Macromolecular Mechanics 
(CHARMM) (Brooks et al., 1983), Assisted Model Building with Energy Refinement (AMBER) 
(Sprenger, Jaeger and Pfaendtner, 2015), Energy Calculation and Dynamics (ENCAD) (González, 
2011), GROningen Molecular Simulation (GROMOS) (Vlachakis et al., 2014) and All-atom 
Optimized Potentials for Liquid Simulations (OPLS-AA) (Siu, Pluhackova and Böckmann, 2012). 
Studies carried out in the following chapters of this thesis utilized the harmonic AMBER force field 
to parameterize molecular systems since AMBER was designed for nucleic acids and proteins 
calculation (Case et al., 2014). 
 
4 Molecular Dynamics 
The principal simulation techniques that exist include molecular dynamics and Monte Carlo. Monte 
Carlo (MC) simulations that use computational algorithms to yield results that depend on replicated 
randomized sampling, which was initially developed in 1955 by Enrico Fermi, John Pasta, Stanislaw 
Ulam and Mary Tsingou (Fermi et al., 1955). Then in 1957, Berni Julian Alder and Tom Everett 
Wainwright developed a liquid dynamic simulation method that analyzed interactions between hard 
spheres (Alder and Wainwright, 1959), followed by J. B. Gibson, A. N. Goland, M. Milgram, and G. 
H. Vineyard in 1960 who simulated radiation damage (Gibson et al., 1960). Aneesur Rahman then 
went on to publishing milestone simulations atoms of liquid argon in 1964 (Rahman, 1964). 
Molecular dynamics (MD) simulations are more useful than MC simulations in the sense that MD 
provides dynamical features of the system. These include rheological properties, transport co-
efficients, spectra and time-based reactions to perturbations (Allen, 2004). Moreover, incomparable 
properties of biological phenomena from atom to organism level can be explained by MD simulations. 
The essential insight of living organisms are being improved by MD simulations, from drug 
development to treat diseases to creation of innovative materials that interact with biological systems 
and naturally replenishable energy sources (Perilla et al., 2015). This simulation technique is 
extensively applied in experimental approaches such as the determination of nuclear magnetic 
resonance (NMR) structure and X-ray crystallography (Karplus and McCammon, 2002). 
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The Newtonian equation of motion of atoms is integrated and determined in the mathematical 
algorithms of MD simulations, which allow both kinetic energy and thermodynamic properties to be 
analyzed (González, 2011). Molecular dynamics simulations are implemented to identify the 
properties and motions of groups of atoms and molecules with respect to the 
interatomic/intermolecular interactions and their structures (Hollingsworth and Dror, 2018). The pre-
requisite initial conditions of atoms include the positions and velocities of every atom, a suitable force 
field to characterize interatomic forces, and applied boundary conditions. 
The equation of motion may be solved: 
𝐅𝐢 =   𝐦𝐢
𝐝𝟐𝐫𝐢(𝐭)
𝐝𝐭𝟐
        (12) 
Where, 
 ri(t) Atomic position vector of ith atom 
 t Time 
 mi Mass of ith atom 
 Fi Interacting force on ith atom 
 
Basically, MD simulations comprise of four continuous stages that are reiterated to produce a 
trajectory. The first stage involves defining the co-ordinates of each atom, interatomic bond 
characteristics and atom acceleration. The second stage is the calculation of potential energy of each 
atom. The third stage solves the equation of motion by applying the energy calculations from stage 
2, and the fourth stage involves capturing the altered atomic co-ordinates and the new state of the 
system, for the cycle to restart from stage one. Upon generation of a complete trajectory, the time-
evolution of the system can be analyzed quantitatively (Jakobsson, 2001). 
4.1 Molecular Dynamics Post Analyses 
The MD trajectories are a sequence of snap shots or system coordinates over the simulation period, 
characterized by velocity vectors and position. Trajectories describe the time evolution of the system 
in phase space (Devadoss and Raj, 2014). Certain conditions must be met before selecting analytical 
software. A program ought to have diverse analysis options, rapid processing software should be 
built-in to hold large quantities of data, and visualization software must be able to generate high 
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quality video clips and snapshots of trajectories (Likhachev, Balabaev and Galzitskaya, 2016). The 
type of the MD study will determine post-analyses that should be carried out, although, the creation 
of new graphical systems must be substantiated by quantifiable assessment. 
For the study herein, post analyses are fundamental in the determination of the dynamic structural 
arrangements, flexibility, energetics and stability of the biomolecular system, the characteristics of 
the ligand binding interactions of the system and the thermodynamic energy fluctuations throughout 
the trajectory of the system. 
4.1.1 Systems Stability 
Convergence – The acquisition of a sufficient number of phase points may be defined as convergence. 
Protein unfolding involves dynamic changes of bond types and vibration of bond angles, which may 
be described by convergence. When a molecular system reaches equilibrium and illustrates a final 
dynamic and conformational plateau, the MD trajectory is considered accurate and reproducible. The 
protein-ligand system shows energetically constant conformations in this area of stability (De 
Simone, Mote and Veglia, 2014). 
Root-mean-square deviation (RMSD) – To compare findings from different MD trajectories on the 
same molecule, the RMSD between the combined averaged structures of the trajectories must be 
determined (Dixit, Ponomarev and Beveridge, 2006). The deviation of two static structures of a single 
trajectory with spatial differences can be measured using RMSD, whose trajectory is defined as: 
   𝐑𝐌𝐒𝐃 =  ൬∑ (𝐑𝐢ି𝐑𝟏
𝟎)𝟐𝐍
𝐍
൰
𝟏
𝟐
     (13) 
Where, 
N Total number of atoms in the system  
Ri Vector position of the Cα atom of the ith atom in the reference conformation- 
calculated after aligning the structure to the initial conformation (O) using the least 
square fitting 
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The mean RMSD is determined by dividing the average by the number of frames in each trajectory, 
which can be calculated for the receptor, ligand and complex of a system (Kufareva and Abagyan, 
2011; Schreiner et al., 2012).  
Radius of gyration (RoG) – A  protein’s  RoG  is  described  as  the  root-mean-square distance between 
atoms and their collective gravitational center, which estimates compactness of a protein along a 
trajectory. The RoG of a system is defined by the following reaction:  
𝐫𝟐𝐠𝐲𝐫 =    (∑ 𝐰𝐢
𝐧
𝐢ష𝟏 (𝐫𝐢ି𝐫ష)𝟐)
∑ 𝐰𝐢𝐧𝐢ష𝟏
    (14) 
Where, 
 ri  Position of the ith atom 
r Center weight of the ith atom 
 
The mean RoG is calculated by dividing the average by the number of frames in a trajectory (Stepto 
et al., 2015). 
4.1.2 Thermodynamic Free Binding Energy Calculations 
Free binding energy (FBE) calculations that incorporate entropic and enthalpic contributions 
substantiate protein-ligand binding mechanisms. Estimation of FBE allows for the generation of more 
approaches and algorithms. Some include molecular docking calculations, thermodynamic 
integration, linear integration energy and free energy perturbation (Du et al., 2016).  
The MM energies integrated with Poisson–Boltzmann or generalized Born surface area (MM/PBSA 
and MM/GBSA) continuum solvation approaches are common techniques to evaluate the FBE of 
small molecules or ligands to large biological molecules. The MM/GBSA and MM/PBSA approaches 
are established on MD simulations of protein–ligand complexes (Figure 3.4), therefore, they are 
transitional in computational effort and precision between severe alchemical perturbation methods 
and empirical scoring (Genheden and Ryde, 2015). 
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Figure 3.4 Illustration of the thermodynamic cycle in MM/PBSA or MM/GBSA calculations. The 
addition of the gas-phase configurational entropy and energy and the difference in solvation free 
energies between the ligand and complex results in the FBE results. The blue surface signifies the 
solvent (Prepared by Author). 
The ultimate goal of drug design is to discover novel compounds that bind to a molecular receptor 
(Genheden and Ryde, 2015). Basically, binding may be described as: 
     L + R ® RL 
Where, 
 L Ligand 
 R Receptor (protein or other biomacromolecule) 
 
The affinity with which the ligand binds to the receptor is known as the FBE or ΔGbind, which is 
calculated using the MM/GBSA and MM/PBSA approaches for a protein system (ligand, receptor 
and complex) is represented as: 
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ΔGbind = Gcomplex − Greceptor −  Gligand     (15) 
ΔGbind = Egas + Gsol – TS      (16) 
Egas = Eint + EvDW + Eele      (17) 
Gsol = GGB + GSA       (18) 
GSA =  γSASA         (19) 
Where, 
Eele Electrostatic potential energy from Coulomb forces 
Egas  Gas-phase energy (based on FF14SB force field terms) 
Eint Internal energy 
EvdW Van der Waals energy 
Gsol Solvation free energy 
GGB Polar solvation energy 
GSA Non-polar solvation energy 
S Total entropy of solute 
SASA Solvent accessible surface area (water probe radius of 1.4 Å) 
T Total entropy of temperature 
 
The MM/GBSA and MM/PBSA methods are quantifiable analyses of ligand-protein binding affinity 
and thus can improve docked molecular structures (Chen et al., 2018). 
4.1.3 Conformational Fluctuations of the System 
Root-mean-square fluctuation (RMSF) – Calculates alpha-carbon atomic fluctuations  of  a  protein’s  
constituent amino acid residues based on the changes in the structure of the protein along the 
trajectory of the system. This allows for the determination of protein flexibility based on calculations 
(Bornot, Etchebest and de Brevern, 2011). Standardized RMSF is calculated using the following 
equation: 
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   𝐬𝐑𝐌𝐒𝐅 =    (𝐑𝐌𝐒𝐅𝐢ି𝐑𝐌𝐒𝐅)
𝛔  (𝐑𝐌𝐒𝐅)
     (20) 
Where, 
 RMSFi  RMSF of the ith residue 
 σ  (RMSF) RMSF’s  standard  deviation 
 
4.1.4 Dynamic Cross Correlation Matrices 
Dynamic Cross Correlation Matrices (DCCM) can quantifies the correlation coefficients of 
interatomic motions. The correlation coefficient ranges from -1 (negative/anti-correlated motion) to 
+1 (positively correlated motion) (Kasahara, Fukuda and Nakamura, 2014). The equation below is 
used to describe DCCM: 
     𝐂𝐢𝐣 =   
ழ𝚫𝐫𝐢.𝚫𝐫𝐣வ
ቀழ𝚫𝐫𝐢
𝟐வழ  𝚫𝐫𝐣
𝟐வቁ
𝟏
𝟐
     (21) 
Where, 
Cij  Cross-correlation  coefficient (-1 to +1) 
i ith residue 
j jth residue 
Δri  ith displacement vector  
Δrj jth displacement vector 
 
Protein-ligand binding results in movements of amino acids within proteins, making DCCM a useful 
tool (Kasahara, Fukuda and Nakamura, 2014; Devnarain and Soliman, 2018).  
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5 Other Computer-Aided Drug Design Techniques Utilized in the Study 
5.1 Molecular Docking 
Molecular docking is one of the most well-known computational methods in drug design. It applies 
several techniques to predict the conformation of a complex and binding affinity between a ligand 
and receptor, which demonstrate the most common application of docking (Alonso, Bliznyuk and 
Gready, 2006; Meng et al., 2011). Several studies have also presented drug delivery/protein-protein 
complexes such as aptamers and nanoparticles (de Ruyck et al., 2016). 
Molecular docking encompasses two key steps. The first step involves evaluating different ligand 
conformations  in  a  protein’s  binding  pocket using different algorithms. The “lock and key”  analogy 
regards the ligand as a rigid key and receptor as a rigid enzyme, where only the appropriately sized 
key (ligand) fits into the key hole (binding site) of the lock (enzyme) to open it (elicit a reaction). The 
ligand can also be regarded as flexible either via simulation-based or random techniques. The flexible 
ligand technique is the preferred approach since the ligand fits more accurately into the protein. The 
second step involves the use of a scoring function to rank the different ligand-enzyme configurations. 
The scoring algorithm may be based on MM force fields, previous binding affinities or statistically 
chosen contacts (Du et al., 2016) 
For the purpose of this study, docked complex were substantiated with MD simulations to show that 
all ligands were stable in the binding pockets of the enzymes. 
5.2 Virtual Screening 
Virtual screening (VS) is an indispensable tool in drug design and discovery since it allows 
researchers to explore through small molecule databases using knowledge of biological targets it may 
bind to (Pyzer-Knapp et al., 2015). The VS method enables sorting of large databases of small 
molecules to a more realistic figure and provides hits that are most likely to qualify lead compounds. 
This approach applies multiple filters to classify biologically active alternatives to existing drugs on 
the basis that molecules of comparable structural are likely to have similar characteristics and features 
(Lionta et al., 2014; Cele, Ramesh and Soliman, 2016).  
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There are two sub-categories of VS, namely the ligand-based and structure-based VS approaches. 
Ligand-based VS works with compounds that are known to interact with a biological target to 
generate libraries of small molecules (Ripphausen, Nisius and Bajorath, 2011). Structure-based VS 
recognizes dynamically favorable ligand binding affinities to a binding site of a biological target, 
allowing for an improved understanding of the binding site and interactions between the ligand and 
enzyme. This category of VS filters compounds from a massive library for molecular docking (Lionta 
et al., 2014). 
In this study, pharmacophore-based VS is applied since it has shown to have various advantages in 
the identification and optimization of lead compounds. The method utilizes pharmacophoric moieties 
based on functional groups of an existing inhibitor, such as aromatics, cations, hydrogen bond 
acceptors and donor, and cations. These pharmacophoric moieties are set as the standards or templates 
to identify a few hit compounds in extensive libraries (Cele, Ramesh and Soliman, 2016; Munir, 
Azam and Mehmood, 2016). 
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Abstract 
The magnetism of the Zika virus to neuronal cells proves to be one of the major concerns in 
the development of effective inhibitors. Although the blood-brain barrier limits the entry of 
most drugs, tailored small molecule inhibitors and drug delivery systems are currently being 
designed to overcome this obstacle. We have identified the core challenge to be addressed - 
blood-brain barrier permeability - and provided insight into strategies that can be used to 
improve drug delivery to the brain. We have compiled drugs that have previously been 
proposed as potential Zika virus inhibitors and classified chemical features of those drugs, 
which influence blood-brain barrier permeability. Thereafter, we created a route map to 
design drugs with improved blood-brain barrier permeability. An alternative approach using 
drug delivery systems to transport membrane-impermeable Zika virus inhibitors to the brain 
is also proposed, along with descriptions of known drug carriers. This review provides 
information for further research toward inhibitors of Zika virus.  
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The Tale of Zika Virus  
The Zika virus (ZIKV), a mosquito-borne virus, belongs to the Flaviviridae family and has similar 
characteristics to other flaviviruses such as Dengue virus, West Nile virus and Japanese Encephalitis 
virus.1 The rapid disseminating potential and repercussion in humans are attributed to the various 
modes of transmission, primarily through the bite of an infected Aedes aegypti mosquito.2 The ZIKV 
is also transmitted through sexual intercourse 3, blood transfusions 4 and from a mother to child 
perinatally.5 
The ZIKV was originally isolated in Uganda in the Zika forest in 1947.6 For nearly 7 decades 
thenceforth, sporadic infections caused by ZIKV were reported in several countries worldwide. These 
include more equatorial countries of Africa such as Tanzania, Egypt, Kenya, Nigeria, Central African 
Republic, and Gabon; some Asian countries including Pakistan, India, Malaysia, Thailand, the 
Philippines and Indonesia; and many islands in the Pacific Ocean.7–10 The most devastating and highly 
publicized outbreak that captured  the  world’s  attention  occurred  in  Brazil  in  2015, which triggered 
global panic as it rapidly spread across America.11 In 2016, the ZIKV broadened its geographic 
spectrum to North American Florida and Texas where the infection was locally transmitted.10 
There has been prior ambiguity regarding the diagnosis of ZIKV, as its infection manifests similarly 
to common colds and other flavivirus infections.12 These symptoms include fever, headaches, 
conjunctivitis, joint pain, muscle pain and skin rash.13,14 The speculation of ZIKV infection depends 
on its manifestation and history of mosquito bites.12 The ZIKV is detectable in bodily fluids such as 
saliva 15, semen 16,17, urine 18 and amniotic fluid 19, which can be verified in the laboratory.20 The 
various modes of transmission of ZIKV make the human body highly susceptible to infection. When 
ZIKV enters the body through an infected female mosquito bite, the infection manifests as a rash in 
the vicinity of the bite.9 This occurs due to the release of virions into dermal and epidermal layers of 
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the skin, where ZIKV is introduced to the bloodstream and advances to the lymph nodes to replicate 
and cause viremia.21 
The ZIKV is an enveloped icosahedral virus that is made up of a single-stranded, positive-sense 
genome. The enveloped virion comprises of an 11 kilobase genome consisting of 10,794 nucleotides 
encoding 3,419 amino acids.22 The  open  reading  frame  (ORF)  of  the  5’  and  3’  untranslated  region  
(UTR) encodes a polyprotein that is cleaved into three structural proteins, being the capsid (C), 
precursor membrane (prM), and envelope (E).23 Seven non-structural (NS) proteins are also found in 
this assembly, namely, NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 (largest viral protein).24 The 
genomic protein organization is   5’-C-prM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3’   25 and 
contains an m7gpppAmpN2 at  the  5’  end  and  lacks  a  poly-A  tail  at  the  3’  end.26 A highly conserved 
90-120-nucleotide  strand  is  situated  close  to  the  3’end  that  develops  into  a  hairpin  loop  and  is  vital  
for replication.26,27 Of the non-structural proteins, NS1, NS3 and NS5 are highly conserved whereas 
the NS2a, NS2b, NS4a and NS4b are small and hydrophobic.24 Of critical importance is the 
proteolytic cleavage of prM to produce the pr and M protein by furin-like protease located in the 
trans-Golgi network during the egress of the particles as this promotes maturation of virions.28 
The ramifications of ZIKV infections have heavily impacted thousands worldwide, particularly in 
newborns, since ZIKV-infected pregnant women have given birth to babies with congenital brain 
abnormalities, predominantly microcephaly and intracranial calcification.13 The ZIKV infection has 
also been shown to elicit Guillain–Barré Syndrome, which ultimately advances to paralysis and 
death.29 
Studies have shown tropism of the ZIKV for cells of the nervous system, whereby entry into neuronal 
and endothelial cells occur via AXL receptors situated on the cell surface.30–32 The ZIKV has also 
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affected retinal cells that line the blood-retinal barrier (i.e. retinal pigment epithelium and retinal 
endothelium) in mice, which also express AXL receptors. This presents as conjunctivitis.33 
 
Blood-Brain Barrier Permeability as a Core Challenge in ZIKV Therapy 
Treating the symptoms of ZIKV will not yield permanent results; hence nipping the cause at the bud 
may be the best route to a solution. The blood-brain barrier (BBB) and placental barrier are 
surrounded by lipophilic membranes and junctions, through which only certain compounds can 
permeate.34 It has been shown that the placenta is permissive to most drugs as it serves to allow for 
the exchange of nutrients for its biological purpose.35 The ZIKV can penetrate these membranes, 
which is evident by its downstream pathogenic effects in fetal nervous systems.13,26,29,30 
 
The specific characteristics of a compound govern the method by which it is transported across the 
BBB, or whether or not it is transported at all. Compounds that have surface hydrogen bonds 
(hydrophilic compounds) are only permissive through tight junctions of the BBB, which ultimately 
serve to prevent the passage of molecules between cells of the endothelium. These hydrophilic 
compounds are impermeable through the lipophilic endothelium and require lipid-mediated transport 
in order to permeate transcellularly. Large molecules, such as insulin and transferrin, require 
receptors, whereas small molecules require carrier-mediated transport to move across the barrier. 
There is also active efflux transport for endogenous BBB transporters (Figure 1- BBB).34,36–38 
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Figure 13: A schematic representation of the blood-brain barrier and pathways across this 
barrier. 
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Bioavailability Features of Screened Drugs as Prospective ZIKV Inhibitors 
There are FDA-approved drugs that have been proposed as anti-ZIKV drugs based on their diverse 
antiviral/antimicrobial/antibacterial activities in diseases other than ZIKV 39, however, the ability of 
those drugs to pass the BBB, their properties as hydrophilic/lipophilic compounds, and their ability 
to be absorbed by the gastrointestinal tract (GIT) have not yet been clearly elucidated. To this effect, 
we have taken a step further and utilized a chemical data base, PubChem, along with ADME 
prediction tools, Swiss ADME 40 to predict specific characteristics of these candidate anti-ZIKV drugs 
and to verify whether or not the proposed compounds by Barrows et al. (2016) could be potential 
anti-ZIKV drugs with BBB-permeable profiles. The proposed compounds are listed in Table 1.  
Table 1: Predicted Bioavailability Features of Prospective Anti-ZIKV Inhibitors. 
Drug name Lipid solubility (logp) Bbb permeation Git absorption 
Auranofin 0.00 No High 
Azathioprine 0.72 No Low 
Bortezomib 0.00 No High 
Clofazimine 4.72 No Low 
Cyclosporine a 6.16 No Low 
Dactinomycin 5.33 No Low 
Daptomycin 0.79 No Low 
Deferasirox 2.48 No High 
Digoxin 4.69 No Low 
Fingolimod 3.76 Yes High 
Gemcitabine hcl 0.00 No High 
Ivermectin 6.31 No Low 
Mebendazole 1.27 No High 
Mefloquine hcl 0.00 No Low 
Mercaptopurine hydrate 0.47 No High 
Methoxsalen 2.22 Yes High 
Micafungin -0.72 No Low 
Mycophenolate mofetil 3.67 No High 
Mycophenolic acid 2.38 No High 
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Nitd008 1.30 No Low 
Palonosetron hcl 0.00 Yes High 
Pyrimethamine 2.15 Yes High 
Sertraline 3.40 Yes High 
Sofosbuvir 3.05 No Low 
Sorafenib tosylate 3.84 No Low 
Thioguanine 0.14 No High 
 
The partition coefficient (LogP) measures how hydrophilic or hydrophobic a molecule is. The desired 
LogP value of a molecule likely to permeate lipophilic membranes should lie between 0-5.41 The 
ability of a drug to pass through the BBB is influenced by their unique but varying properties.36 In 
Table 1, ~80% of the drugs described have the ability to pass through lipophilic membranes, however, 
less than 20% of those drugs can penetrate the BBB 40. Efficient GIT absorption of orally administered 
drugs is required for entry into the bloodstream and sufficient drug delivery 42, although, just half the 
drugs mentioned are highly absorbed via the GIT. The results of this table suggest that the ability of 
a compound to pass through the BBB depends on factors additional to lipophilicity. From this exercise 
we highlight 5 compounds that are predicted to pass the BBB and the hydrophobic spots of each 
compound are shadowed in yellow in Figure 2.  
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Figure 14: Hydrophobic footprints (highlighted in yellow) in chemical structures of potential 
anti-ZIKV compounds which have the ability to permeate the BBB. 
Hydrophobic groups of compounds are required for hydrophobic interactions with target molecules. 
Hydrophobic interactions are comparably stronger than some weak intermolecular forces, such as 
Hydrogen bonds or Van der Waals interactions, and ensure protein-ligand complexes remain stable 
and biologically active.43 As depicted in Figure 2, all five compounds from Table 1 that have the 
ability to pass the BBB bear hydrophobic groups and therefore, possess the potential to form 
hydrophobic interactions with target molecules. Although, fingomolid and sertraline have more 
hydrophobic spots than the other compounds in Figure 2, and therefore, are more likely to form 
stronger hydrophobic interactions. 
Systematic Approach to Tackle the Challenge 
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To overcome the hurdle faced by most drug therapies, we are presenting two main strategies 
that could potentially assist with the design and bioavailability of compounds with an 
improved BBB permeability profile. Furthermore, we include an approach that relies on the 
pre-existing BBB-impermeable drugs conjugated to drug delivery systems. These strategies 
are: (1) improve the inhibitor and (2) carry the cargo.  
Improve the Inhibitor 
In this approach, in silico tools may be used to model and optimize potential compounds (Figure 3), 
followed by compound synthesis and biological testing. Phase 1 includes targeted selection of 
potential anti-ZIKV compounds. This incorporates screening for potential compounds with specific 
physicochemical properties and antiviral activities using chemical databases, and the use of 
absorption, distribution, metabolism, excretion (ADME) prediction tools such as Swiss ADME, in 
order to filter out compounds that encompass the ability to pass the BBB. The ability of a compound 
to pass through the BBB is governed by a function of lipophilicity, the molecular characteristics of 
charged and hydrophobic residues of the compound as well as molecular weight.37 The main 
lipophilic properties that must be considered  include  the  Hansch  constant  (π),  hydrophobic  fragmental  
constant (f), LogP, capacity factor values from RP-HPLC (Logkw), calculated log P values (CLOGP) 
and molecular lipophilic potential (MLP).44 With regard to the charge of the compound, only 
uncharged molecules can diffuse across the membrane to become reprotonated once it leaves the 
membrane and enters the brain fluid.37 As the size of a compound gets larger, its ability to permeate 
the BBB decreases.45  
Phase 2 involves the prediction of lipid permeability of the potential anti-ZIKV compounds using 
molecular dynamic simulations and 3D-modelled lipid bilayer simulations. Due to the surrounding 
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lipid membrane in the BBB, it is necessary to assess compound interactions with the target enzyme 
within lipid membrane.46 
Phase 3 involves the estimation of binding affinities between potential compounds, which pass 
through the BBB, and viral enzymes. This may be achieved via binding free energy calculations or 
molecular docking of the compound of interest into the active site of the target enzyme.47  
 
Figure 15: Phases involved in the suggested approach to improve the BBB-permeability 
profile of the inhibitor.  
Following the design process, the compounds must be synthesized for further testing. Synthesis of 
the compound involves construction of the carbon framework and the 
addition/deletion/transformation of functional groups for functionality of compound. Validation of 
synthesis is carried out by ligand-binding assays which involves placing the target enzyme and 
compound of interest into a solvent (e.g. water) to allow the compound to interact with the active site 
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residues of the enzyme.48 Binding studies provide reliable assessments of binding affinities, errors 
and binding mode.48 Further studies including biological testing will investigate toxicity and efficacy 
of the compound, including in vitro studies (cellular level), in vivo studies (organism level) and 
ultimately clinical trials. Microscale thermophoresis (MST) may also be used in order to analyze the 
interaction between the inhibitors and receptors, experimentally, which is established on the 
controlled movement of particles along a temperature gradient. 49 
Carry the Cargo 
An alternate to creating new BBB-permeable drugs will involve the utilization of drug carriers that 
have already been successful in delivering drugs to the brain. This approach eliminates the additional 
time and expense required to design and formulate new drugs and drug delivery systems. A drug 
carrier could be used to transport a BBB-impermeable drug to the brain and allow for the drug to 
carry out its function against ZIKV.  
 
There are existing drugs that have been proven to inhibit ZIKV replication in isolated ZIKV infected 
cells, such as NITD008 50 and sofosbuvir 51, however the drugs cannot pass the BBB to counteract 
the virus (Table 1). With half the battle won due to their ability to inhibit ZIKV, ultimate triumph 
over ZIKV would entail overcoming impermeability, which requires the potential ZIKV inhibitors to 
be transported across the BBB.  
 
Previously utilized membrane-permeable drug delivery approaches have been successful in 
transporting membrane-impermeable drugs across the BBB for other infections and diseases, such as 
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Parkinson’s  disease  and  Alzheimer’s  disease.52–55 Some known drug delivery systems used in various 
disease cases include polymers and polymeric nanoparticles such as micro/nanospheres, 
micro/nanocapsules, dendrimers, liposomes, hydrogels, gold nanoparticles, micelles; others include 
lipoproteins and aptamers (Table 2).54,56  
Table 2: Pre-existing drug delivery systems and their principle roles in disease and virus 
therapies 
Drug delivery 
system 
Description  Disease/viral target References 
Dendrimer 
 
• Hyperbranched, 
monodispersed, water 
soluble (1-100 nm) 
macoromolecule 
• Encapsulated drug in its 
interior or adsorbs drug on 
and conjugates to its 
surface groups 
• Releases free 5-fluorouracil 
upon hydrolysis 
• Intracellular delivery of 
poorly soluble drugs 
• Carriers in gene therapy 
• Inhibitors of 
haemagglutinin of human 
erythrocytes by Influenza 
virus 
• Amino groups of 
dendrimer react with 
nucleic acid phosphate 
groups to form 
transfection complexes 
56,57 
Microsphere 
& 
nanocapsule 
• Microsphere –drug is 
dispersed within polymer 
throughout particle 
• Nanocapsule- cavity 
contains drug surrounded 
by polymer membrane 
• Drug release through 
diffusion through polymer 
or degradation of polymer 
• Entraps luteinizing 
hormone-releasing 
hormone in prostate 
cancer 
57,58 
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Liposomes • Amphiphilic vesicular 
structures made up of 
cholesterol & 
phospholipids 
• Core suited for hydrophilic 
drug delivery 
• Phospholipid membrane 
encapsulate hydrophobic 
drugs 
• Facultative intracellular 
bacteria-mediated 
infections 
• Parasites (e.g. 
Leishmania) 
• Viruses 
• Systemic fungal diseases 
in cancer 
• Melanomas 
56,59,60 
Micelles • Core comprised of 
hydrophobic polymers 
• Shell comprised of 
hydrophilic polymers 
• Suitable for drugs with 
poor solubility 
• Nanosize; in vivo 
endurance; remains stable 
in plasma 
• Delivery of drugs & small 
interfering RNA 
• Targets tumour sites in 
cancer by active/passive 
mechanisms 
56,61,62 
Hydrogel • Network of 
natural/synthetic 
hydrophilic polymers that 
are cross-linked  
• Highly absorbent, 
biodegradable, high 
porosity, biocompatible 
• Swell rapidly in aqueous 
solution 
• Used in oral & topical drug 
delivery 
• Local & systemic diseases 
• Oral delivery of insulin in 
diabetes; salmon 
calcitonin for 
postmenopausal 
osteoporosis; growth 
hormone for 
decelerated/stunted 
growth-associated 
diseases 
56,63,64 
Gold/silver 
nanoparticle 
• Low toxicity; high 
specificity & selectivity 
• Easily controlled & 
modifiable 
• High ratio of surface 
area:amount  
• Selective damage of 
tumour cells 
• Certain infectious & 
dermal diseases 
• H1N1, H3N2, H5N1 
Influenza A virus 
• Herpes Simplex Virus 
65–68  
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• Conjugation of proteins on 
colloidal gold nanoparticles 
occurs via electrostatic 
interactions between 
citrate(-) on surfaces of gold 
nanoparticles & groups(+) 
on proteins 
• Effortless cellular 
penetration 
• Human 
Immunodeficiency Virus  
• Hepatitus B Virus 
• Metapneumovirus 
• Respiratory syncytial 
virus 
Lipid 
nanoparticle 
• 10-1000 nm 
• Carriers with dispersed 
melted lipid in surfactant 
• Colloidal system with 
hydrophobic core that 
encloses drug & surface 
coated with hydrophilic 
polymers 
• Humoral immunity 
against Ebola infection. 
• Silencing of hepatitis C 
virus replication 
• Gene therapy 
56,69–72 
Aptamer • Short, single-stranded (ss) 
DNA or RNA that have 
definitive 2° & 3° structures 
that strongly bind to specific 
target proteins 
• Low immunogenicity & 
toxicity 
• Variety of targets & 
modifiable chemical 
structure 
• α-Thrombin in thrombosis 
• PTK7 and nucleoin in 
cancer 
• IGHM in lymphoma 
• VEGF in age-related 
macular degeneration 
• A1 domain of vWF in 
thrombotic 
microangiopathies & 
carotid artery disease 
• Neutralizes r5 strains of 
HIV-1 
• Blocks gp120-CCRF 
interaction 
73–77 
 
The inhibitor-carrier approach will involve techniques similar to the previous suggested approach. 
The first step would be to create an inhibitor-carrier complex by binding the known ZIKV inhibitor 
to the carrier. The complex must then be simulated to analyze the trajectory of the complex as well 
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as the potential energy of the entire complex through a lipid bilayer. Once there is computational 
evidence to show that the inhibitor can theoretically bind to the carrier and move through a lipid 
membrane, the inhibitor-carrier complex must be synthesized to test it biologically (e.g. in vivo 
testing), which will be used to confirm drug delivery through the BBB to the brain. Technical 
guidance related to the in silico tools involved in these approaches and examples of computationally 
docking a compound-polymer complex is provided in the supplementary information. 
Conclusion 
The various challenges associated with ZIKV treatment has led to the ongoing search for a cure - one 
of the major problems being drug delivery across the BBB. The approaches described in this review 
serve to provide information that can be used for further research into the design of drugs with 
improved BBB-permeability profile that may have a greater ability to inhibit ZIKV. Though 
experimental validation is necessary, this is not the scope of the current study. Instead, this study 
serves as a cornerstone that will open doors to further experimental and molecular validation 
regarding ZIKV therapy. 
 
Conflicts of interest 
Authors declare no potential conflicts of interest. 
 
Acknowledgements 
The authors acknowledge the College of Health Sciences, UKZN. 
 
83 
 
References 
1 I. Briguglio, S. Piras, P. Corona and A. Carta, Int. J. Med. Chem., 2011, 2011, 1–22. 
2 R. K. Singh, K. Dhama, Y. S. Malik, M. A. Ramakrishnan, K. Karthik, R. Tiwari, S. Saurabh, 
S. Sachan and S. K. Joshi, Vet. Q., 2016, 36, 150–175. 
3 D. Musso, C. Roche, E. Robin, T. Nhan, A. Teissier and V. M. Cao-Lormeau, Emerg. Infect. 
Dis., 2015, 21, 359–361. 
4 D. Musso, T. Nhan, E. Robin, C. Roche, D. Bierlaire, K. Zisou, A. Shan Yan, V. M. Cao-
Lormeau and J. Broult, Eurosurveillance, 2014, 19, 14–16. 
5 M. Besnard, S. Lastère, A. Teissier, V. M. Cao-Lormeau and D. Musso, Eurosurveillance, 
2014, 19, 8–11. 
6 G. W. A. Dick, S. F. Kitchen and A. J. Haddow, Trans. R. Soc. Trop. Med. Hyg., 1952, 55, 
509–520. 
7 M. R. Duffy, C. Tai-Ho, T. Hancock, A. M. Powers, J. L. Kool, R. S. Lanciotti, M. Pretrick, 
C. Dubray, L. Guillaumot, A. Griggs, M. Bel, A. J. Lambert, J. Laven, O. Kosoy, A. Panella, 
B. J. Biggerstaff, M. Fischer and E. B. Hayes, N. Engl. J. Med., 2009, 360, 2536–2543. 
8 D. Musso, E. J. Nilles and V. M. Cao-Lormeau, Clin. Microbiol. Infect., 2014, 20, O595–
O596. 
9 V. Sikka, V. K. Chattu, R. K. Popli and T. J. Galwankar, Sagar C, Kelkar, Dhanashree, 
Sawicki, Stanley G, Stawicki, Stanislaw P, Papadimos, J. Glob. Infect. Dis., 2016, 8, 3–15. 
10 S.-I. Yun and Y.-M. Lee, J. Microbiol., 2017, 55, 204–219. 
11 G. S. Campos, A. C. Bandeira and S. I. Sardi, Emerg. Infect. Dis., 2015, 21, 1885–1886. 
12 D. Musso and D. J. Gubler, Nature, 2016, 11, 10–20. 
13 F. Krauer, M. Riesen, L. Reveiz, O. T. Oladapo, R. Martínez-Vega, T. V Porgo, A. Haefliger, 
N. J. Broutet and N. Low, PLOS Med., 2017, 14, 1–27. 
14 P. Ramharack and M. E. S. Soliman, R. Soc. Chem., 2016, 6, 68719 – 68731. 
15 D. Musso, C. Roche, T. X. Nhan, E. Robin, A. Teissier and V. M. Cao-Lormeau, J. Clin. 
Virol., 2015, 68, 53–55. 
16 J. M. Mansuy, M. Dutertre, C. Mengelle, C. Fourcade, B. Marchou, P. Delobel, J. Izopet and 
G. Martin-Blondel, Lancet Infect. Dis., 2016, 16, 405. 
84 
 
17 J. M. Turmel, P. Abgueguen, B. Hubert, Y. M. Vandamme, M. Maquart, H. Le Guillou-
Guillemette and I. Leparc-Goffart, Lancet, 2016, 387, 2501. 
18 A.  C.  Gourinat,  O.  O’Connor, E. Calvez, C. Goarant and M. Dupont-Rouzeyrol, Emerg. Infect. 
Dis., 2015, 21, 84–86. 
19 G. Calvet, R. S. Aguiar, A. S. O. Melo, S. A. Sampaio, I. de Filippis, A. Fabri, E. S. M. Araujo, 
P. C. de Sequeira, M. C. L. de Mendonça, L. de Oliveira, D. A. Tschoeke, C. G. Schrago, F. 
L. Thompson, P. Brasil, F. B. dos Santos, R. M. R. Nogueira, A. Tanuri and A. M. B. de 
Filippis, Lancet Infect. Dis., 2016, 16, 653–660. 
20 O. Faye, O. Faye, A. Dupressoir, M. Weidmann, M. Ndiaye and A. Alpha Sall, J. Clin. Virol., 
2008, 43, 96–101. 
21 R. Hamel, O. Dejarnac, S. Wichit, P. Ekchariyawat, A. Neyret, N. Luplertlop, M. Perera-
Lecoin, P. Surasombatpattana, L. Talignani, F. Thomas, V. M. Cao-Lormeau, V. Choumet, L. 
Briant, P. Despres, A. Amara, H. Yssel and D. Misse, J. Virol., 2015, 89, 8880–8896. 
22 O. Faye, C. C. M. Freire, A. Iamarino, O. Faye, J. Velasco, C. De Oliveira, M. Diallo, P. M. 
A. Zanotto and A. A. Sall, PLoS Negl Trop Dis, 2014, 8, 1–10. 
23 H. Tian, X. Ji, X. Yang, W. Xie, K. Yang, C. Chen, C. Wu, H. Chi, Z. Mu, Z. Wang and H. 
Yang, Protein Cell, 2016, 7, 450–454. 
24 H. Tian, X. Ji, X. Yang, Z. Zhang, Z. Lu, K. Yang, C. Chen, Q. Zhao, H. Chi, Z. Mu, W. Xie, 
Z. Wang, H. Lou, H. Yang and Z. Rao, Protein Cell, 2016, 7, 562–570. 
25 B. Ganguly and E. Ganguly, bioRxiv, 2016, 54486. 
26 M. K. White, H. S. Wollebo, J. David Beckham, K. L. Tyler and K. Khalili, Ann. Neurol., 
2016, 80, 479–489. 
27 N. J. da Fonseca, M. Q. Lima Afonso, N. G. Pedersolli, L. C. de Oliveira, D. S. Andrade and 
L. Bleicher, Biochem. Biophys. Res. Commun., , DOI:10.1016/j.bbrc.2017.01.041. 
28 G. Li, M. Poulsen, C. Fenyvuesvolgyi, Y. Yashiroda, M. Yoshida and J. M. Simard, Proc. 
Natl. Acad. Sci., 2016, 114, 201619735. 
29 P. Brasil, P. C. Sequeira, A. D. Freitas, H. E. Zogbi, G. A. Calvet, R. V de Souza, A. M. 
Siqueira, M. C. de Mendonca, R. M. Nogueira, A. M. de Filippis and T. Solomon, Lancet, 
2016, 387, 1482. 
30 J. J. Miner and M. S. Diamond, Cell Stem Cell, 2016, 18, 559–560. 
31 T. J. Nowakowski, A. A. Pollen, E. Di Lullo, C. Sandoval-Espinosa, M. Bershteyn and A. R. 
Kriegstein, Cell Stem Cell, 2016, 18, 591–596. 
85 
 
32 H. Retallack, E. Di Lullo, C. Arias, K. A. Knopp, M. T. Laurie, C. Sandoval-Espinosa, W. R. 
M. Leon, R. Krencik, E. M. Ullian, J. Spatazza, A. A. Pollen, C. Mandel-Brehm, T. J. 
Nowakowski, A. R. Kriegstein, J. L. Derisi, N. Sestan and P.-Y. Shi, Proc. Natl. Acad. Sci., 
2016, 113, 14408–14413. 
33 P. K. Singh, J.-M. Guest, M. Kanwar, J. Boss, N. Gao, M. S. Juzych, G. W. Abrams, F.-S. Yu 
and A. Kumar, , DOI:10.1172/jci.insight.92340. 
34 N. R. Saunders, M. D. Habgood, K. Møllgård and K. M. Dziegielewska, F1000Research, 
2016, 5, 1–15. 
35 M. R. Syme, J. W. Paxton and J. a Keelan, Clin. Pharmacokinet., 2004, 43, 487–514. 
36 W. A. Banks, BMC Neurol., 2009, 9, S3. 
37 A. Seelig, R. Gottschlich and R. M. Devant, Proc. Natl. Acad. Sci., 2016, 91, 68–72. 
38 J. M. Tarbell and M. Y. Pahakis, J. Intern. Med., 2006, 259, 339–350. 
39 N. J. Barrows, R. K. Campos, S. T. Powell, K. R. Prasanth, G. Schott-Lerner, R. Soto-Acosta, 
G. Galarza-Mu??oz, E. L. McGrath, R. Urrabaz-Garza, J. Gao, P. Wu, R. Menon, G. Saade, I. 
Fernandez-Salas, S. L. Rossi, N. Vasilakis, A. Routh, S. S. Bradrick and M. A. Garcia-Blanco, 
Cell Host Microbe, 2016, 20, 259–270. 
40 A. Daina, O. Michielin and V. Zoete, Sci. Rep., 2017, 7, 1–13. 
41 A. Daina, O. Michielin and V. Zoete, Jounral Chem. Inf. Model., 2014, 54, 3284–3301. 
42 Y. N. Gavhane and A. V. Yadav, Saudi Pharm. J., 2012, 20, 331–344. 
43 P. Atkins and J. De Paula, Physical chemistry for the life sciences, 2011. 
44 P. P. Kore, M. M. Mutha, R. V. Antre, R. J. Oswal and S. S. Kshirsagar, J. Med. Chem., 2012, 
2, 139–148. 
45 J. A. Arnott and S. L. Planey, Expert Opin. Drug Discov., 2012, 7, 863–875. 
46 R. Guixà-Gonzá Lez, I. Rodriguez-Espigares, J. M. Ramírez-Anguita, P. Carrió-Gaspar, H. 
Martinez-Seara, T. Giorgino and J. Selent, 2014, 30, 1478–1480. 
47 X.-Y. Meng, H.-X. Zhang, M. Mezei and M. Cui, Curr. Comput. Drug Des., 2011, 7, 146–
157. 
48 E. C. Hulme and M. A. Trevethick, Br. J. Pharmacol., 2010, 161, 1219–1237. 
49 Duhr, S., Baaske, P. and Bigus, H., 2016. Nanotemper Technologies Gmbh, Hirschmann 
86 
 
Laborgerate Gmbh & Co. Kg. Patent no.: US9389211 B2. 
50 Y. Q. Deng, N. N. Zhang, C. F. Li, M. Tian, J. N. Hao, X. P. Xie, P. Y. Shi and C. F. Qin, 
Open Forum Infect. Dis., 2016, 3, 6–9. 
51 S. E. Reznik and J. C. R. Ashby, Int. J. Infect. Dis., 2016, 55, In press. 
52 C. Roney, P. Kulkarni, V. Arora, P. Antich, F. Bonte, A. Wu, N. N. Mallikarjuana, S. 
Manohar, H.-F. Liang, A. R. Kulkarni, H.-W. Sung, M. Sairam and T. M. Aminabhavi, J. 
Control. Release, 2005, 108, 193–214. 
53 C. Spuch and C. Navarro, J. Drug Deliv., 2011, 2011, 1–12. 
54 M. S. Gunay, A. Y. Ozer and S. Chalon, Curr Neuropharmacol, 2016, 14, 376–391. 
55 E. Blanco, H. Shen and M. Ferrari, Nat. Biotechnol., 2015, 33, 941–951. 
56 A. Srivastava, T. Yadav, S. Sharma, A. Nayak, A. Kumari and N. Mishra, J. Biosci. Med., 
2016, 4, 69–84. 
57 N. A. Liechty, W. B., Kryscio, D.R., Slaughter, B. V. and Peppas, Annu. Rev. Chem. Biomol. 
Eng., 2010, 1, 149–173. 
58 Z. Abouelfadel and D. Crawford, Ther. Clin. Risk Manag., 2008, 4, 513–526. 
59 A. Coune, Infection, 1988, 16, 141–147. 
60 M. A. Tran, R. J. Watts and G. P. Robertson, Pigment Cell Melanoma Res., 2009, 22, 388–
399. 
61 U. Kedar, P. Phutane, S. Shidhaye and V. Kadam, Nanomedicine Nanotechnology, Biol. Med., 
2010, 6, 714–729. 
62 X.-B.  Xiong,  H.  Uludağ  and  A.  Lavasanifar,  Biomaterials, 2010, 31, 5886–5893. 
63 D. Bhowmik, H. Gopinath, B. Pragati Kumar, S. Duraivel and K. P. Sampath Kumar, Pharma 
Innov., 2012, 1, 12–31. 
64 L. A. Sharpe, A. M. Daily, S. D. Horava and N. A. Peppas, Expert Opin. Drug Deliv., 2014, 
11, 901–915. 
65 X. Yu, I. Trase, M. Ren, K. Duval, X. Guo and Z. Chen, J. Nanomater., , 
DOI:10.1155/2016/1087250.Design. 
66 H. Daraee, A. Eatemadi, E. Abbasi, S. Fekri Aval, M. Kouhi and A. Akbarzadeh, Artif. cells, 
nanomedicine, Biotechnol., 2014, 1401, 1–13. 
87 
 
67 W. Tao, B. L. Hurst, A. K. Shakya, M. J. Uddin, R. S. J. Ingrole, M. Hernandez-Sanabria, R. 
P. Arya, L. Bimler, S. Paust, E. B. Tarbet and H. S. Gill, Antiviral Res., 2017, 141, 62–72. 
68 M. Rai, S. D. Deshmukh, A. P. Ingle, I. R. Gupta, M. Galdiero and S. Galdiero, Crit. Rev. 
Microbiol., 2014, 42, 46–56. 
69 S. Mukherjee, S. Ray and R. S. Thakur, Indian J Pharm Sci, 2009, 71, 349–358. 
70 J. D. Bazzill, C. L. Cooper, Y. Fan, S. Bavari and J. J. Moon, J. Immunol. 
71 J. Torrecilla, A. del Pozo-Rodríguez, M. ÿngeles Solinís, P. S. Apaolaza, B. Berzal-Herranz, 
C. Romero-López, A. Berzal-Herranz and A. Rodríguez-Gascón, Colloids Surfaces B 
Biointerfaces, 2016, 146, 808–817. 
72 A. del Pozo-Rodríguez, M. Á. Solinís and A. Rodríguez-Gascón, Eur. J. Pharm. Biopharm., 
2016, 109, 184–193. 
73 A. K. Dey, M. Khati, M. Tang, R. Wyatt, S. M. Lea and W. James, J. Virol., 2005, 79, 13806–
10. 
74 F. Jiang, B. Liu, J. Lu, F. Li, D. Li, C. Liang, L. Dang, J. Liu, B. He, S. A. Badshah, C. Lu, X. 
He, B. Guo, X. B. Zhang, W. Tan, A. Lu and G. Zhang, Int. J. Mol. Sci., 2015, 16, 23784–
23822. 
75 S. D. Jayasena, Clin. Chem., 1999, 45, 1628–1650. 
76 P. Ray and R. R. White, Pharmaceuticals, 2010, 3, 1761–1778. 
77 M. Blind and M. Blank, Mol. Ther. - Nucleic Acids, 2015, 4, e223. 
 
  
88 
 
CHAPTER 5 
A Panoptic Uncovering of the Dynamical Evolution of the Zika Virus NS5 
Methyltransferase Binding Site Loops–Zeroing in on the Molecular Landscape 
  
89 
 
A Panoptic Uncovering of the Dynamical Evolution of the Zika 
Virus NS5 Methyltransferase Binding Site Loops– Zeroing in on 
the Molecular Landscape 
 
Short running title: The Dynamical Evolution of Zika Virus 
Methyltransferase 
 
Nikita Devnarain1 and Mahmoud E. S. Soliman1* 
1Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, 
University of KwaZulu-Natal, Westville, Durban 4001, South Africa 
*Mahmoud E. S. Soliman; Email: soliman@ukzn.ac.za; Tel: 0312607413 
 
  
90 
 
Abstract 
The global threat of the Zika virus to humanity is real. Innovative and potent anti-Zika virus 
drugs are still at large, due to the lack of anti-Zika virus drugs that have passed phase 1 trials. 
Experimental research has revealed novel inhibitors of Zika virus NS5 methyltransferase 
enzyme. This study has taken a step further to provide insight into the molecular dynamics 
of Zika virus and inhibitor binding, which have not been established experimentally. 
Movements of the methyltransferase binding site loops have a large role to play in the 
methylation of the viral mRNA cap, which is essential for Zika virus replication. Here we 
pinpoint the binding interactions between each potential inhibitor and the methyltransferase, 
residues that are responsible for binding, as well as which inhibitor-bound complex renders 
the methyltransferase more stable. We also highlight the conformational changes that occur 
within the methyltransferase to accommodate binding of inhibitors and consequences of 
those changes upon the RNA- and cap-binding sites in the methyltransferase. This research 
will improve the understanding of the Zika virus NS5 methyltransferase enzyme, and will be 
beneficial in driving the development of anti-Zika virus drugs. 
 
Keywords 
Zika virus inhibitors, NS5, Methyltransferase, Molecular dynamics  
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1   Introduction 
In the beginning of 2016, the World Health Organization declared the escalating Zika virus 
(ZIKV) a public health crisis due to its association with neonatal microcephaly and Guillain-
Barré syndrome [1]. ZIKV, the rapidly disseminating pathogen, which belongs to the 
flavivirus genus of the Flaviviridae family, is related to other flaviviruses, including West 
Nile virus (WNV), Yellow fever virus (YFV), Japanese encephalitis virus (JEV) and Dengue 
virus (DENV) [2]. ZIKV has revealed a tropism for a broad range of tissues including sensory 
organs and organs of the gastrointestinal tract, respiratory system and reproductive system [3–
6]. 
The preeminent mode of transmission of ZIKV is through the bite of a previously infected 
Aedes aegypti mosquito, which acts as a viral vector. ZIKV may also be distributed via sexual 
intercourse, blood transfusion, maternal transmission and physical contact [7]. Control 
measures have been put in place to curb the spread of the virus, however, ultimate success is 
yet to be attained [8]. Vaccine development is still several years away since vaccine candidates 
are still in pre-clinical trials [9]. Additionally, due to the erratic and spontaneous temperament 
of flavivirus outbreaks, vaccine development against flaviviruses is restricted [10]. 
As a result of the extensive period involved in establishing a ZIKV vaccine, there are current 
endeavors toward developing antiviral therapeutics [11]. To date, flavivirus infections prevail 
with no approved antiviral treatment. Present-day treatment of ZIKV is based on the 
symptoms of infection [12]. There is also the question of whether or not novel inhibitors will 
pass the blood-brain barrier [13]. Generally, research is turned toward drugs that inhibit 
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enzymes involved in critical steps in the life cycle of the virus [14–16].There has been a 
compelling amount of research in the last ten years, which had been directed toward the 
establishment of inhibitors of targeted enzymes of other flaviviruses including DENV, WNV 
and YFV [17,18].  
There may be no elixir for treating ZIKV, but recognizing the targets that provide optimal 
therapy will aid science in establishing the most effective therapeutics. The flavivirus NS5 
methyltransferase (MTase) enzyme is an attractive target for the development of inhibitors 
due to its fundamental roles in viral replication via formation of the viral mRNA cap as well 
as modulation of immune response [16]. We illustrate in Figure 1, the ZIKV NS5 MTase 
responsible for methylation of the viral mRNA cap, as well as the RNA-dependent RNA-
polymerase (RdRp) responsible for viral RNA replication [17]. Together, these subunits work 
in harmony to ensure viral replication [19]. 
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Figure 16: A schematic representation of the Zika virus NS5 enzyme. The structural protein 
of zika virus NS5 is divided into its two major subunits, the methyltransferase (bound to its 
natural substrate) and the RNA-dependent RNA-polymerase. 
 
By virtue of the resemblance between flaviviruses, particularly between DENV and ZIKV, 
as we have presented in Figure 2, a great deal of the information regarding the drug discovery 
of DENV may possibly be enforced toward the establishment of ZIKV inhibitors [7,20]. 
Inhibitors that have been shown to suppress the MTase of DENV have also been potent in 
the inhibition of ZIKV MTase [14,21,22]. 
 
Figure 2: A. Superimposed crystal structures of DENV and ZIKV NS5 MTases showing 
similarities  and  differences  in  coils,  β-sheets  and  α-helices. B. Structures of ZIKV and DENV 
MTases illustrating similar binding pockets and solvent accessible surface areas. C. Sequence 
similarities and differences between ZIKV and DENV. 
 
A profoundly essential molecule for both DENV and ZIKV replication, particularly regarding the 
MTase component, includes S-adenosyl-L-methionine (SAM) [21]. Being the natural substrate of the 
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MTase, SAM serves as a methyl donor and allows for methylation of the mRNA cap, which is 
imperative for viral replication [23]. We demonstrate in Figure 3, that an absence of SAM-binding, as 
a result of displacement by an alternative compound, causes avoidance of viral replication since 
methylation of RNA does not occur. 
 
Figure 3: Implications of lack of SAM binding to MTase. Illustration of SAM-binding to the 
MTase as a prerequisite for viral RNA methylation and viral replication (left), and the 
consequence of an alternative molecule binding in the SAM-binding pocket and inhibiting 
viral RNA methylation and replication (right). 
 
The adenosine derivative, sinefungin (SFG), was initially isolated as an antifungal antibiotic from 
Streptomyces griseolus, and accomplishes its inhibition by competitively binding to the SAM-binding 
pocket in the MTase [24]. Previously, SFG demonstrated inhibitory effects on MTases of DENV, WNV 
and YFV [17], and thus presented as a potential inhibitor of ZIKV [25]. Experimental evidence shows 
that even low concentrations of SFG inhibit ZIKV MTase and terminates internal methylation in vitro 
[21]. Coutard et al (2017) also demonstrations ZIKV suppression by another DENV inhibitor, 
Compound 5, which inhibits ZIKV MTase activity and is more potent against ZIKV MTase compared 
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to MTases of DENV and WNV [14,21,22]. In Figure 4, we illustrate the structures of SFG and Compound 
5. 
 
Figure 4: Potential ZIKV inhibitors. Chemical structure of SFG and Compound 5 (left), as 
well as the chemical formula and functional groups of SFG (top right) and Compound 5 
(bottom right). 
 
Based on preliminary viral inhibition and structural novelty, we considered further exploring the 
structural dynamics that take place at a molecular level within the independent ZIKV MTase (Apo), 
as well as ZIKV MTase bound to SFG and Compound 5, distinctly. We also compare the binding 
affinity, binding mode and stability of the bound complex of SFG to that of Compound 5. Two major 
loops in the MTase were focused on more than the rest, as one of the loops surrounds the SAM-
binding pocket and the other surround the RNA-binding site. To our knowledge, this is the first study 
that utilizes integrated computational methods to analyze how binding of inhibitors, SFG and 
Compound 5, impact the conformational changes that occur within the ZIKV NS5 MTase. 
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Furthermore, we speculate that this study will improve the understanding of the structural information 
of the inhibitors and the ZIKV NS5 MTase, and will be valuable in anti-ZIKV drug design. 
 
2   Computational Methods 
2.1   System Preparation 
The crystal structure of the NS5 MTase of ZIKV in complex with SFG was accessed from RCSB 
Protein Data Bank (PDB code: 5MRK) [25]. The protein (MTase) and ligands (SFG and Compound 5) 
were prepared using Molegro Molecular Viewer software (Molegro-a CLC bio company, Aarhus, 
Denmark) and UCSF Chimera software package [12]. The crystal structure of the MTase protein 
consists of chains A and B, however, in order to save computational time and expense, the distinct 
ligands conjugated to the singular chain A was utilized. Compound 5 was modeled using Avodagro 
[26]. Three systems including the Apo MTase, SFG-bound MTase and Compound 5-bound MTase 
were subjected to a 200 ns molecular dynamic simulation (described in section 2.3). 
2.2   Molecular Docking 
Molecular docking was used to predict optimized conformations and binding affinities of SFG and 
Compound 5 within the SAM-binding pocket of ZIKV NS5 MTase.[27] Docking software that was 
used in this study include UCSF Chimera [12,27] and AutoDock Vina [28]. SFG and Compound 5 were 
docked into the SAM-binding pocket of the NS5 MTase (grid box spacing of 0.375 Å and x, y, z 
dimensions of 28 x 32 x 34). The complex with the most negative binding energy (kcal.mol-1) was 
subjected to molecular dynamic simulations. A greater expansion of molecular docking can be found 
in the referenced articles [29–31]. 
 
97 
 
2.3   Molecular Dynamic Simulation 
Molecular dynamic simulations were implemented using AMBER PMEMD dynamics engine with 
GPU acceleration and the protein was parameterized with the AMBER force field, FF14SB [32–35]. 
Hydrogen atoms were removed from the MTase protein, while SFG and Compound 5 were 
hydrogenated and charged with Gasteiger charges preceding the simulation. Antechamber created 
atomic partial charges for SFG and Compound 5 using the general AMBER force field (GAFF) and 
restrained electrostatic potential (RESP) methods [36–38]. The LEAP module implemented in AMBER 
14 was used to combine, neutralize and solvate the systems by adding hydrogen atoms, chloride and 
sodium ions and suspending them in an orthorhombic box of TIP3P water molecules such that all 
atoms were within 10 Å of the box edges. The amino acid residues of the protein were renumbered 
due to missing residues in the initial crystal structure; therefore, all residue numbers reported from 
these findings are in fact four residues less than stated. An initial energy minimization of 2500 steps 
was performed with a restraint potential of 10 kcal.mol-1 Å-2 applied to the solutes, for 1000 steps of 
steepest descent followed by 1000 steps of conjugate gradient minimization. An additional 
unrestrained full minimization of 200 steps was performed by conjugate gradient algorithm. 
A canonical ensemble (NVT) simulation was carried out for 50 ps from 0 K to 300 K, so that a fixed 
volume and number of atoms in each system was maintained. The systems’  solutes  were enforced 
with Langevin thermostat collision frequency of 1.0 ps-1 and a potential harmonic restraint of 10 
kcal.mol-1 Å-2. Thereafter, each system was equilibrated for 500 ps with a constant operating 
temperature of 300 K, as well as a constant pressure of 1 bar using the Berendsen barostat and number 
of atoms resembling an isobaric-isothermal ensemble. The overall simulation was conducted for 200 
ns, where each simulation incorporated the shake algorithm to restrain hydrogen bonds. An SPFP 
precision model was utilized. 
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2.4   Post-dynamic Analysis 
2.4.1   Computation of Thermodynamic Binding Free Energy & Per-Residue 
Decomposition Analysis 
A well-known method utilized to determine the binding free energy (ΔGbind) of small ligands to 
biological macromolecules includes molecular mechanics incorporated with the Poisson-Boltzmann 
or generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) approach 
[39]. These methods are generally established on molecular dynamics simulations of the protein-ligand 
complex and are thus transitional in precision between empirical scoring and strict enzymatic 
perturbation methods [40].  
ΔGbind was averaged over 50 000 snapshots derived from the 200 ns trajectory. The binding strength 
estimated using this method for the MTase, SFG- and Compound 5-complexes could be represented 
as: 
(1) ΔGbind = Gcomplex − Greceptor −  Gligand 
(2) ΔGbind = Egas + Gsol – TS 
(3) Egas = Eint + EvDW + Eele 
(4) Gsol = GGB + GSA   
(5) GSA =  γSASA 
where: 
Eele  Electrostatic potential energy from Coulomb forces 
Egas   Gas-phase energy (based on FF14SB force field terms) 
Eint  Internal energy 
EvdW  van der Waals energy 
Gsol  Solvation free energy 
GGB  Polar solvation energy 
GSA  non-polar solvation energy 
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S  Total entropy of solute 
SASA  Solvent accessible surface area (water probe radius of 1.4 Å) 
T  Total entropy of temperature 
To determine the per-residue contribution of SFG and compound 5 to the total ΔGbind at the SAM-
binding site, atomic level per-residue free energy decomposition was implemented for significant 
residues of each ligand using the AMBER14 MM/GBSA approach. The SFG- and Compound 5-
bound complexes were subjected to further analysis. 
2.4.2   Dynamic Cross-Correlation 
Dynamic Cross-Correlation (DCC) is a well-known approach that may be utilized in the interpretation 
of molecular dynamic simulation-derived trajectories, by quantifying the correlation coefficients of 
motions between atoms [41]. The analysis of fluctuations between residues within the Apo MTase, 
SFG-bound MTase and Compound 5-bound Mtase were calculated using the CPPTRAJ module in 
the AMBER 14 suite. The equation that defines DCC is provided below: 
   𝐶௜௝ =   
〈୼௥೔୼௥ೕ〉
൫〈୼௥೔మ〉〈୼௥ೕమ〉൯
భ
మ
 
where: 
Cij  Cross-correlation coefficient (-1 [fully correlated] to +1 [anti-correlated]) 
i ith residue 
j jth residue 
Δri displacement vectors correspond to ith 
Δrj displacement vectors correspond to jth 
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The DCC matrix produced from each simulated system was constructed using Origin software. 
2.5   Pharmacophore Model Generation and Structure-based Screening 
The creation and analysis of a pharmacophore model is established as a vital part of drug design, as 
it is a beneficial tool for detection and development of new chemical entities (NCEs) [42]. LigandScout 
[43] tool was used to generate a pharmacophore model from the simulation of SFG. 
 
3   Results & Discussion 
3.1 Molecular dynamic simulations & Systems Stability 
Trajectories of the Apo MTase system, as well as the SFG- and Compound 5-bound MTase systems 
were monitored during a   200   ns   simulation   to   confirm   the   systems’   stability,   together   with   the  
precision of ensuing post-dynamic analyses. 
3.1.1      Deviation  of  α-carbons within NS5 MTase  
The stability of the 200 ns molecular dynamic simulations of the Apo MTase vs. SFG-bound MTase 
vs. Compound 5-bound MTase systems were explored by calculating the RMSD. In Figure 5, we 
demonstrate that during the simulation, the two inhibitor-bound complexes showed various RMSD 
patterns. 
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Figure 5: Fluctuations in rigidity of SFG-bound and Compound 5-bound complexes 
compared to apo are shown in A and B, respectively, with emphasis on loop movements 
during the 52ns, 122ns and 173ns periods of the simulation. C shows that SFG reached 
convergence and was less flexible toward the latter period of the simulation, as compared to 
that of the apo and Compound 5-bound systems. 
 
The Compound 5-bound complex had reached convergence after 20 ns; however, the system began 
to fluctuate after 143 ns, although remaining within a 2.0 Å range until the end of the simulation. The 
SFG-MTase complex reached convergence after 169 ns, with fluctuations less than 1.5 Å. Indeed, 
both bound systems demonstrate stability; however, binding of SFG to the NS5 MTase renders the 
enzyme more stable than that of Compound 5, as convergence was maintained upon SFG-binding.  
 
It was also noticed that binding of SFG to the MTase not only causes the SAM-binding site to become 
closed by the surround binding site loop (residues 100-110), but the MTase also conforms to close 
the RNA-binding site as the surrounding loop (residues 30-60) moves to prevent RNA from binding. 
Should RNA not bind to the MTase, replication off viral RNA by the RdRp will most likely not occur, 
preventing viral replication from occurring. 
The fluctuation in rigidity in the Apo MTase (greater than 2 Å) prevented the system from reaching 
convergence, even toward the latter period of the simulation, indicating instability of the Apo MTase. 
These major rigorous fluctuations, as well as the fact that the bound systems had reached convergence 
whilst the unbound system had not, suggest that the MTase only stabilized upon binding of inhibitors, 
SFG and Compound 5. 
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3.1.2   Atomic Distribution of NS5 MTase Backbone 
The  radius  of  gyration  (RoG)  is  an  indicator  of  a  structure’s  stability  during  a  molecular  dynamic  
simulation, as is associated with the compactness of secondary protein structures into 3D structures 
[44]. To assess the conformations of the Apo MTase, SFG- and Compound 5-bound MTase complexes, 
RoG was analyzed and plotted (Figure S1). 
 
Figure S1: Graphs illustrating the radius of gyration (RoG) showing the variation of MTase 
compactness of the apo vs SFG-bound system (left) and the apo vs Compound 5-bound 
system (right) throughout a 200ns molecular dynamic simulation. 
 
It was noticed that in the RMSD plot (Figure 6), at 52 ns, 122 ns and 173 ns the Apo MTase fluctuated 
significantly, whilst binding of both inhibitors, SFG and Compound 5, had stabilized the enzyme at 
those points in the simulation. Correspondingly, the RoG plots showed similar trends at 52 ns, 122 ns 
and 173 ns, as both inhibitors caused the MTase to become more compact to accommodate binding. 
The Apo MTase had a greater atomic distribution than the inhibitor-bound complexes and is therefore, 
more flexible and less compact than when bound.  
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3.2   Intra- and Intermolecular Interactions in ZIKV NS5 MTase 
3.2.1   Intermolecular Hydrogen Bond Patterns 
Hydrogen bonding between amino acid residues is subject to the spatial arrangement of the associated 
atoms, and is a major driving force in structural changes that occur within proteins. To further analyze 
the forces that drive the conformational changes within the enzyme, we evaluated the hydrogen 
bonding pattern of the apo, SFG-bound and Compound 5-bound MTase systems throughout the 
simulation.  
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Figure 6: (Top left) Graph depicts hydrogen-bonding analysis of the apo and bound systems. 
(Top right) Bond and non-bond interactions that exist between each inhibitor and their 
binding site residues, as well as the interacting areas of the ligand which are hydrogen donors 
and acceptors. (Bottom) Surface areas of each inhibitor in the MTase pocket describing the 
hydrogen bonding capacity of each ligand during parts of the simulation that correspond to 
fluctuations in energy, along with the solvent accessible surface areas of the MTase at those 
points which correspond to ligand movement in the SAM-binding pocket. 
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We present in Figure 6 very similar hydrogen bonding patterns between the SFG-bound and 
Compound 5-bound MTase complexes. The SFG-bound MTase exhibited a slightly lesser number of 
hydrogen bonds than the Compound 5-bound MTase, during 25-75 ns and 130-155 ns, which 
correspond with the flexibility of the protein during that period of the simulation. Nonetheless, toward 
the latter period of the simulation, i.e. between 170-200 ns, the number of hydrogen bonds were 
approximately consistent in both inhibitor-bound MTase complexes. Although, the apo MTase 
displayed a reduced number of hydrogen bonds than both inhibitor-bound complexes, indicating that 
the apo system was less stable than bound systems. 
3.2.2   Residual Variations within the NS5 MTase 
To determine the flexibility of amino acid residues in the Apo and bound systems, root of mean square 
fluctuation (RMSF) of the residue α-carbons were calculated. In Figures 7 and 8, we illustrate that 
the MTase is more flexible when unbound, as compared to SFG- and Compound 5-bound enzymes, 
respectively.  Binding  of  SFG  and  Compound  5  lower  the  systems’  energy fluctuations making them 
more stable.  
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Figure 7: The average energy interpretation of each residue throughout the simulation of the 
apo MTase vs SFG-bound MTase. Highly fluctuating residues in the system are also 
illustrated in the crystal structure of the MTase and correlated with the peaks in the graph. 
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Figure 8: The average energy interpretation of each residue throughout the simulation of the 
apo MTase vs Compound 5-bound MTase. Highly fluctuating residues in the system are also 
illustrated in the crystal structure of the MTase and correlated with the peaks in the graph. 
 
Most binding site residues displayed resemblance in energy patterns in both inhibitor-bound and 
unbound conformations (binding site residues of SFG: Ser52, Gly54, Ser55, Asp75, Gly77, Cys78, 
Gly79, Gly82, Trp83, Tyr99, Thr100, Lys101, Gly102, His106, Glu107, Val126, Asp127, Va128, 
Phe129, Asp142, Ile143 and Lys178; binding site residues of Compound 5: Lys57, Gly77, Cys78, 
Gly79, Arg80, Gly81, Gly82, Thr100, Lys101, His106, Glu107, Asp127, Val128, Phe129, Asp142, 
Ile143, Gly144, Glu145, Ser146, Arg159, and Lys178), while others fluctuated significantly. Those 
binding site residues that altered in motion greatly throughout the simulation include 106 and 107 
upon SFG binding, as well as 100, 101,102, 127, 128 and 129 upon Compound 5 binding. An 
intriguing observation is that although the residues that form a loop at the binding site (residues 100-
107) altered in conformation majorly throughout the simulation, the residues that form a loop beneath 
the SAM-binding site (residues 34-53) fluctuated more. This finding was observed in the SFG-MTase 
complex (Figure 7), but quite the opposite in the Compound 5-MTase complex (Figure 8), where 
more fluctuation occurred at the binding site loop rather than the loop below the binding site. Binding 
of inhibitors rendered the MTase more stable as the flexibility of those residues decreased and the 
enzyme became more compact to accommodate inhibitor binding. The presence of these inhibitors in 
the SAM-binding site strongly affected the global dynamics of most loops and helices in the MTase 
enzyme. 
 
These results are concurrent to those of DCC, which was utilized in the analysis of fluctuations of 
atoms within the NS5 MTase backbone, as well as domain motions, focusing specifically on the α-
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carbons. Variations of colors represent residue distance analysis plots, where red to yellow areas 
signify positive/strong-correlated movements between α-carbons of residues and blue to black areas 
signify negative/anti-correlated movements. In Figure S2, it can be noticed that the Apo MTase 
fluctuates more than when bound. It is evident that highly fluctuating residues that are shown in 
RMSF graphs are parallel to the anti-correlative residual movements in the DCC plots of each system. 
Likewise, residues that follow similar trends in movement throughout the simulation show strong 
correlation patterns. 
 
Figure S2: Dynamic  cross  correlation  of  the  α-carbon atoms of the apo MTase (A), SFG-
bound MTase complex (B) and Compound 5-bound-MTase complex (C). 
 
A B 
C 
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3.2.3   Binding Free Energy Calculations 
Average measures of the all factors of molecular mechanics computed over the 200 ns molecular 
dynamic simulation of the SFG-MTase and the Compound 5-MTase systems are tabulated below 
(Table 1). 
Table 1: An outline of the MM/PBSA binding free energy contributions to the SFG-MTase 
system and the Compound 5-MTase system. 
 
The approximated binding free energy between SFG and the MTase is -34.99 kcal.mol-1, while that 
of Compound 5 and the MTase is -21.27 kcal.mol-1. This substantial difference in binding energy 
(~13 kcal.mol-1) between the individual inhibitors and the enzyme corresponds with experimental 
evidence that SFG binding to the MTase is potent at a lower IC50 than that of Compound 5 [21]. The 
                     Energy Components (kcal.mol-1) 
  ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
 
 
SFG-
MTase 
System 
MTase -2047.42 ± 20.73 
-16727.67 
± 113.43 
-18775.10 
± 111.10 
-3474.49 
± 96.04 
-22249.58 
± 52.82 
SFG -4.37 ± 1.59 
-93.06 ± 
7.97 
-97.43 ± 
7.75 
-42.69 ± 
3.32 
-140.12 ± 
6.51 
Complex -41.73 ± 4.86 
-60.32 ± 
23.63 
-102.04 ± 
26.13 
67.05 ± 
19.46 
-34.99 ± 
8.02 
 
 
Compoun
d 5-
MTase 
System 
MTase -2041.29 ± 20.69 
-16849.53 
± 96.53 
-18890.82 
± 93.77 
-3372.78 
± 80.45 
-22263.60 
± 46.55 
Compoun
d 5 
-5.06 ± 
1.39 
-21.99 ± 
3.36 
-27.05 ± 
3.34 
-44.43 ± 
4.63 
-71.48 ± 
4.32 
Complex -34.06 ± 6.27 
-35.87 ± 
14.03 
-69.93 ± 
15.25 
48.66 ± 
12.89 
-21.27 ± 
5.21 
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estimated van der Waals contributions (ΔEvdW) and electrostatic contributions (ΔEelec) towards total 
binding free energy in the SFG-MTase system (−41.73  kcal.mol−1 and -60.32 kcal.mol−1, respectively) 
are higher than that of the Compound 5-MTase  system  (−34.06  kcal  mol−1 and -35.87 kcal mol−1, 
respectively). The estimated solvation contribution (ΔGsolv) toward the binding free energy in the 
SFG-MTase system (67.05 kcal mol−1) is slightly higher than that of the Compound 5-MTase system 
(48.66 kcal mol−1). In Table 1, the energy components presented indicate that the most favorable 
contributions for binding of inhibitors, SFG and Compound 5, derived from ΔEvdW and ΔEelec. 
3.2.3   Decomposition Analysis of Binding Site Interaction Energy. 
The binding free energy was decomposed further into contributions from specific amino acid residues 
of the MTase. We present via the graphs in Figures 9 and 10 the contrasting protein–ligand interaction 
continua between the SFG-bound MTase and the Compound 5-bound MTase, respectively.  
 
Figure 9: MTase residues that interact with SFG (left) and energy contributions of the highest 
interacting residues at the SAM-binding site (right). 
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The per-residue energy decomposition analysis that we’ve  presented  in  Figure  9  show  that the highly 
contributing binding site amino acid residues toward the energy of the SFG-bound complex were 
His106 (-2.806 kcal.mol-1 [vdW]; -2.747 kcal.mol-1 [elec]), Glu107 (-3.857 kcal.mol-1 [elec]), Asp142 
(-5.139 kcal.mol-1 [elec]) and Ile143 (-2.321 kcal.mol-1 [vdW]). Whereas, energy contributions of 
other binding site residues that were less include Asp75 (-1,586 kcal.mol-1 [elec]), Gly77 (-1.452 
kcal.mol-1 [vdW]; -1.886 kcal.mol-1 [elec]), Thr100 (-1.082 kcal.mol-1 [vdW]; -0.553 kcal.mol-1 
[elec]), Lys101 (-1.563 kcal.mol-1 [vdW]; -1.15 kcal.mol-1 [elec]), Val126 (-1.032 kcal.mol-1 [elec]), 
Asp127 (-0.883 kcal.mol-1 [vdW]; -1.99 kcal.mol-1 [elec]) and Val128 (-0.959 kcal.mol-1 [vdW]; -
1.09 kcal.mol-1 [elec]). From Figure 9, it can be observed that the electrostatic energy contribution 
from residues 106, 107 and 142, and the van der Waals energy from residues 77, 106 and 143 in the 
SFG-MTase complex are most likely responsible for the high interaction energy in the system (ΔGbind 
= -34.99 kcal.mol-1). 
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Figure 10: MTase residues that interact with Compound 5 (left) and energy contributions of 
the highest interacting residues at the SAM-binding site (right). 
High-energy contribution from the Compound 5-bound complex stem from interacting residues 
Gly77 (-1.977 kcal.mol-1 [elec]), His106 (-2.043 kcal.mol-1 [vdW]), Glu107 (-3.94 kcal.mol-1 [elec]), 
Asp142 (-2.67 kcal.mol-1 [elec]), Ile143 (-1.922 kcal.mol-1 [vdW]), Glu145 (-3.746 kcal.mol-1 [elec]) 
and Lys178 (-2.19 kcal.mol-1 [elec]). Binding site residues with slightly lower energy contribution to 
the system were Cys78 (-0.391 kcal.mol-1 [vdW]; -0.602 kcal.mol-1 [elec]), Thr100 (-1.541 kcal.mol-
1 [elec]) and Val128 (-0.81 kcal.mol-1 [vdW]). From Figure 10, it can be concluded that the 
electrostatic energy contribution from residues 107, 142 and 145, and the van der Waals energy from 
residues 106 and 143 in the Compound 5-MTase complex may be accountable for the high interaction 
energy in the system (ΔGbind = -21.27). 
The large difference in binding affinity between the SFG-bound and Compound 5-bound complexes 
(~13 kcal.mol-1) may be owing to the increase in electrostatic binding energy of Asp142 of the MTase 
to SFG, as well as van der Waals and electrostatic energies of His106, as compared to that of 
Compound 5.  
3.3   Fingerprints for the Design of New Chemical Entities (NCEs)  
Looking at the binding implications of SFG to the ZIKV NS5 MTase, potential use of SFG could be 
a promising starting point as a prototype candidate for ZIKV treatment. We therefore created a map 
depicting the key chemical, structural and pharmacophoric fingerprints of SFG that will assist 
medicinal chemists and researchers in the identification and design of future new chemical entities 
for potential ZIKV inhibitors. The pharmacophoric elements that associate with highly contributing 
residues of the MTase were chosen to build our ensemble as we have illustrated in Figure 11. 
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Figure 11: Schematic representation of the key chemical, structural and pharmacophoric 
fingerprints of SFG. 
As we have presented in Figure 11, it can be noticed that the N6 and N7 atoms are crucial to interact 
with the target by creating positive ionization with Glu107 and Asp142 of the ZIKV MTase, 
respectively. Retention of N6 and N7 will contribute positive ionizations responsible for ligand-
enzyme interactions. Furthermore, the N2, N5, O2, O3 and O5 atoms are essential in the formation 
of strong hydrogen bonds with Arg159, His106, Gly79, Thr100, Lys101 and Arg80 respectively, 
which are mandatory for enzyme stability. Preservation of the N2, N5, O2, O3, and O5 atoms will 
induce stability and strong binding of NCEs to the ZIKV MTase.  
4   Conclusion 
The ZIKV is a "public health emergency of international concern" and therefore a serious global 
threat. Apart from ZIKV, Compound 5 and SFG have also shown inhibitory effects in other 
flaviviruses, including DENV, WNV, YFV and JEV. The molecular dynamic analyses described this 
study reveal the conformational evolutions, i.e. variations in the ZIKV NS5 MTase after binding of 
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these inhibitors at a molecular level. Molecular dynamic simulations of 200 ns demonstrate radical 
movements within the MTase, particularly of the loops surrounding the SAM-binding pocket and 
RNA-binding site. The dynamic loop fluctuations in motion were uncovered in the RMSD and RMSF 
analyses and substantiated by examining the 3-dimensional molecular landscape of the loops at 
specific time intervals throughout the simulation.  
Upon binding to the MTase, both SFG and Compound 5 have shown to stabilize the rather erratic apo 
system, although, it was noticed that SFG renders the MTase more stable and more compact than 
Compound 5. The SFG-bound system also reached convergence while the Compound 5-bound 
system did not. The binding affinity and binding site interactions (bond and non-bond interactions) 
between SFG and the SAM-binding pocket of the MTase were stronger than those of Compound 5. 
Binding energy calculations identified His106, Glu107, Asp127, Asp142 and Ile143 as key players 
in the binding of SFG to the MTase; and Gly77, Thr100, His106, Glu107, Asp142, Glu145 and 
Lys178 in the binding of Compound 5 to the MTase. 
Binding of SFG to the SAM-binding pocket caused the loop surrounding the pocket (residues 100-
110) to shift so that SFG is held tighter in a more compact conformation. SFG-binding also resulted 
in the loop surrounding the RNA-binding site (residues 30-60) to cover the binding site, to prevent 
RNA from binding and replication from occurring. Strong and stable binding of SFG would also 
prevent SAM from binding and activating the MTase, avoiding methylation of RNA and the mRNA 
cap. 
To explore the use of SFG as a potential starting point as a prototype candidate for ZIKV treatment, 
we created a pharmacophore of SFG that will assist medicinal chemists and researchers in the 
identification and design of future new chemical entities for potential ZIKV inhibitors. 
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The information interpreted in this study will improve the understanding of ZIKV and will be 
beneficial in driving the development of anti-Zika virus drugs. Further experimentation is required to 
elucidate the roles of SFG and Compound 5 in ZIKV treatment. 
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Summary 
Aim: Zika virus (ZIKV) still poses a health risk to women and their babies without FDA-
approved vaccines or treatments. Experimentation has proved resveratrol inhibition of ZIKV 
NS3 helicase without specifying the molecular events during inhibition.  
Methods: Herein, we leaped forward to study the molecular dynamics of the bound and 
unbound  enzyme,   identifying  precise  binding   residues  and   interactions,  and   the  enzyme’s  
adaptation to support binding, since loop dynamics affect viral RNA replication. 
Results: Resveratrol stabilizes the P-loop and causes the RNA-binding loop to block the 
RNA-binding pocket for 200ns, which is concurrent with experimental evidence that 
resveratrol binding significantly reduces ATP hydrolysis activity. 
Conclusion: This study illuminates the structural dynamics of ZIKV helicase and 
druglikeness of resveratrol, which will advance anti- ZIKV drug development. 
 
Keywords (in alphabetical order) 
Antiviral therapy; Flavivirus; Molecular Dynamics; NS3 Helicase; Resveratrol; Zika virus  
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1. Introduction 
The Zika virus (ZIKV) is infecting country to country around the globe [1]. With devastating 
consequences on pregnant women, mothers and their families, the ZIKV remains an 
unresolved scientific challenge [2]. The global expansion of ZIKV may be due to an 
increased frequency of travelling that occurs on an international scale, the susceptibility of 
remote populations, as well as the rise in the vector range due to global warming [3–5]. 
The ZIKV is composed of multiple enzymes, some of which have been proposed as targets 
for therapy [6]. The NS3 protein encodes one of the most important viral enzymes and is 
crucial for polyprotein processing and replication of flaviviruses [7]. The NS3 is comprised 
of an N-terminal protease and a C-terminal RNA helicase domain [8]. The helicase is central 
to the life cycle and survival of ZIKV [3,9]. Simulation of the helicase by RNA triggers 
underlying nucleoside triphosphatase activity, which supplies energy for unwinding of 
intermediates of viral replication [10]. For these reasons, the ZIKV NS3 helicase represents 
an ideal target for therapy. 
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Figure 17: Superimposition of the Zika virus and Dengue virus NS3 helicases as well as 
their corresponding overlapping sequences showing the similarities and differences in their 
amino acid residues. 
The ZIKV resembles Dengue virus (DENV) (Figure 1), therefore, inhibitors of DENV helicase may 
exhibit potency in ZIKV helicase inhibition [11]. Pan et al., 2017, have shown that the ATPase 
inhibitor, resveratrol, substantially reduces NS3 helicase ATP-hydrolysis activity in DENV [12]. 
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Figure 18: Chemical structure of resveratrol. 
 
Resveratrol, or 3,5,4ʹ-trihydroxy-trans-stilbene, is a natural polyphenol present in red wine, 
nuts, berries and traditional Asian medicines (Figure 2) [13]. The antioxidant potential of 
resveratrol is brought about via inhibition of reactive oxygen species, which involves 
scavenging free radicals such as superoxide anion (O2-), hydroxyl radical (OH-) and lipid 
hydroperoxyl radicals, as well as the inhibition of glutathione depletion [14]. Resveratrol was 
reported to have inhibitory effects on gene expression, nucleic acid synthesis, viral 
replication and protein synthesis for several viruses including hepatitis C virus, influenza 
virus, human immunodeficiency virus, herpes simplex virus and others [14–17]. The 
antioxidant and anti-inflammatory effects of resveratrol also benefit the cardiovascular 
system and function in neuroprotection, as well as treatment of diabetes mellitus [18–20]. 
127 
 
Additionally, resveratrol possesses several anticancer properties, which are critical in cancer 
prevention and treatment [21]. 
Experimental evidence has shown the ability of resveratrol to significantly decrease ATP 
hydrolysis activity of the ZIKV helicase [15], although, the molecular structural dynamics 
within the unbound ZIKV helicase (apo) and the ZIKV helicase bound to resveratrol have 
not been elucidated. We determine the affinity of resveratrol to the helicase, along with the 
binding mode and stability of the unbound and bound complexes. The loops surrounding the 
RNA binding site and the ATP-binding site (P-loop) were focused on, as flexibility of these 
loops play major roles in viral RNA replication. To our understanding, this is the primary 
study applying incorporated computational tools to analyze the way resveratrol binding 
influences the conformation of the ZIKV NS3 helicase. We postulate that this study will 
enhance the understanding of the structural dynamics of the inhibitor and the ZIKV NS3 
helicase and will aid in the search for anti-ZIKV treatment. 
 
2. Zika Virus NS3 Helicase 
The ZIKV NS3 protein constitutes 617 amino acid residues, which make up the protease 
(residues 1-167) and helicase (residues 168-617) enzymes. Processing of the polyprotein as 
well as viral replication are dependent on the activities of both these enzymes [7]. The serine 
protease is required for viral maturation via polyprotein processing, while the helicase is 
essential for RNA synthesis and genome replication of the virus [22]. 
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Figure 19: Protein sequences of the different domains of Zika virus NS3 helicase, as well as 
the major binding sites and loops. ATP: adenosine triphosphate; ssRNA: single-stranded 
RNA. 
The serine protease can be described as a folded globular domain comprising of two β-barrels 
[23]. The helicase constitutes three domains that resemble each other in size (Figure 3). 
Domain 1 (residues 182–327) and domain 2 (residues 328-480)  are  made  up  of  tandem  α/β  
RecA-like folds, which are present in helicases of superfamily 1 and 2. Domain 1 comprises 
motifs I (Walker A or P loop), Ia, II (Walker B) and III, which line a cleft between motifs 
IV, IVa, V and VI of domain 2. Motifs I, II and VI are involved in ATP binding and/or 
hydrolysis, and motifs Ia, IV and V are associated with interdomain communication and RNA 
binding. The ZIKV helicase, as with the DENV4 helicase, binds ATP at the lower end of the 
cleft at the interface of domains 1 and 2, while the pocket dividing domains 1 and 2 from 
domain 3 house the RNA.  Domains  2  and  3  interact  via  a  β-hairpin extension of domain 2, 
which functions as a wedge that facilitates unwinding of double-stranded RNA. Structures 
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within  domain  3  primarily  consist  of  α-helices. Domain 3 interacts with RNA as well as the 
NS5 RNA-dependent RNA polymerase in other flaviviruses [10].  
To date, several strains of ZIKV have been isolated. Due to interest in the helicases of 
different strains, we examined the similarities/differences in the helicase sequences. Multiple 
sequence analysis showed that the helicases of the French Polynesian (H/PF/2013), African 
(MR766) and Brazilian (BRA/2016) strains were almost identical, with very few differences 
in amino acid residues (Figure 4). Certain amino acid residues in the African strain are 
different from the other two strains. The distinguishing amino acid residues are at positions 
41, 226, 233, 298, 309, 409 and 410, none of which are in the ATPase pocket. We can 
therefore deduce that the manner in which resveratrol binds to this helicase will be 
comparable to helicases of other strains.  
 
Figure 20: Multiple sequence alignment of three strains of helicase sequences (strains: 
H/PF/2013, BRA/2016 and MR766). 
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3. Computational Methods 
3.1 Ligand and Receptor Preparation 
The crystal structure of the ZIKV NS3 helicase was obtained from RCSB Protein DataBank 
(PDB: 5JMT) [24,25]. The structure of resveratrol was obtained from PubChem [26] and 
prepared using Molegro Molecular Viewer software (Molegro-a CLC bio company, Aarhus, 
Denmark) and UCSF Chimera software package [27]. An apo system (NS3 helicase) and a 
resveratrol-bound system were subjected to 200 ns molecular dynamic simulations. 
 
3.2 Molecular Docking 
Optimized conformations and binding affinities of resveratrol within the ATP-binding pocket 
of the ZIKV NS3 helicase was achieved through molecular docking. Resveratrol was docked 
into the ATP-binding pocket (competitive inhibitor of ATP) of the NS3 helicase (grid box of 
spacing of 0.375 Å and x, y, z dimensions of 32 x 26 x 30) via the AutoDock vina plugin of 
UCSF Chimera software [27–29]. Ten docked poses of the ligand in the binding pocket of 
the enzyme were generated in pdbqt format by AutoDock Vina and the most favorable 
geometric pose with the most negative binding energy (kcal.mol-1) was saved from the 
ViewDock feature. The best complexes were subjected to molecular dynamic simulations. 
More detailed information regarding molecular docking can be found in the referenced 
articles [30–32]. To verify that resveratrol was docked into the correct pocket, Figure S4 
demonstrates the superimposition of ATP bound to the helicase (PDB: 5GJC) and the docked 
complex of resveratrol to the helicase. 
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3.3 Molecular Dynamic Simulations 
Molecular dynamic simulations were carried out using AMBER PMEMD dynamics engine 
with GPU acceleration [33,34]. The helicase was parameterized using the AMBER force 
field, FF14SB [35,36]. The inhibitor was hydrogenated and charged with Gasteiger charges, 
while the helicase protein was dehydrogenated preceding the simulation. Atomic partial 
charges were created for resveratrol using antechamber which applies the general AMBER 
force field (GAFF) and restrained electrostatic potential (RESP) methods [35,37,38]. The 
AMBER 14 LEAP module was used to combine, neutralize and solvate all systems via 
addition of hydrogen atoms, sodium and chloride ions, followed by suspension into an 
orthorhombic box of TIP3P water molecules to ensure all atoms were within 10 Å of the box 
edges. The amino acid residues of the helicase were renumbered from 1. The systems were 
initially minimized (2500 steps) using a restraint potential of 10 kcal.mol-1 Å-2 applied to the 
solutes, for 1000 steps of steepest descent followed by 1000 steps of conjugate gradient 
minimization. Thereafter, the systems were further fully minimized (200 steps) via 
unrestrained conjugate gradient algorithm. 
A constant-temperature, constant-volume ensemble simulation was carried out for 50 ps from 
0 K to 300 K, to preserve a fixed volume and number of atoms in each system. A harmonic 
restraint of 10 kcal.mol-1 Å-2 and Langevin thermostat collision frequency of 1.0 ps-1 were 
applied to the solutes. All systems were then subjected to equilibration (500 ps) with a 
constant operating temperature (300 K) and pressure (1 bar) using the Berendsen barostat 
and number of atoms resembling an isobaric-isothermal ensemble. The shake algorithm was 
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applied to restrain hydrogen bonds during the simulations, which were conducted for 200 ns 
per system using an SPFP precision model. 
 
3.4 Per-Residue Decomposition Analysis & Binding Free Energy Computation  
To   establish   the   binding   free   energy   (ΔGbind) of resveratrol to the ZIKV NS3 helicase 
enzyme, we employed molecular mechanics integrated with the Poisson-Boltzmann or 
generalized Born and surface area continuum solvation (MM/PBSA and MM/GBSA) 
approach [39,40]. These methods have been elaborated in the referred papers [41,42]. 
The molecular dynamic simulation yielded a trajectory depicted by 50,000 snapshots, which 
were  averaged  to  generate  ΔGbind. The binding strengths between resveratrol and the helicase 
may be defined as: 
(1) ΔGbind = Gcomplex − Greceptor −  Gligand 
(2) ΔGbind = Egas + Gsol – TS 
(3) Egas = Eint + EvDW + Eele 
(4) Gsol = GGB + GSA   
(5) GSA =  γSASA 
where: 
Eele  Electrostatic potential energy from Coulomb forces 
Egas   Gas-phase energy (based on FF14SB force field terms) 
Eint  Internal energy 
EvdW  van der Waals energy 
Gsol  Solvation free energy 
GGB  Polar solvation energy 
GSA  non-polar solvation energy 
S  Total entropy of solute 
SASA  Solvent accessible surface area (water probe radius of 1.4 Å) 
T  Total entropy of temperature 
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A per-residue free energy atomistic decomposition was adopted to estimate the contribution 
of  each  residue  to  the  total  ΔGbind at the binding site, for significant residues of the helicase 
using the AMBER14 MM/GBSA method. Further analyses were carried out on the 
resveratrol-bound complex. 
3.5 ADME Assessment of Resveratrol 
Using the absorption, distribution, metabolism and excretion (ADME) online prediction tool, SWISS 
ADME, we assessed the druglikeness of resveratrol. The SWISS ADME website allows the 
computation of physicochemical descriptors and provides a prediction of druglike nature, 
pharmacokinetic properties, medicinal chemistry friendliness and ADME parameters small molecules 
to support drug discovery [43]. 
 
4. Results 
4.1 Molecular Dynamic Simulations & Systems Stability 
The trajectories of 200 ns molecular dynamic simulations of the apo and resveratrol-bound 
systems were monitored and analyzed post-dynamically to verify stability of the systems. 
 
4.1.1 Atomic  Distribution  of  α-carbons of NS3 Helicase 
The  deviation  of  α-carbons within the NS3 helicase during simulation of the systems were 
established by calculating the root-mean-square deviation (RMSD). In Figure 5, we show 
that resveratrol brought about different atomic changes in the helicase during the simulation, 
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when compared to the apo system. Both systems remained within a 1.5 Å range throughout 
the simulation.  
 
Figure 21: Resveratrol binding to ZIKV NS3 helicase stabilizes the enzyme. Snapshots at 
10 ns intervals from 150-200 ns show the spontaneous behaviour of the RNA-binding loop 
(green) in the apo enzyme (grey), while the same loop (blue) in the bound enzyme (red) 
becomes stable via formation of a 310-helix.  
The RMSD pattern of the apo system indicates major fluctuations of the system between 34-
40 ns and 164-167 ns and convergence in the latter part of the simulation (after 175 ns). The 
fluctuations of the resveratrol-helicase complex dropped between 180-200 ns, where the 
helicase became more compact when compared to the apo helicase (Figure S1). The P-loop 
in the apo also undergoes constant structural variations (deviation=1.783Å), whereas that of 
the bound enzyme is stable (deviation=0.637Å). Resveratrol also stabilized the helicase 
during the 34-40 ns and 164-167 ns period when the apo fluctuated. It is noticed in Figure 5 
that as the end of the simulation approached, the RNA binding loop moved closer toward the 
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RNA binding pocket. This may have impeding effects on the entry and binding of RNA in 
that pocket.  
 
Figure 22: Resveratrol binding to the NS3 helicase (red) induces compactness of the enzyme, 
as compared to the apo (grey). 
Superimposition of the bound (red) and unbound (grey) helicase at 200 ns (Figure 6) 
demonstrates the impact of resveratrol binding to the ZIKV NS3 helicase. The overall 
configuration of the helicase is more compact when bound, as the outer loops and coils move 
inward, suggesting a looser apo conformation. As emphasized in Figure 6, distances between 
loops on the top, left and right regions (Domain III, II and I, respectively) of the enzyme 
decreased in the bound complex when compared to the apo. The RNA binding loop and 
extended coil surrounding the inhibitor (enlarged in bottom right) move inward and the outer 
loop in Domain II (enlarged in bottom left) move upward conforming the enzyme to a more 
compact shape. 
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4.2 Intra- and Intermolecular Interactions in ZIKV NS3 Helicase 
4.2.1 Fluctuating Residues within the NS3 Helicase 
To provide a better understanding of the residues responsible for the fluctuating energy 
patterns in Figure 5, we calculated the root-mean-square fluctuation (RMSF) of each residue 
of both systems.  
 
Figure 23: Residues of the apo helicase (grey) fluctuate more than residues of the resveratrol-
bound helicase (red). 
The pattern in the fluctuation of residues in the apo system bear resemblance to the 
resveratrol-bound complex, however, residues 1-43, 129-137, 201-208, 389-414 in the apo 
fluctuate more than the bound complex. In Figure 7, we demonstrate that Domain I of the 
helicase (green) fluctuates more than Domains II and III. Binding of resveratrol to the 
helicase decreases movements of the P-loop and causes and increases in movements of the 
RNA-binding loop. Considering both systems, residues of the apo system are more energetic 
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and therefore, the apo system is a lot more flexible than the resveratrol-bound system, 
suggesting that the inhibitor reduces the energies of the residues within the helicase. 
4.2.2 Binding Free Energy Calculations and Binding Site Interaction 
Decomposition Analysis 
The intensity of interactions between a ligand and receptor may be quantified by the binding 
free energy obtained from molecular mechanics with Poisson-Boltzmann surface area 
(MM/PBSA) calculations. Mean calculations of internal energy changes of the resveratrol-
helicase system, and resveratrol and the helicase alone, totaled over the 200 ns simulation are 
presented in Table 1. 
Table 3: A representation of the binding free energy contributions to the Resveratrol-bound 
system. 
 Energy Components (kcal.mol-1) 
 ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Helicase -3555.87 ± 29.16 
-29681.50 ± 
134.2 
-33237.37 ± 
133.18 
-4769.99 ± 
104.63 
-38007.37 ± 
63.52 
Resveratrol -0.25 ± 0.66 65.32 ± 0.86 65.07 ± 1.08 -18.85 ± 0.3 46.22 ± 1.21 
Complex -26.86 ± 2.53 -36.54 ± 4.69 -63.4 ± 4.64 33.05 ± 3.23 -30.35 ± 2.86 
ΔEelec, electrostatic energy; ΔEvdW, van der Waals forces; ΔGbind, binding free energy; ΔGgas, free energy in gas 
phase; ΔGsolv, solvation energy 
The estimated binding free energy between resveratrol and the helicase is -30.35 kcal.mol-1. This 
strong binding is concurrent with experimental evidence that resveratrol binding to the helicase 
significantly reduces ATP hydrolysis activity and is potent at an IC50 of 94.25 ± 5.02 µM [15]. The 
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energies shown in Table 1 suggest that the most favorable conditions for resveratrol binding are 
derived from ΔGgas and ΔEelec. 
 
Figure 24: Exploration of the interactions that exist between resveratrol and residues of the 
ZIKV NS3 helicase. A. Resveratrol within binding pocket of helicase zooming into the 
hydrophobic interactions and hydrogen bonds between ligand binding residues and 
resveratrol. B. Per-residue decomposition analysis of ligand binding residues. C. Hydrogen 
bonding in ligand binding pocket. EEL: electrostatic energy; vdW: van der Waals. 
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The analysis was expanded into per-residue energy decomposition of resveratrol-binding 
residues of the helicase. In Figure 8, we show the resveratrol-helicase interaction spectrum. 
The ligand interaction diagram in Figure 8A clearly illustrates hydrophobic interactions 
between resveratrol and the helicase, particularly residues Leu20, His21, Pro22, Ala24, 
Thr27, Arg28, Glu57 and Ala143. Hydrogen bonding is also clearly apparent between Gly23 
and Gly25 with the O1 atom of resveratrol, and between Lys26 and the O3 atom of resveratrol. 
The graph in Figure S3 and the hydrogen bond surface surrounding resveratrol in Figure 8C 
coincide with these results. The results from the graph in Figure 8B is concurrent with the 
findings in Table 1 that the electrostatic energy contributes more toward total binding free 
energy than van der Waals forces. Residues His21, Lys26 and Gly57 contributed mostly 
toward the electrostatic energy that was responsible for binding, and Lys26 and Thr27 
contributed more toward van der Waals forces than other binding site residues.  
4.3 Resveratrol ADME assessment 
Using the online tool, SwissADME, the druglikeness of resveratrol was elucidated (Table 2). 
Resveratrol is likely to permeate lipophilic membranes, as well as the blood brain barrier (BBB). 
Clarification of the concept of LogP may be found in Devnarain et al (2017) [44]. Resveratrol is water 
soluble,   which   is   favorable   for   oral   bioavailability.   Lipinski’s   rule   of   five   is   used   to   evaluate  
druglikeness of a chemical compound [45].  Resveratrol  does  not  violate  any  of  Lipinski’s  rules,  and  
also adheres to other filters that define druglinekness, including Ghose, Veber, Egan and Muegge. 
The BOILED-egg diagram of resveratrol generated by SwissADME is represented by Figure S2. The 
physicochemical and pharmacokinetic properties of resveratrol are favorable for drug discovery 
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Table 4: Druglikeness of Resveratrol 
Formula C14H12O3 
Molecular weight  228.24 g.mol-1 
Lipophilicity (LogP) 1.71 
Water solubility (Log S) Soluble 
GI absorption High 
BBB permeant Yes 
Lipinski’s  Rules Yes 
Ghose, Veber, Egan, Muegge Yes 
 
5. Discussion 
The effects of resveratrol have been studied previously for its inhibition of nucleic acid 
synthesis, gene expression, viral replication and protein synthesis in several viruses. 
Experimental studies have shown that resveratrol inhibits ZIKV in vitro, however, the 
binding mechanism and binding interactions of resveratrol to the ZIKV NS3 helicase were 
not elucidated. The 200 ns molecular dynamic simulations of the apo helicase and 
resveratrol-bound helicase have allowed us to understand the shifts that occur in the enzyme 
upon binding and the affinity of the helicase for resveratrol. 
A  “loose”  and  expanded  structure  of  the  helicase  is  necessary  to  accommodate  RNA  in  its  
binding pocket for viral RNA replication. Resveratrol binding renders the helicase more 
compact than when unbound, limiting the space within the RNA-binding pocket. The P-loop 
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regulates ATP binding and hydrolysis during ZIKV replication. Resveratrol stabilized the P-
loop when compared to the apo and resulted in major shifts and conformational changes in 
the RNA-binding loop. Since resveratrol binding to the helicase decreases ATP hydrolysis, 
we speculate that resveratrol binding may also hinder RNA binding and replication due to 
movements of the RNA-binding loop in front of the entrance of the RNA-binding pocket, 
however, further experimentation is required to substantiate this theory. Strong binding 
interactions, including hydrophobic and hydrogen bonding, between resveratrol and residues 
of the helicase also reduce fluctuations of the enzyme domains, thus explaining the high 
potency of resveratrol inhibition on the ZIKV NS3 helicase. Conformational ensembles 
generated from the molecular dynamic simulations in this study match with the experimental 
data. 
 
6 Conclusion 
To our understanding, this is the first study to have presented data describing the events that 
occur at a molecular level when resveratrol binds to the ZIKV NS3 helicase enzyme. Since 
resveratrol is a competitive-inhibitor of ATP and stably binds to the ATPase pocket in the 
helicase, we can speculate that inhibition of ZIKV by resveratrol at an organism level may 
render  the  enzyme  “powerless”  and  may  even  lead  to  resveratrol  being  a  potent  inhibitor  of  
multiple viruses including other flaviviruses such as DENV, WNV and JEV. Resveratrol is 
also a natural antioxidant, therefore, its use as a multipurpose antiviral implies safety, easy 
availability and accessibility, and cost effectiveness, particularly in rural communities. 
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This material refines the knowledge surrounding resveratrol inhibition of the ZIKV NS3 
helicase and will aid the search for anti-ZIKV drugs. Additional investigations are vital to 
substantiate the role of resveratrol in the treatment of ZIKV. Further analysis will also include 
the interactions between resveratrol and other members of the Flavivirus genus of viruses. 
 
Summary Points 
 The Zika virus (ZIKV) continues to affect pregnant women and their infants without 
FDA-approved vaccines or treatments.  
 There is still very much to learn about ZIKV before we can effectively treat it. 
 Understanding the molecular dynamics behind potential organism level inhibition 
could help prevent future resistance of ZIKV to drugs.  
 Hence, we studied the molecular dynamics of the unbound and resveratrol-bound 
helicase for 200ns. 
 Molecular dynamic simulations and post-dynamic analyses allowed us to pinpoint the 
precise residues and interactions that are key in the binding of resveratrol to the 
helicase.  
 The movements of loops surrounding RNA and inhibitor binding sites also regulate 
binding and replication, therefore, we analyzed the shifts in loops surrounding the 
ATPase pocket and RNA binding site. 
 The druglikeness of resveratrol was also established using computational tools, which 
led to the conclusion that resveratrol follows all  of  Lipinski’s  rules  and  can  pass  the  
blood-brain barrier, making it suitable for the treatment of ZIKV. 
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 This material demonstrates the structural dynamics of the ZIKV NS3 helicase upon 
resveratrol binding, which will advance anti- ZIKV drug development. 
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CHAPTER 7: SYNTHESIS 
1 Conclusion 
The rampant ZIKV and its devastating clinical outcomes led to a rapid research response since the 
2015 ZIKV epidemic in Brazil (Campos, Bandeira and Sardi, 2015), which have begun explaining 
why ZIKV shifted from being inconspicuous to notorious. It has become critical that a cure for ZIKV 
is discovered. Major breakthroughs have been made in the scientific community surrounding the 
design of potential anti-ZIKV small molecule inhibitors and vaccines, although, none have passed 
clinical trials (da Silva, Martins and Jardim, 2018).  
In this study, a major challenge of anti-ZIKV drug design - the ability of a drug to cross the BBB – is 
addressed by providing a route map of strategic approaches to design drugs with improved BBB 
permeability and to transport drugs that are BBB-impermeable. Moreover, an assessment of the 
bioavailability of screened drugs as potential ZIKV inhibitors is presented.  
This study also improves the knowledge base surrounding the structural and functional features of 
pharmacological targets of ZIKV, in this case being the NS3 helicase and NS5 MTase enzymes, to 
enable the design and discovery of effective ZIKV inhibitors. The binding mechanisms of two 
potential ZIKV MTase inhibitors – Sinefungin and compound 5- were elucidated using molecular 
dynamics, which revealed that Sinefungin is a more stable inhibitor of the MTase than compound. 
This is also in agreement with experimental findings (Coutard et al., 2017). The molecular mechanism 
of inhibition by resveratrol, an antioxidant, on the NS3 helicase describes the modification of the 
enzyme to accommodate inhibitor binding, particularly since ZIKV RNA replication is influenced by 
loop movements. The druglike nature of resveratrol was established and based on its chemical 
features, it has the ability to pass the BBB. Additionally, this study provided specific amino acid 
residues of the NS3 helicase and NS5 MTase enzymes that highly contribute to inhibitor-binding, as 
well as precise moieties of potential ZIKV inhibitors that are of significance, to assist in the discovery 
of more potent ZIKV inhibitors. 
In conclusion, the outcomes presented in this study are of scientific merit and should serve as a 
cornerstone for anti-ZIKV drug design and discovery through molecular modeling and CADD. 
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2 Future Perspectives 
The potential ZIKV inhibitors referred to in this study have demonstrated favorable protein-ligand 
binding energies and interactions, thus hold potential as lead compounds. Although, these in silico 
studies must be further validated through biological testing.  
The substantial research response after the ZIKV outbreak triggered the discovery of a flood of 
potential small molecule inhibitors and vaccines, which are now in clinical trials. However, the effects 
of these potential vaccines and inhibitors on humans, particularly on pregnant women and their 
infants, are yet to be established. Since neuronal cells are predominantly affected by ZIKV, more 
validations are required to learn the effects of vaccines and inhibitors on neurons to eliminate the risk 
of any further damage to the brain. Moreover, further research must be put into the design of drugs 
that can pass the BBB to allow it to act on neuronal cells. This study described approaches that may 
be used to ensure anti-ZIKV drugs can pass the BBB, however, experiments must be designed and 
carried out to analyze its efficacy. 
The outcomes of this study and future studies of effective ZIKV inhibitors may be applicable to other 
viruses that result in future unforeseen clinical conditions. 
 
3 References 
 Campos,  G.  S.,  Bandeira,  A.  C.  and  Sardi,  S.  I.  (2015)  ‘Zika  Virus  Outbreak,  Bahia  Brazil’,  Emerging 
Infectious Diseases, 21(10), pp. 1885–1886. doi: 10.32301/eid2110.150847. 
Coutard, B. et al. (2017)  ‘Zika  Virus Methyltransferase: Structure and Functions for Drug Design 
Perspectives’,  Journal of Virology, 91(5), pp. e02202-16. doi: 10.1128/JVI.02202-16. 
da Silva, S., Martins, D. O. S. and  Jardim,  A.  C.  G.  (2018)  ‘A  Review  of  the  Ongoing  Research  on  
Zika Virus Treatment.’,  Viruses. Multidisciplinary Digital Publishing Institute (MDPI), 10(255), pp. 
1–18. doi: 10.3390/v10050255. 
150 
 
APPENDICES 
Biomedical Research Ethics Committee (BREC) exemption letter 
 
 
Brain grants permission of access to Zika virus but
denies entry to drugs: a molecular modeling
perspective to infiltrate the boundary†
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The magnetism of the Zika virus to neuronal cells proves to be one of the major concerns in the
development of effective inhibitors. Although the blood–brain barrier limits the entry of most drugs,
tailored small molecule inhibitors and drug delivery systems are currently being designed to overcome
this obstacle. We have identified the core challenge to be addressed – blood–brain barrier permeability
– and provided insight into strategies that can be used to improve drug delivery to the brain. We have
compiled drugs that have previously been proposed as potential Zika virus inhibitors and classified
chemical features of those drugs, which influence blood–brain barrier permeability. Thereafter, we
created a route map to design drugs with improved blood–brain barrier permeability. An alternative
approach using drug delivery systems to transport membrane-impermeable Zika virus inhibitors to the
brain is also proposed, along with descriptions of known drug carriers. This review provides information
for further research toward inhibitors of Zika virus.
The tale of Zika virus
The Zika virus (ZIKV), a mosquito-borne virus, belongs to the
Flaviviridae family and has similar characteristics to other a-
viviruses such as Dengue virus, West Nile virus and Japanese
Encephalitis virus.1 The rapid disseminating potential and
repercussion in humans are attributed to the various modes of
transmission, primarily through the bite of an infected Aedes
aegypti mosquito.2 The ZIKV is also transmitted through sexual
intercourse,3 blood transfusions4 and from a mother to child
perinatally.5
The ZIKV was originally isolated in Uganda in the Zika forest
in 1947.6 For nearly 7 decades thenceforth, sporadic infections
caused by ZIKV were reported in several countries worldwide.
These include more equatorial countries of Africa such as
Tanzania, Egypt, Kenya, Nigeria, Central African Republic, and
Gabon; some Asian countries including Pakistan, India,
Malaysia, Thailand, the Philippines and Indonesia; and many
islands in the Pacic Ocean.7–10 The most devastating and
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highly publicized outbreak that captured the world's attention
occurred in Brazil in 2015, which triggered global panic as it
rapidly spread across America.11 In 2016, the ZIKV broadened its
geographic spectrum to North American Florida and Texas
where the infection was locally transmitted.10
There has been prior ambiguity regarding the diagnosis of
ZIKV, as its infection manifests similarly to common colds and
other avivirus infections.12 These symptoms include fever,
headaches, conjunctivitis, joint pain, muscle pain and skin
rash.13,14 The speculation of ZIKV infection depends on its
manifestation and history of mosquito bites.12 The ZIKV is
detectable in bodily uids such as saliva,15 semen,16,17 urine18
and amniotic uid,19 which can be veried in the laboratory.20
The various modes of transmission of ZIKV make the human
body highly susceptible to infection.When ZIKV enters the body
through an infected female mosquito bite, the infection mani-
fests as a rash in the vicinity of the bite.9 This occurs due to the
release of virions into dermal and epidermal layers of the skin,
where ZIKV is introduced to the bloodstream and advances to
the lymph nodes to replicate and cause viremia.21
The ZIKV is an enveloped icosahedral virus that is made up
of a single-stranded, positive-sense genome. The enveloped
virion comprises of an 11 kilobase genome consisting of 10 794
nucleotides encoding 3419 amino acids.22 The open reading
frame (ORF) of the 50 and 30 untranslated region (UTR) encodes
a polyprotein that is cleaved into three structural proteins,
being the capsid (C), precursor membrane (prM), and envelope
(E).23 Seven non-structural (NS) proteins are also found in this
assembly, namely, NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5
(largest viral protein).24 The genomic protein organization is 50-
C-prM-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5-3025 and contains
an m7gpppAmpN2 at the 50 end and lacks a poly-A tail at the 30
end.26 A highly conserved 90–120-nucleotide strand is situated
close to the 30end that develops into a hairpin loop and is vital
for replication.26,27 Of the non-structural proteins, NS1, NS3 and
NS5 are highly conserved whereas the NS2a, NS2b, NS4a and
NS4b are small and hydrophobic.24 Of critical importance is the
proteolytic cleavage of prM to produce the pr and M protein by
furin-like protease located in the trans-Golgi network during the
egress of the particles as this promotes maturation of virions.28
The ramications of ZIKV infections have heavily impacted
thousands worldwide, particularly in newborns, since ZIKV-
infected pregnant women have given birth to babies with
congenital brain abnormalities, predominantly microcephaly
and intracranial calcication.13 The ZIKV infection has also
been shown to elicit Guillain–Barre´ Syndrome, which ultimately
advances to paralysis and death.29
Studies have shown tropism of the ZIKV for cells of the
nervous system, whereby entry into neuronal and endothelial
cells occur via AXL receptors situated on the cell surface.30–32
The ZIKV has also affected retinal cells that line the blood-
retinal barrier (i.e. retinal pigment epithelium and retinal
endothelium) in mice, which also express AXL receptors. This
presents as conjunctivitis.33
Blood–brain barrier permeability as
a core challenge in ZIKV therapy
Treating the symptoms of ZIKV will not yield permanent results;
hence nipping the cause at the bud may be the best route to
a solution. The blood–brain barrier (BBB) and placental barrier
are surrounded by lipophilic membranes and junctions, through
which only certain compounds can permeate.34 It has been
shown that the placenta is permissive tomost drugs as it serves to
allow for the exchange of nutrients for its biological purpose.35
The ZIKV can penetrate these membranes, which is evident by its
downstream pathogenic effects in fetal nervous systems.13,26,29,30
The specic characteristics of a compound govern the
method by which it is transported across the BBB, or whether or
not it is transported at all. Compounds that have surface
hydrogen bonds (hydrophilic compounds) are only permissive
through tight junctions of the BBB, which ultimately serve to
prevent the passage of molecules between cells of the endo-
thelium. These hydrophilic compounds are impermeable
through the lipophilic endothelium and require lipid-mediated
transport in order to permeate transcellularly. Large molecules,
such as insulin and transferrin, require receptors, whereas
small molecules require carrier-mediated transport to move
across the barrier. There is also active efflux transport for
endogenous BBB transporters (Fig. 1 – BBB).34,36–38
Bioavailability features of screened
drugs as prospective ZIKV inhibitors
There are FDA-approved drugs that have been proposed as anti-
ZIKV drugs based on their diverse antiviral/antimicrobial/
antibacterial activities in diseases other than ZIKV,39 however,
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the ability of those drugs to pass the BBB, their properties as
hydrophilic/lipophilic compounds, and their ability to be
absorbed by the gastrointestinal tract (GIT) have not yet been
clearly elucidated. To this effect, we have taken a step further
and utilized a chemical data base, PubChem, along with ADME
prediction tools, Swiss ADME40 to predict specic characteris-
tics of these candidate anti-ZIKV drugs and to verify whether or
not the proposed compounds by Barrows et al. (2016) could be
potential anti-ZIKV drugs with BBB-permeable proles. SWISS
ADME is a “website allows you to compute physicochemical
descriptors as well as to predict ADME parameters, pharmaco-
kinetic properties, druglike nature and medicinal chemistry
friendliness of one or multiple small molecules to support drug
discovery”.40 The proposed compounds are listed in Table 1.
The partition coefficient (log P) measures how hydrophilic or
hydrophobic a molecule is. The desired log P value of a mole-
cule likely to permeate lipophilic membranes should lie
between 0–5.41 The ability of a drug to pass through the BBB is
inuenced by their unique but varying properties.36 In Table 1,
!80% of the drugs described have the ability to pass through
lipophilic membranes, however, less than 20% of those drugs
can penetrate the BBB.40 Efficient GIT absorption of orally
administered drugs is required for entry into the bloodstream
and sufficient drug delivery,42 although, just half the drugs
mentioned are highly absorbed via the GIT. The results of this
table suggest that the ability of a compound to pass through the
BBB depends on factors additional to lipophilicity. From this
exercise we highlight 5 compounds that are predicted to pass
the BBB and the hydrophobic spots of each compound are
shadowed in yellow in Fig. 2.
Hydrophobic groups of compounds are required for hydro-
phobic interactions with target molecules. Hydrophobic inter-
actions are comparably stronger than some weak
intermolecular forces, such as hydrogen bonds or van der Waals
interactions, and ensure protein–ligand complexes remain
stable and biologically active.43 As depicted in Fig. 2, all ve
compounds from Table 1 that have the ability to pass the BBB
bear hydrophobic groups and therefore, possess the potential to
form hydrophobic interactions with target molecules. Although,
ngomolid and sertraline have more hydrophobic spots than
the other compounds in Fig. 2, and therefore, are more likely to
form stronger hydrophobic interactions.
Systematic approach to tackle the
challenge
To overcome the hurdle faced by most drug therapies, we are
presenting two main strategies that could potentially assist with
the design and bioavailability of compounds with an improved
BBB permeability prole. Furthermore, we include an approach
Fig. 1 A schematic representation of the blood–brain barrier and pathways across this barrier.
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that relies on the pre-existing BBB-impermeable drugs conju-
gated to drug delivery systems. These strategies are: (1) improve
the inhibitor and (2) carry the cargo.
Improve the inhibitor
In this approach, in silico tools may be used to model and
optimize potential compounds (Fig. 3), followed by compound
synthesis and biological testing. Phase 1 includes targeted
selection of potential anti-ZIKV compounds. This incorporates
screening for potential compounds with specic physicochem-
ical properties and antiviral activities using chemical databases,
and the use of absorption, distribution, metabolism, excretion
(ADME) prediction tools such as Swiss ADME, in order to lter
out compounds that encompass the ability to pass the BBB. The
ability of a compound to pass through the BBB is governed by
a function of lipophilicity, the molecular characteristics of
charged and hydrophobic residues of the compound as well as
molecular weight.37 The main lipophilic properties that must be
considered include the Hansch constant (p), hydrophobic
fragmental constant (f), log P, capacity factor values from RP-
HPLC (log kw), calculated log P values (CLOGP) and molecular
lipophilic potential (MLP).44 With regard to the charge of the
compound, only uncharged molecules can diffuse across the
membrane to become reprotonated once it leaves the
membrane and enters the brain uid.37 As the size of
a compound gets larger, its ability to permeate the BBB
decreases.45
Phase 2 involves the prediction of lipid permeability of the
potential anti-ZIKV compounds using molecular dynamic
simulations and 3D-modelled lipid bilayer simulations. Due to
the surrounding lipid membrane in the BBB, it is necessary to
assess compound interactions with the target enzyme within
lipid membrane.46
Phase 3 involves the estimation of binding affinities between
potential compounds, which pass through the BBB, and viral
enzymes. This may be achieved via binding free energy calcu-
lations or molecular docking of the compound of interest into
the active site of the target enzyme.47
Following the design process, the compounds must be
synthesized for further testing. Synthesis of the compound
involves construction of the carbon framework and the
addition/deletion/transformation of functional groups for
functionality of compound. Validation of synthesis is carried
out by ligand-binding assays which involves placing the target
Table 1 Predicted bioavailability features of prospective anti-ZIKV
inhibitors
Drug name
Lipid solubility
(log P)
BBB
permeation
GIT
absorption
Auranon 0.00 No High
Azathioprine 0.72 No Low
Bortezomib 0.00 No High
Clofazimine 4.72 No Low
Cyclosporine A 6.16 No Low
Dactinomycin 5.33 No Low
Daptomycin 0.79 No Low
Deferasirox 2.48 No High
Digoxin 4.69 No Low
Fingolimod 3.76 Yes High
Gemcitabine HCl 0.00 No High
Ivermectin 6.31 No Low
Mebendazole 1.27 No High
Meoquine HCl 0.00 No Low
Mercaptopurine hydrate 0.47 No High
Methoxsalen 2.22 Yes High
Micafungin !0.72 No Low
Mycophenolate mofetil 3.67 No High
Mycophenolic acid 2.38 No High
NITD008 1.30 No Low
Palonosetron HCl 0.00 Yes High
Pyrimethamine 2.15 Yes High
Sertraline 3.40 Yes High
Sofosbuvir 3.05 No Low
Sorafenib tosylate 3.84 No Low
Thioguanine 0.14 No High
Fig. 2 Hydrophobic footprints (highlighted in yellow) in chemical structures of potential anti-ZIKV compounds which have the ability to
permeate the BBB.
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enzyme and compound of interest into a solvent (e.g. water) to
allow the compound to interact with the active site residues of
the enzyme.48 Binding studies provide reliable assessments of
binding affinities, errors and binding mode.48 Further studies
including biological testing will investigate toxicity and efficacy
of the compound, including in vitro studies (cellular level), in
vivo studies (organism level) and ultimately clinical trials.
Microscale thermophoresis (MST) may also be used in order to
analyze the interaction between the inhibitors and receptors,
experimentally, which is established on the controlled move-
ment of particles along a temperature gradient.49
Carry the cargo
An alternate to creating new BBB-permeable drugs will involve
the utilization of drug carriers that have already been successful
in delivering drugs to the brain. This approach eliminates the
additional time and expense required to design and formulate
new drugs and drug delivery systems. A drug carrier could be
used to transport a BBB-impermeable drug to the brain and
allow for the drug to carry out its function against ZIKV.
There are existing drugs that have been proven to inhibit
ZIKV replication in isolated ZIKV infected cells, such as
NITD008 (ref. 50) and sofosbuvir,51 however the drugs cannot
pass the BBB to counteract the virus (Table 1). With half the
battle won due to their ability to inhibit ZIKV, ultimate triumph
over ZIKV would entail overcoming impermeability, which
requires the potential ZIKV inhibitors to be transported across
the BBB.
Previously utilized membrane-permeable drug delivery
approaches have been successful in transporting membrane-
impermeable drugs across the BBB for other infections and
diseases, such as Parkinson's disease and Alzheimer's
disease.52–55 Some known drug delivery systems used in various
disease cases include polymers and polymeric nanoparticles
such as micro/nanospheres, micro/nanocapsules, dendrimers,
liposomes, hydrogels, gold nanoparticles, micelles; others
include lipoproteins and aptamers (Table 2).54,56
The inhibitor–carrier approach will involve techniques
similar to the previous suggested approach. The rst step would
be to create an inhibitor–carrier complex by binding the known
ZIKV inhibitor to the carrier. The complex must then be simu-
lated to analyze the trajectory of the complex as well as the
potential energy of the entire complex through a lipid bilayer.
Once there is computational evidence to show that the inhibitor
can theoretically bind to the carrier and move through a lipid
membrane, the inhibitor–carrier complex must be synthesized
to test it biologically (e.g. in vivo testing), which will be used to
conrm drug delivery through the BBB to the brain. Examples of
computationally docking a compound–polymer complex are
provided in the ESI.†
Technical guidance
A number of tools are available which can be utilized to screen
for compounds on chemical databases based on a set of criteria.
Structure-based virtual screening will allow searching through
combinatorial chemistry libraries for compounds that may be
potential inhibitors of a target protein and will rapidly dock
them into the 3D target's active pocket.47,78 Screening for
potential compounds can be carried out on ZINC Database79 or
ZincPharmer.80 Several molecules may have the potential to
bind to the active site of the protein; therefore, the free binding
energy of every pose is calculated. Binding affinity estimations
may be carried out using molecular docking approaches and
free binding energy calculations. This will generate a scoring
function to rank the ligands that best suit the target protein.47
Computational soware that can be used to calculate binding
affinities include UCSF Chimera81 and AutoDock Vina.82
Protein–ligand complexes of lowest free binding energy may be
used as inhibitor candidates, which may subsequently be vali-
dated via molecular dynamic simulations, as binding affinity
predictions may not be one hundred percent accurate.78,83–86
Molecular dynamic simulations calculate the potential
energy of a system and analyze free binding energies and
binding modes between compounds and enzymes.87 Force
Fig. 3 Phases involved in the suggested approach to improve the BBB-permeability profile of the inhibitor.
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elds are used to calculate potential energies of particles and
electrostatic forces that occur between atoms in a system.88
Some force elds that can be used for molecular dynamic
simulations include NAMD,89 Gromacs,90 Amber91 and
Charrm.92 Complexes can also be simulated through lipid
bilayer, in cases where potential compounds need to enter
certain target tissues, which are surrounded by lipophilic
membranes. This can give a prediction as to whether or not the
potential compound will be able to pass through the lipid
membrane or not. Sowares that can be used to generate a 3D
lipid bilayer model include CHARRM-GUI and Visual Molecular
Dynamics (MEMBPLUGIN).46,93 A brief background and the
Table 2 Pre-existing drug delivery systems and their principle roles in disease and virus therapies
Drug delivery system Description Disease/viral target References
Dendrimer ! Hyperbranched, monodispersed, water soluble
(1–100 nm) macromolecule
! Inhibitors of haemagglutinin of human
erythrocytes by Inuenza virus
56 and 57
! Encapsulated drug in its interior or adsorbs
drug on and conjugates to its surface groups
! Amino groups of dendrimer react with
nucleic acid phosphate groups to
form transfection complexes! Releases free 5-uorouracil upon hydrolysis
! Intracellular delivery of poorly soluble drugs
! Carriers in gene therapy
Microsphere &
nanocapsule
! Microsphere – drug is dispersed within
polymer throughout particle
! Entraps luteinizing hormone-releasing
hormone in prostate cancer
57 and 58
! Nanocapsule-cavity contains drug surrounded
by polymer membrane
! Drug release through diffusion through
polymer or degradation of polymer
Liposomes ! Amphiphilic vesicular structures made
up of cholesterol & phospholipids
! Facultative intracellular
bacteria-mediated infections
56, 59 and 60
! Core suited for hydrophilic drug delivery ! Parasites (e.g. Leishmania)
! Phospholipid membrane encapsulate
hydrophobic drugs
! Viruses
! Systemic fungal diseases in cancer
! Melanomas
Micelles ! Core comprised of hydrophobic polymers ! Targets tumour sites in cancer
by active/passive mechanisms
56, 61 and 62
! Shell comprised of hydrophilic polymers
! Suitable for drugs with poor solubility
! Nanosize; in vivo endurance; remains stable in plasma
! Delivery of drugs & small interfering RNA
Hydrogel ! Network of natural/synthetic hydrophilic polymers
that are cross-linked
! Local & systemic diseases 56, 63 and 64
! Highly absorbent, biodegradable, high
porosity, biocompatible
! Oral delivery of insulin in diabetes;
salmon calcitonin for postmenopausal
osteoporosis; growth hormone for
decelerated/stunted growth-associated diseases
! Swell rapidly in aqueous solutio006E
! Used in oral & topical drug delivery
Gold/silver
nanoparticle
! Low toxicity; high specicity & selectivity ! Selective damage of tumour cells 65–68
! Easily controlled & modiable ! Certain infectious & dermal diseases
! High ratio of surface area:amount ! H1N1, H3N2, H5N1 Inuenza A virus
! Conjugation of proteins on colloidal gold
nanoparticles occurs via
electrostatic interactions between citrate (") on
surfaces of gold nanoparticles & groups (+) on proteins
! Herpes simplex virus
! Effortless cellular penetration ! Human immunodeciency virus
! Hepatitus B virus
! Metapneumovirus
! Respiratory syncytial virus
Lipid nanoparticle ! 10–1000 nm ! Humoral immunity against Ebola infection 56 and 69–72
! Carriers with dispersed melted lipid in surfactant ! Silencing of hepatitis C virus replication
! Colloidal system with hydrophobic core that encloses
drug & surface coated with hydrophilic polymers
! Gene therapy
Aptamer ! Short, single-stranded (ss) DNA or RNA that have
denitive 2# & 3# structures that strongly
bind to specic target proteins
! a-Thrombin in thrombosis 73–77
! Low immunogenicity & toxicity ! PTK7 and nucleoin in cancer
! Variety of targets & modiable chemical structure ! IGHM in lymphoma
! VEGF in age-related macular degeneration
! A1 domain of vWF in thrombotic
microangiopathies & carotid artery disease
! Neutralizes r5 strains of HIV-1
! Blocks gp120-CCRF interaction
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 47416–47424 | 47421
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applications of the methods that have been mentioned above
are shown in Table 3.
A full expansion of the methods explained in Table 3 may be
found in Honarparvar et al., 2014.97
Conclusion
The various challenges associated with ZIKV treatment has led
to the ongoing search for a cure – one of the major problems
being drug delivery across the BBB. The approaches described
in this review serve to provide information that can be used for
further research into the design of drugs with improved BBB-
permeability prole that may have a greater ability to inhibit
ZIKV. Though experimental validation is necessary, this is not
the scope of the current study. Instead, this study serves as
a cornerstone that will open doors to further experimental and
molecular validation regarding ZIKV therapy.
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1 |  INTRODUCTION
In the beginning of 2016, the World Health Organization 
declared the escalating Zika virus (ZIKV) a public health 
crisis due to its association with neonatal microcephaly and 
Guillain- Barré syndrome.[1] ZIKV, the rapidly disseminat-
ing pathogen, which belongs to the flavivirus genus of the 
Flaviviridae family, is related to other flaviviruses, including 
West Nile virus (WNV), Yellow fever virus (YFV), Japanese 
encephalitis virus (JEV), and Dengue virus (DENV).[2] ZIKV 
has revealed a tropism for a broad range of tissues including 
sensory organs and organs of the gastrointestinal tract, respi-
ratory system, and reproductive system.[3–6]
The preeminent mode of transmission of ZIKV is through 
the bite of a previously infected Aedes aegypti mosquito, 
which acts as a viral vector. ZIKV may also be distributed 
via sexual intercourse, blood transfusion, maternal trans-
mission, and physical contact.[7] Control measures have 
been put in place to curb the spread of the virus, however, 
ultimate success is yet to be attained.[8] Vaccine development 
is still several years away since vaccine candidates are still 
in preclinical trials.[9] Additionally, due to the erratic and 
spontaneous temperament of flavivirus outbreaks, vaccine 
development against flaviviruses is restricted.[10]
As a result of the extensive period involved in establishing 
a ZIKV vaccine, there are current endeavors toward devel-
oping antiviral therapeutics.[11] To date, flavivirus infections 
prevail with no approved antiviral treatment. Present- day 
treatment of ZIKV is based on the symptoms of infection.[12] 
There is also the question of whether or not novel inhibitors 
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The global threat of the Zika virus to humanity is real. Innovative and potent anti- 
Zika virus drugs are still at large, due to the lack of anti- Zika virus drugs that have 
passed phase 1 trials. Experimental research has revealed novel inhibitors of Zika 
virus NS5 methyltransferase enzyme. This study has taken a step further to provide 
insight into the molecular dynamics of Zika virus and inhibitor binding, which have 
not been established experimentally. Movements of the methyltransferase binding 
site loops have a large role to play in the methylation of the viral mRNA cap, which 
is essential for Zika virus replication. Here, we pinpoint the binding interactions be-
tween each potential inhibitor and the methyltransferase, residues that are responsi-
ble for binding, as well as which inhibitor- bound complex renders the methyltransferase 
more stable. We also highlight the conformational changes that occur within the 
methyltransferase to accommodate binding of inhibitors and consequences of those 
changes upon the RNA- and cap- binding sites in the methyltransferase. This research 
will improve the understanding of the Zika virus NS5 methyltransferase enzyme, and 
will be beneficial in driving the development of anti- Zika virus drugs.
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will pass the blood- brain barrier.[13] Generally, research is 
turned toward drugs that inhibit enzymes involved in critical 
steps in the life cycle of the virus.[14–16] There has been a 
compelling amount of research in the last 10 years, which had 
been directed toward the establishment of inhibitors of tar-
geted enzymes of other flaviviruses including DENV, WNV, 
and YFV.[17,18]
There may be no elixir for treating ZIKV, but recognizing 
the targets that provide optimal therapy will aid science in es-
tablishing the most effective therapeutics. The flavivirus NS5 
methyltransferase (MTase) enzyme is an attractive target for 
the development of inhibitors due to its fundamental roles 
in viral replication via formation of the viral mRNA cap as 
well as modulation of immune response.[16] We illustrate in 
F I G U R E  1  A schematic representation of the Zika virus NS5 enzyme. The structural protein of zika virus NS5 is divided into its two 
major subunits, the methyltransferase (bound to its natural substrate) and the RNA- dependent RNA- polymerase [Colour figure can be viewed at 
wileyonlinelibrary.com]
F I G U R E  2  (a) Superimposed crystal structures of DENV and ZIKV NS5 MTases showing similarities and differences in coils, β- sheets 
and α- helices. (b) Structures of ZIKV and DENV MTases illustrating similar binding pockets and solvent accessible surface areas. (c) Sequence 
similarities and differences between ZIKV and DENV [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 1, the ZIKV NS5 MTase responsible for methylation 
of the viral mRNA cap, as well as the RNA- dependent RNA- 
polymerase (RdRp) responsible for viral RNA replication.[17] 
Together, these subunits work in harmony to ensure viral 
replication.[19]
By virtue of the resemblance between flaviviruses, par-
ticularly between DENV and ZIKV, as we have presented in 
Figure 2, a great deal of the information regarding the drug 
discovery of DENV may possibly be enforced toward the es-
tablishment of ZIKV inhibitors.[7,20] Inhibitors that have been 
shown to suppress the MTase of DENV have also been potent 
in the inhibition of ZIKV MTase.[14,21,22]
A profoundly essential molecule for both DENV and 
ZIKV replication, particularly regarding the MTase compo-
nent, includes S- adenosyl- L- methionine (SAM).[21] Being 
the natural substrate of the MTase, SAM serves as a methyl 
donor and allows for methylation of the mRNA cap, which 
is imperative for viral replication.[23] We demonstrate in 
Figure 3, that an absence of SAM- binding, as a result of dis-
placement by an alternative compound, causes avoidance of 
viral replication since methylation of RNA does not occur.
The adenosine derivative, sinefungin (SFG), was initially 
isolated as an antifungal antibiotic from Streptomyces gris-
eolus, and accomplishes its inhibition by competitively bind-
ing to the SAM- binding pocket in the MTase.[24] Previously, 
SFG demonstrated inhibitory effects on MTases of DENV, 
WNV, and YFV,[17] and thus presented as a potential inhibi-
tor of ZIKV.[25] Experimental evidence shows that even low 
concentrations of SFG inhibit ZIKV MTase and terminates 
internal methylation in vitro.[21] Coutard et al. in 2017 also 
demonstrations ZIKV suppression by another DENV inhib-
itor, Compound 5, which inhibits ZIKV MTase activity and 
is more potent against ZIKV MTase compared to MTases of 
DENV and WNV.[14,21,22] In Figure 4, we illustrate the struc-
tures of SFG and Compound 5.
Based on preliminary viral inhibition and structural 
novelty, we considered further exploring the structural 
dynamics that take place at a molecular level within the 
independent ZIKV MTase (Apo), as well as ZIKV MTase 
bound to SFG and Compound 5, distinctly. We also com-
pare the binding affinity, binding mode and stability of the 
bound complex of SFG to that of Compound 5. Two major 
loops in the MTase were focused on more than the rest, as 
one of the loops surrounds the SAM- binding pocket and 
the other surround the RNA- binding site. To our knowl-
edge, this is the first study that utilizes integrated compu-
tational methods to analyze how binding of inhibitors, SFG 
and Compound 5, impact the conformational changes that 
occur within the ZIKV NS5 MTase. Furthermore, we spec-
ulate that this study will improve the understanding of the 
structural information of the inhibitors and the ZIKV NS5 
MTase, and will be valuable in anti- ZIKV drug design.
F I G U R E  3  Implications of lack of SAM binding to MTase. Illustration of SAM- binding to the MTase as a prerequisite for viral RNA 
methylation and viral replication (left), and the consequence of an alternative molecule binding in the SAM- binding pocket and inhibiting viral 
RNA methylation and replication (right) [Colour figure can be viewed at wileyonlinelibrary.com]
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2 |  COMPUTATIONAL METHODS
2.1 | System preparation
The crystal structure of the NS5 MTase of ZIKV in complex 
with SFG was accessed from RCSB Protein Data Bank (PDB 
code: 5MRK).[25] The protein (MTase) and ligands (SFG 
and Compound 5) were prepared using Molegro Molecular 
Viewer software (Molegro- a CLC bio company, Aarhus, 
Denmark) and UCSF Chimera software package.[12] The 
crystal structure of the MTase protein consists of chains A 
and B, however, in order to save computational time and ex-
pense, the distinct ligands conjugated to the singular chain A 
was utilized. Compound 5 was modeled using Avodagro.[26] 
Three systems including the Apo MTase, SFG- bound MTase 
and Compound 5- bound MTase were subjected to a 200 ns 
molecular dynamic simulation (described in Section 2.3).
2.2 | Molecular docking
Molecular docking was used to predict optimized confor-
mations and binding affinities of SFG and Compound 5 
within the SAM- binding pocket of ZIKV NS5 MTase.[27] 
Docking software that was used in this study includes UCSF 
Chimera[12,27] and AutoDock Vina.[28] SFG and Compound 
5 were docked into the SAM- binding pocket of the NS5 
MTase (grid box spacing of 0.375 Å and x, y, z dimensions 
of 28 × 32 × 34). The complex with the most negative bind-
ing energy (kcal/mol) was subjected to molecular dynamic 
simulations. A greater expansion of molecular docking can 
be found in the referenced articles.[29–31]
2.3 | Molecular dynamic simulation
Molecular dynamic simulations were implemented using 
AMBER PMEMD dynamics engine with GPU acceleration 
and the protein was parameterized with the AMBER force 
field, FF14SB.[32–35] Hydrogen atoms were removed from 
the MTase protein, while SFG and Compound 5 were hydro-
genated and charged with Gasteiger charges preceding the 
simulation. Antechamber created atomic partial charges for 
SFG and Compound 5 using the general AMBER force field 
(GAFF) and restrained electrostatic potential (RESP) meth-
ods.[36–38] The LEAP module implemented in AMBER 14 
was used to combine, neutralize, and solvate the systems by 
adding hydrogen atoms, chloride and sodium ions and sus-
pending them in an orthorhombic box of TIP3P water mol-
ecules such that all atoms were within 10 Å of the box edges. 
The amino acid residues of the protein were renumbered due 
to missing residues in the initial crystal structure; therefore, 
all residue numbers reported from these findings are in fact 
four residues less than stated. An initial energy minimiza-
tion of 2,500 steps was performed with a restraint potential 
of 10 kcal mol−1 Å−2 applied to the solutes, for 1,000 steps 
F I G U R E  4  Potential ZIKV inhibitors. Chemical structure of SFG and Compound 5 (left), as well as the chemical formula and functional 
groups of SFG (top right) and Compound 5 (bottom right) [Colour figure can be viewed at wileyonlinelibrary.com]
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of steepest descent followed by 1,000 steps of conjugate 
gradient minimization. An additional unrestrained full mini-
mization of 200 steps was performed by conjugate gradient 
algorithm.
A canonical ensemble (NVT) simulation was carried out 
for 50 ps from 0 to 300 K, so that a fixed volume and num-
ber of atoms in each system was maintained. The systems’ 
solutes were enforced with Langevin thermostat collision 
frequency of 1.0 ps−1 and a potential harmonic restraint of 
10 kcal mol−1 Å−2. Thereafter, each system was equilibrated for 
500 ps with a constant operating temperature of 300 K, as well 
as a constant pressure of 1 bar using the Berendsen barostat and 
number of atoms resembling an isobaric- isothermal ensemble. 
The overall simulation was conducted for 200 ns, where each 
simulation incorporated the shake algorithm to restrain hydro-
gen bonds. An SPFP precision model was utilized.
2.4 | Postdynamic analysis
2.4.1 | Computation of thermodynamic 
binding free energy and per- residue 
decomposition analysis
A well- known method utilized to determine the binding 
free energy (ΔGbind) of small ligands to biological macro-
molecules includes molecular mechanics incorporated with 
the Poisson- Boltzmann or generalized Born and surface 
area continuum solvation (MM/PBSA and MM/GBSA) 
approach.[39] These methods are generally established on 
molecular dynamics simulations of the protein- ligand com-
plex and are thus transitional in precision between empiri-
cal scoring and strict enzymatic perturbation methods.[40]
ΔGbind was averaged over 50,000 snapshots derived from 
the 200 ns trajectory. The binding strength estimated using 
this method for the MTase, SFG- and Compound 5- complexes 
could be represented as:
where Eele, Electrostatic potential energy from Coulomb 
forces; Egas, Gas- phase energy (based on FF14SB force field 
terms); Eint, Internal energy; EvdW, van der Waals energy; 
Gsol, Solvation free energy; GGB, Polar solvation energy; GSA, 
non- polar solvation energy; S, Total entropy of solute; SASA, 
Solvent accessible surface area (water probe radius of 1.4 Å). 
T, Total entropy of temperature.
To determine the per- residue contribution of SFG and 
Compound 5 to the total ΔGbind at the SAM- binding site, 
atomic level per- residue free energy decomposition was im-
plemented for significant residues of each ligand using the 
AMBER14 MM/GBSA approach. The SFG- and Compound 
5- bound complexes were subjected to further analysis.
2.4.2 | Dynamic cross- correlation
Dynamic Cross- Correlation (DCC) is a well- known ap-
proach that may be utilized in the interpretation of molecular 
dynamic simulation- derived trajectories, by quantifying the 
correlation coefficients of motions between atoms.[41] The 
analysis of fluctuations between residues within the Apo 
MTase, SFG- bound MTase and Compound 5- bound Mtase 
were calculated using the CPPTRAJ module in the AMBER 
14 suite. The equation that defines DCC is provided below:
where Cij, Cross- correlation coefficient (−1 [fully correlated] 
to +1 [anti- correlated]); i, ith residue; j, jth residue; Δri, dis-
placement vectors correspond to ith; Δrj, displacement vec-
tors correspond to jth.
The DCC matrix produced from each simulated system 
was constructed using Origin software.
2.5 | Pharmacophore model generation and 
structure- based screening
The creation and analysis of a pharmacophore model is es-
tablished as a vital part of drug design, as it is a beneficial 
tool for detection and development of new chemical entities 
(NCEs).[42] LigandScout[43] tool was used to generate a phar-
macophore model from the simulation of SFG.
3 |  RESULTS AND DISCUSSION
3.1 | Molecular dynamic simulations and 
systems stability
Trajectories of the Apo MTase system, as well as the SFG- 
and Compound 5- bound MTase systems were monitored 
during a 200- ns simulation to confirm the systems’ stability, 
together with the precision of ensuing postdynamic analyses.
3.1.1 | Deviation of α- carbons within 
NS5 MTase
The stability of the 200- ns molecular dynamic simulations of 
the Apo MTase versus SFG- bound MTase versus Compound 
5- bound MTase systems were explored by calculating the 
(1)ΔGbind=Gcomplex−Greceptor−Gligand
(2)ΔGbind=Egas+Gsol−TS
(3)Egas=Eint+EvdW+Eele
(4)Gsol=GGB+GSA
(5)GSA=γSASA
Cij=
⟨ΔriΔrj⟩(⟨Δr2
i
⟩⟨Δr2
j
⟩)1∕2
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RMSD. In Figure 5, we demonstrate that during the simu-
lation, the two inhibitor- bound complexes showed various 
RMSD patterns.
The Compound 5- bound complex had reached conver-
gence after 20 ns; however, the system began to fluctuate 
after 143 ns, although remaining within a 2.0 Å range until 
the end of the simulation. The SFG- MTase complex reached 
convergence after 169 ns, with fluctuations less than 1.5 Å. 
Indeed, both bound systems demonstrate stability; however, 
binding of SFG to the NS5 MTase renders the enzyme more 
stable than that of Compound 5, as convergence was main-
tained upon SFG- binding.
It was also noticed that binding of SFG to the MTase not 
only causes the SAM- binding site to become closed by the 
surround binding site loop (residues 100–110), but the MTase 
also conforms to close the RNA- binding site as the surround-
ing loop (residues 30–60) moves to prevent RNA from bind-
ing. Should RNA not bind to the MTase, replication off viral 
F I G U R E  5  Fluctuations in rigidity 
of SFG- bound and Compound 5- bound 
complexes compared to apo are shown in (a) 
and (b), respectively, with emphasis on loop 
movements during the 52, 122, and 173 ns 
periods of the simulation. (c) SFG reached 
convergence and was less flexible toward the 
latter period of the simulation, as compared 
to that of the apo and Compound 5- bound 
systems [Colour figure can be viewed at 
wileyonlinelibrary.com]
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RNA by the RdRp will most likely not occur, preventing viral 
replication from occurring.
The fluctuation in rigidity in the Apo MTase (greater than 
2 Å) prevented the system from reaching convergence, even 
toward the latter period of the simulation, indicating insta-
bility of the Apo MTase. These major rigorous fluctuations, 
as well as the fact that the bound systems had reached con-
vergence while the unbound system had not, suggest that the 
MTase only stabilized upon binding of inhibitors, SFG and 
Compound 5.
3.1.2 | Atomic distribution of NS5 
MTase backbone
The radius of gyration (RoG) is an indicator of a structure’s 
stability during a molecular dynamic simulation, as is asso-
ciated with the compactness of secondary protein structures 
into 3D structures.[44] To assess the conformations of the Apo 
MTase, SFG- and Compound 5- bound MTase complexes, 
RoG was analyzed and plotted (Supporting Information 
Figure S1).
It was noticed that in the RMSD plot (Figure 6), at 52, 
122 and 173 ns the Apo MTase fluctuated significantly, 
while binding of both inhibitors, SFG and Compound 5, 
had stabilized the enzyme at those points in the simulation. 
Correspondingly, the RoG plots showed similar trends at 
52, 122 and 173 ns, as both inhibitors caused the MTase to 
become more compact to accommodate binding. The Apo 
MTase had a greater atomic distribution than the inhibitor- 
bound complexes and is therefore, more flexible and less 
compact than when bound.
3.2 | Intra- and intermolecular interactions 
in ZIKV NS5 MTase
3.2.1 | Intermolecular hydrogen 
bond patterns
Hydrogen bonding between amino acid residues is subject 
to the spatial arrangement of the associated atoms, and 
is a major driving force in structural changes that occur 
within proteins. To further analyze the forces that drive 
the conformational changes within the enzyme, we evalu-
ated the hydrogen bonding pattern of the apo, SFG- bound 
and Compound 5- bound MTase systems throughout the 
simulation.
We present in Figure 6 very similar hydrogen bonding pat-
terns between the SFG- bound and Compound 5- bound MTase 
complexes. The SFG- bound MTase exhibited a slightly lesser 
number of hydrogen bonds than the Compound 5- bound 
F I G U R E  6  (Top left) Graph depicts 
hydrogen- bonding analysis of the apo and 
bound systems. (Top right) Bond and non- 
bond interactions that exist between each 
inhibitor and their binding site residues, as 
well as the interacting areas of the ligand 
which are hydrogen donors and acceptors. 
(Bottom) Surface areas of each inhibitor in 
the MTase pocket describing the hydrogen 
bonding capacity of each ligand during 
parts of the simulation that correspond 
to fluctuations in energy, along with the 
solvent accessible surface areas of the 
MTase at those points which correspond 
to ligand movement in the SAM- binding 
pocket [Colour figure can be viewed at 
wileyonlinelibrary.com]
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MTase, during 25–75 and 130–155 ns, which correspond 
with the flexibility of the protein during that period of the 
simulation. Nonetheless, toward the latter period of the sim-
ulation, i.e. between 170 and 200 ns, the number of hydrogen 
bonds was approximately consistent in both inhibitor- bound 
MTase complexes. Although, the apo MTase displayed a re-
duced number of hydrogen bonds than both inhibitor- bound 
complexes, indicating that the apo system was less stable than 
bound systems.
3.2.2 | Residual variations within the 
NS5 MTase
To determine the flexibility of amino acid residues in the Apo 
and bound systems, root of mean square fluctuation (RMSF) 
of the residue α- carbons were calculated. In Figures 7 and 8, 
we illustrate that the MTase is more flexible when unbound, 
as compared to SFG- and Compound 5- bound enzymes, 
respectively. Binding of SFG and Compound 5 lower the 
systems’ energy fluctuations making them more stable.
Most binding site residues displayed resemblance in en-
ergy patterns in both inhibitor- bound and unbound confor-
mations (binding site residues of SFG: Ser52, Gly54, Ser55, 
Asp75, Gly77, Cys78, Gly79, Gly82, Trp83, Tyr99, Thr100, 
Lys101, Gly102, His106, Glu107, Val126, Asp127, Va128, 
Phe129, Asp142, Ile143, and Lys178; binding site resi-
dues of Compound 5: Lys57, Gly77, Cys78, Gly79, Arg80, 
Gly81, Gly82, Thr100, Lys101, His106, Glu107, Asp127, 
Val128, Phe129, Asp142, Ile143, Gly144, Glu145, Ser146, 
Arg159, and Lys178), while others fluctuated significantly. 
Those binding site residues that altered in motion greatly 
throughout the simulation include 106 and 107 upon SFG 
binding, as well as 100, 101, 102, 127, 128, and 129 upon 
Compound 5 binding. An intriguing observation is that al-
though the residues that form a loop at the binding site (res-
idues 100–107) altered in conformation majorly throughout 
F I G U R E  7  The average energy 
interpretation of each residue throughout the 
simulation of the apo MTase versus SFG- 
bound MTase. Highly fluctuating residues in 
the system are also illustrated in the crystal 
structure of the MTase and correlated with 
the peaks in the graph [Colour figure can be 
viewed at wileyonlinelibrary.com]
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the simulation, the residues that form a loop beneath the 
SAM- binding site (residues 34–53) fluctuated more. This 
finding was observed in the SFG- MTase complex (Figure 7), 
but quite the opposite in the Compound 5- MTase complex 
(Figure 8), where more fluctuation occurred at the bind-
ing site loop rather than the loop below the binding site. 
Binding of inhibitors rendered the MTase more stable as 
the flexibility of those residues decreased and the enzyme 
became more compact to accommodate inhibitor binding. 
The presence of these inhibitors in the SAM- binding site 
strongly affected the global dynamics of most loops and he-
lices in the MTase enzyme.
These results are concurrent to those of DCC, which was 
utilized in the analysis of fluctuations of atoms within the 
NS5 MTase backbone, as well as domain motions, focus-
ing specifically on the α- carbons. Variations of colors rep-
resent residue distance analysis plots, where red to yellow 
areas signify positive/strong- correlated movements between 
α- carbons of residues and blue to black areas signify neg-
ative/anti- correlated movements. In Supporting Information 
Figure S2, it can be noticed that the Apo MTase fluctuates 
more than when bound. It is evident that highly fluctuating 
residues that are shown in RMSF graphs are parallel to the 
anti- correlative residual movements in the DCC plots of 
each system. Likewise, residues that follow similar trends in 
movement throughout the simulation show strong correlation 
patterns.
3.2.3 | Binding free energy calculations
Average measures of the all factors of molecular mechan-
ics computed over the 200- ns molecular dynamic simulation 
of the SFG- MTase and the Compound 5- MTase systems are 
tabulated in Table 1.
The approximated binding free energy between SFG and 
the MTase is −34.99 kcal/mol, while that of Compound 5 
and the MTase is −21.27 kcal/mol. This substantial differ-
ence in binding energy (~13 kcal/mol) between the individ-
ual inhibitors and the enzyme corresponds with experimental 
evidence that SFG binding to the MTase is potent at a lower 
IC50 than that of Compound 5.[21] The estimated van der 
Waals contributions (ΔEvdW) and electrostatic contributions 
F I G U R E  8  The average energy 
interpretation of each residue throughout 
the simulation of the apo MTase versus 
Compound 5- bound MTase. Highly 
fluctuating residues in the system are also 
illustrated in the crystal structure of the 
MTase and correlated with the peaks in 
the graph [Colour figure can be viewed at 
wileyonlinelibrary.com]
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(ΔEelec) towards total binding free energy in the SFG- MTase 
system (−41.73 and −60.32 kcal/mol, respectively) are 
higher than that of the Compound 5- MTase system (−34.06 
and −35.87 kcal/mol, respectively). The estimated solvation 
contribution (ΔGsolv) toward the binding free energy in the 
SFG- MTase system (67.05 kcal/mol) is slightly higher than 
that of the Compound 5- MTase system (48.66 kcal/mol). In 
Table 1, the energy components presented indicate that the 
most favorable contributions for binding of inhibitors, SFG 
and Compound 5, derived from ΔEvdW and ΔEelec.
3.2.4 | Decomposition analysis of binding 
site interaction energy
The binding free energy was decomposed further into con-
tributions from specific amino acid residues of the MTase. 
We present via the graphs in Figures 9 and 10 the contrasting 
protein- ligand interaction continua between the SFG- bound 
MTase and the Compound 5- bound MTase, respectively.
The per- residue energy decomposition analysis that we’ve 
presented in Figure 9 show that the highly contributing bind-
ing site amino acid residues toward the energy of the SFG- 
bound complex were His106 (−2.806 kcal/mol [vdW]; 
−2.747 kcal/mol [elec]), Glu107 (−3.857 kcal/mol [elec]), 
Asp142 (−5.139 kcal/mol [elec]) and Ile143 (−2.321 kcal/mol 
[vdW]). Whereas, energy contributions of other binding site 
residues that were less include Asp75 (−1.586 kcal/mol [elec]), 
Gly77 (−1.452 kcal/mol [vdW]; −1.886 kcal/mol [elec]), 
Thr100 (−1.082 kcal/mol [vdW]; −0.553 kcal/mol [elec]), 
Lys101 (−1.563 kcal/mol [vdW]; −1.15 kcal/mol [elec]), 
Val126 (−1.032 kcal/mol [elec]), Asp127 (−0.883 kcal/mol 
[vdW]; −1.99 kcal/mol [elec]) and Val128 (−0.959 kcal/mol 
[vdW]; −1.09 kcal/mol [elec]). From Figure 9, it can be ob-
served that the electrostatic energy contribution from residues 
T A B L E  1  An outline of the MM/PBSA binding free energy contributions to the SFG- MTase system and the Compound 5- MTase system
Energy components (kcal/mol)
ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind
SFG- MTase system
MTase −2047.42 ± 20.73 −16727.67 ± 113.43 −18775.10 ± 111.10 −3474.49 ± 96.04 −22249.58 ± 52.82
SFG −4.37 ± 1.59 −93.06 ± 7.97 −97.43 ± 7.75 −42.69 ± 3.32 −140.12 ± 6.51
Complex −41.73 ± 4.86 −60.32 ± 23.63 −102.04 ± 26.13 67.05 ± 19.46 −34.99 ± 8.02
Compound 5- MTase system
MTase −2041.29 ± 20.69 −16849.53 ± 96.53 −18890.82 ± 93.77 −3372.78 ± 80.45 −22263.60 ± 46.55
Compound 5 −5.06 ± 1.39 −21.99 ± 3.36 −27.05 ± 3.34 −44.43 ± 4.63 −71.48 ± 4.32
Complex −34.06 ± 6.27 −35.87 ± 14.03 −69.93 ± 15.25 48.66 ± 12.89 −21.27 ± 5.21
F I G U R E  9  MTase residues that interact with SFG (left) and energy contributions of the highest interacting residues at the SAM- binding site 
(right) [Colour figure can be viewed at wileyonlinelibrary.com]
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106, 107, and 142, and the van der Waals energy from resi-
dues 77, 106, and 143 in the SFG- MTase complex are most 
likely responsible for the high interaction energy in the system 
(ΔGbind = −34.99 kcal/mol). Binding site interactions of SFG 
to the MTase in the original 5MRK pdb is shown in Supporting 
Information Figure S3 for comparison purposes.
High- energy contribution from the Compound 5- bound 
complex stem from interacting residues Gly77 (−1.977 kcal/
mol [elec]), His106 (−2.043 kcal/mol [vdW]), Glu107 
(−3.94 kcal/mol [elec]), Asp142 (−2.67 kcal/mol [elec]), 
Ile143 (−1.922 kcal/mol [vdW]), Glu145 (−3.746 kcal/mol 
[elec]), and Lys178 (−2.19 kcal/mol [elec]). Binding site resi-
dues with slightly lower energy contribution to the system were 
Cys78 (−0.391 kcal/mol [vdW]; −0.602 kcal/mol [elec]), 
Thr100 (−1.541 kcal/mol [elec]), and Val128 (−0.81 kcal/
mol [vdW]). From Figure 10, it can be concluded that the 
electrostatic energy contribution from residues 107, 142, and 
145, and the van der Waals energy from residues 106 and 143 
in the Compound 5- MTase complex may be accountable for 
the high interaction energy in the system (ΔGbind = −21.27).
The large difference in binding affinity between the SFG- 
bound and Compound 5- bound complexes (~13 kcal/mol) 
may be owing to the increase in electrostatic binding energy 
of Asp142 of the MTase to SFG, as well as van der Waals 
and electrostatic energies of His106, as compared to that of 
Compound 5.
3.3 | Fingerprints for the design of new 
chemical entities (NCEs)
Looking at the binding implications of SFG to the ZIKV 
NS5 MTase, potential use of SFG could be a promising 
starting point as a prototype candidate for ZIKV treatment. 
We therefore created a map depicting the key chemical, 
structural, and pharmacophoric fingerprints of SFG that 
will assist medicinal chemists and researchers in the iden-
tification and design of future new chemical entities for po-
tential ZIKV inhibitors. The pharmacophoric elements that 
associate with highly contributing residues of the MTase 
were chosen to build our ensemble as we have illustrated 
in Figure 11.
As we have presented in Figure 11, it can be noticed that 
the N6 and N7 atoms are crucial to interact with the target 
by creating positive ionization with Glu107 and Asp142 
of the ZIKV MTase, respectively. Retention of N6 and N7 
will contribute positive ionizations responsible for ligand- 
enzyme interactions. Furthermore, the N2, N5, O2, O3, and 
O5 atoms are essential in the formation of strong hydrogen 
bonds with Arg159, His106, Gly79, Thr100, Lys101, and 
Arg80, respectively, which are mandatory for enzyme sta-
bility. Preservation of the N2, N5, O2, O3, and O5 atoms 
will induce stability and strong binding of NCEs to the 
ZIKV MTase.
F I G U R E  1 0  MTase residues that interact with Compound 5 (left) and energy contributions of the highest interacting residues at the SAM- 
binding site (right) [Colour figure can be viewed at wileyonlinelibrary.com]
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4 |  CONCLUSIONS
The ZIKV is a “public health emergency of international con-
cern” and therefore a serious global threat. Apart from ZIKV, 
Compound 5 and SFG have also shown inhibitory effects in 
other flaviviruses, including DENV, WNV, YFV, and JEV. 
The molecular dynamic analyses described this study reveal 
the conformational evolutions, i.e. variations in the ZIKV 
NS5 MTase after binding of these inhibitors at a molecular 
level. Molecular dynamic simulations of 200 ns demonstrate 
radical movements within the MTase, particularly of the loops 
surrounding the SAM- binding pocket and RNA- binding site. 
The dynamic loop fluctuations in motion were uncovered in 
the RMSD and RMSF analyses and substantiated by examin-
ing the three- dimensional molecular landscape of the loops at 
specific time intervals throughout the simulation.
Upon binding to the MTase, both SFG and Compound 5 have 
shown to stabilize the rather erratic apo system, although, it was 
noticed that SFG renders the MTase more stable and more com-
pact than Compound 5. The SFG- bound system also reached 
convergence while the Compound 5- bound system did not. The 
binding affinity and binding site interactions (bond and non- bond 
interactions) between SFG and the SAM- binding pocket of the 
MTase were stronger than those of Compound 5. Binding energy 
calculations identified His106, Glu107, Asp127, Asp142, and 
Ile143 as key players in the binding of SFG to the MTase; and 
Gly77, Thr100, His106, Glu107, Asp142, Glu145, and Lys178 
in the binding of Compound 5 to the MTase.
Binding of SFG to the SAM- binding pocket caused the loop 
surrounding the pocket (residues 100–110) to shift so that SFG 
is held tighter in a more compact conformation. SFG- binding 
also resulted in the loop surrounding the RNA- binding site (res-
idues 30–60) to cover the binding site, to prevent RNA from 
binding and replication from occurring. Strong and stable bind-
ing of SFG would also prevent SAM from binding and activating 
the MTase, avoiding methylation of RNA and the mRNA cap.
To explore the use of SFG as a potential starting point 
as a prototype candidate for ZIKV treatment, we created a 
pharmacophore of SFG that will assist medicinal chemists 
and researchers in the identification and design of future new 
chemical entities for potential ZIKV inhibitors.
The information interpreted in this study will improve the 
understanding of ZIKV and will be beneficial in driving the de-
velopment of anti- ZIKV drugs. Further experimentation is re-
quired to elucidate the roles of SFG and Compound 5 in ZIKV 
treatment.
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Aim: Zika virus (ZIKV) still poses a health risk towomen and their babies without US FDA-approved vaccines
or treatments. Experimentation has proved resveratrol inhibition of ZIKV NS3 helicase without specifying
the molecular events during inhibition. Materials & methods: Herein, we leaped forward to study the
molecular dynamics of the bound and unbound enzyme, identifying precise binding residues and inter-
actions, and the enzyme’s adaptation to support binding, since loop dynamics affect viral RNA replica-
tion. Results: Resveratrol stabilizes the P-loop and causes the RNA-binding loop to block the RNA-binding
pocket for 200 ns, which is concurrent with experimental evidence that resveratrol binding signi!cantly
reduces ATP hydrolysis activity. Conclusion: This study illuminates the structural dynamics of ZIKV helicase
and druglikeness of resveratrol, which will advance anti-ZIKV drug development.
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The Zika virus (ZIKV) is infecting country to country around the globe [1]. With devastating consequences on
pregnant women, mothers and their families, the ZIKV remains an unresolved scientific challenge [2]. The global
expansion of ZIKV may be due to an increased frequency of traveling that occurs on an international scale, the
susceptibility of remote populations, as well as the rise in the vector range due to global warming [3–5].
The ZIKV is composed of multiple enzymes, some of which have been proposed as targets for therapy [6].
The NS3 protein encodes one of the most important viral enzymes and is crucial for polyprotein processing and
replication of flaviviruses [7]. The NS3 is comprised of an N-terminal protease and a C-terminal RNA helicase
domain [8]. The helicase is central to the life cycle and survival of ZIKV [3,9]. Simulation of the helicase by RNA
triggers underlying nucleoside triphosphatase activity, which supplies energy for unwinding of intermediates of
viral replication [10]. For these reasons, the ZIKV NS3 helicase represents an ideal target for therapy.
The ZIKV resembles dengue virus (DENV) (Figure 1); therefore, inhibitors of DENV helicase may exhibit
potency in ZIKV helicase inhibition [11]. Pan et al., 2017, have shown that the ATPase inhibitor, resveratrol,
substantially reduces NS3 helicase ATP hydrolysis activity in DENV [12].
Resveratrol or 3,5,4′-trihydroxy-trans-stilbene is a natural polyphenol present in red wine, nuts, berries and
traditional Asian medicines (Figure 2) [13]. The antioxidant potential of resveratrol is brought about via inhibition
of reactive oxygen species, which involves scavenging free radicals such as superoxide anion (O2-), hydroxyl radical
(OH-) and lipid hydroperoxyl radicals, as well as the inhibition of glutathione depletion [14]. Resveratrol was
reported to have inhibitory effects on gene expression, nucleic acid synthesis, viral replication and protein synthesis
for several viruses including hepatitis C virus, influenza virus, human immunodeficiency virus, herpes simplex
virus and others [14–17]. The antioxidant and anti-inflammatory effects of resveratrol also benefit the cardiovascular
system and function in neuroprotection, as well as treatment of diabetes mellitus [18–20]. Additionally, resveratrol
possesses several anticancer properties that are critical in cancer prevention and treatment [21].
Experimental evidence has shown the ability of resveratrol to significantly decrease ATP hydrolysis activity of
the ZIKV helicase [15], although the molecular structural dynamics within the unbound ZIKV helicase (apo) and
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Figure 1. Superimposition of the Zika virus and dengue virus NS3 helicases as well as their corresponding overlapping sequences
showing the similarities and differences in their amino acid residues.
HO
OH
Resveratrol
OH
Figure 2. Chemical structure of resveratrol.
the ZIKV helicase bound to resveratrol have not been elucidated. We determine the affinity of resveratrol to the
helicase, along with the binding mode and stability of the unbound and bound complexes. The loops surrounding
the RNA-binding site and the ATP-binding site (P-loop) were focused on, as flexibility of these loops play major
roles in viral RNA replication. To our understanding, this is the primary study applying incorporated computational
tools to analyze the way resveratrol binding influences the conformation of the ZIKV NS3 helicase. We postulate
that this study will enhance the understanding of the structural dynamics of the inhibitor and the ZIKV NS3
helicase and will aid in the search for anti-ZIKV treatment.
ZIKV NS3 helicase
The ZIKV NS3 protein constitutes 617 amino acid residues, which make up the protease (residues 1–167) and
helicase (residues 168–617) enzymes. Processing of the polyprotein as well as viral replication are dependent on the
10.2217/fvl-2018-0170 Future Virol. (Epub ahead of print) future science group
Resveratrol inhibition of Zika virus helicase Research Article
483
618
334
482
175
333
P-loop
L D L H P G A G K T R
R Y M T T A V N V T H
E
I
A
E
P
T
M
K
D
R
I
W
G
G
K
T
F
N
C
I
A
N
C
M
S
K
N
R
E
V
F
L
L
A
K
A
T
G
V
I
I
Q
T
A
P
G
R
G
T
E
F
W
A
Q
K
T
D
V
P
R
D
D
V
D
F
A
L
T
D
R
I
M
G
E
E
W
V
C
S
K
I
V
L
P
R
Y
V
V
P
L
R
H
S
I
D
V
I
L
E
D
V
K
T
E
M
S
E
H
R
G
A
S
N
G
E
D
A
R
V
S
P
G
P
V
E
A
L
T
L
A
T
P
Domain III
Domain II
Domain I
RNA-binding
loop
ATP-binding
site
ssRNA-binding
site VL
I
P
P
E
Q
H
R
P
E
P
A
V
M
L
V
P
G
D
P
G
I
A
T
M
P
S
E
A
L
K
R
M
V
A
N
A
A
D
K
T
L
E
N
T
L
A
I
S
K
R
R
E
V
F
Y
R
F
N
K
R
T
A
T
T
I
G
M
S
Q
V
V
L
H
S
M
Y
T
P
L
L
I
R
S
R
D
I
A
T
P
L
G
G
L
E
S
T
M
G
T
E
A
H
Y
I
A
P
S
A
K
A
T
C
N
S
A
F
F
H
E
V
Y
D
R
D
M
R
C
L
R
R
R
V
I
T
E
T
E
D
V
T
V
I
P
F
V
G
R
H
R
A
F
W
G
R
R
A
N
G
P
T
S
T
K
Q
E
D
G
T
G
Y
D
S
T
E
V
F
V
K
K
A
Q
P
E
D
Y
D
Q
V
D
E
R
H
H
L
K
R
W
R
D
V
A
A
Q
V
K
L
R
S
L
A
H
D
A
T
A
W
V
K
L
W
G
A
F
Y
C
P
P
K
L
L
I
V
Q
F
A
R
S
M
L
F
K
A
T
T
A
F
L
R
L
G
I
N
H
V
A
D
P
R
D
T
T
G
C
G
N
E
T
L
Y
I
E
S
K
L
Y
K
R
G
N
R
R
A
R
S
E
M
S
T
W
D
E
A
A
G
L
A
G
V
M
K
E
I
E
E
V
D
E
W
F
Figure 3. Protein sequences of the different domains of Zika virus NS3 helicase, as well as the major binding sites and loops.
activities of both these enzymes [7]. The serine protease is required for viral maturation via polyprotein processing,
while the helicase is essential for RNA synthesis and genome replication of the virus [22].
The serine protease can be described as a folded globular domain comprising of two β-barrels [23]. The helicase
constitutes three domains that resemble each other in size (Figure 3). Domain 1 (residues 182–327) and domain 2
(residues 328–480) are made up of tandem α/β RecA-like folds, which are present in helicases of superfamily 1 and
2. Domain 1 comprises motifs I (Walker A or P-loop), Ia, II (Walker B) and III, which line a cleft between motifs
IV, IVa, V and VI of domain 2. Motifs I, II and VI are involved in ATP binding and/or hydrolysis, and motifs
Ia, IV and V are associated with interdomain communication and RNA binding. The ZIKV helicase, as with the
DENV4 helicase, binds ATP at the lower end of the cleft at the interface of domains 1 and 2, while the pocket
dividing domains 1 and 2 from domain 3 house the RNA. Domains 2 and 3 interact via a β-hairpin extension
of domain 2, which functions as a wedge that facilitates unwinding of double-stranded RNA. Structures within
domain 3 primarily consist of α-helices. Domain 3 interacts with RNA as well as the NS5 RNA-dependent RNA
polymerase in other flaviviruses [10].
To date, several strains of ZIKV have been isolated. Due to interest in the helicases of different strains, we
examined the similarities/differences in the sequences of the helicases. Multiple sequence analysis showed that the
helicases of the French Polynesian (H/PF/2013), African (MR766) and Brazilian (BRA/2016) strains were almost
identical, with very few differences in amino acid residues (Figure 4). Certain amino acid residues in the African
strain are different from the other two strains. The distinguishing amino acid residues are at positions 41, 226,
233, 298, 309, 409 and 410, none of which are in the ATPase pocket. We can, therefore, deduce that the manner
in which resveratrol binds to this helicase will be comparable with helicases of other strains.
Computational methods
Ligand & receptor preparation
The crystal structure of the ZIKV NS3 helicase was obtained from RCSB Protein DataBank (PDB: 5JMT) [24,25].
The structure of resveratrol was obtained from PubChem [26] and prepared using Molegro Molecular Viewer
future science group 10.2217/fvl-2018-0170
Research Article Devnarain & Soliman
P
X
G
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
HPF2013
BRA2016
MR766
V
X
A
E
X
M
C
X
A
F
X
F
E
E
E
P
P
P
P
P
P
S
S
S
M
M
M
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
K
K
K
K
K
K
K
K
K
Q
Q
Q
T
T
T
T
T
T
T
T
T
T
T
T
H
H
H
S
S
S
G
G
G
T
T
T
E
E
E
V
V
V
D
D
D
L
L
L
M
M
M
C
C
C
H
H
H
A
A
A
T
T
T
F
F
F
T
T
T
S
S
S
R
R
R
L
L
L
L
L
L
Q
Q
Q
P
P
P
I
I
I
I
I
I
V
V
V
L
L
L
L
L
L
H
H
H
P
P
P
P
P
P
G
G
G
G
G
G
K
K
K
K
K
K
T
T
K
T
T
T
T
T
T
V
V
V
R
R
R
R
R
R
V
V
V
L
L
L
L
L
L
L
L
L
A
A
A
P
P
P
P
P
P
E
E
E
E
E
E
E
E
E
M
M
M
M
M
M
A
A
A
N
N
N
M
M
M
D
D
D
N
N
N
N
N
N
E
E
E
E
E
E
E
E
E
A
A
A
I
I
I
I
I
I
I
I
I
V
V
V
R
R
R
R
R
R
R
R
R
Y
Y
Y
G
G
G
Y
Y
Y
Y
Y
Y
V
V
V
V
V
V
V
V
V
I
I
I
I
I
I
I
I
I
I
I
I
R
R
R
R
R
R
A
A
A
C
C
C
L
L
L
T
T
T
K
K
K
A
A
A
G
G
G
G
G
G
G
G
G
G
G
G
C
C
C
A
A
A
D
D
D
D
D
G
H
H
H
H
H
H
W
W
W
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
K
K
K
S
S
S
E
E
E
F
F
F
F
F
F
K
K
K
A
A
A
A
A
A
A
A
A
G
G
G
K
K
K
R
R
R
E
E
E
V
V
V
V
V
V
W
W
W
W
W
W
M
M
M
D
D
D
C
C
C
S
S
S
D
D
D
H
H
H
T
T
T
A
A
A
A
A
A
A
A
A
A
A
A
S
S
S
E
E
E
E
E
E
E
E
E
L
L
L
L
L
L
L
L
L
M
M
M
D
D
D
D
D
D
D
D
D
D
D
D
I
I
I
G
G
G
T
T
T
T
T
T
I
T
T
P
P
P
R
R
K
R
R
R
L
L
L
L
L
L
H
H
Y
G
G
G
E
E
E
P
P
P
P
P
P
R
R
R
R
R
R
V
V
V
K
K
K
K
K
K
V
V
V
W
W
W
A
A
A
A
A
A
A
A
A
S
S
S
Y
Y
Y
K
K
K
R
R
R
R
R
R
R
R
R
W
W
W
N
N
N
M
M
M
E
E
E
N
N
N
C
C
C
F
F
F
G
G
G
G
G
G
T
T
T
T
T
T
Y
Y
Y
I
I
I
Q
Q
Q
Q
Q
Q
V
V
V
E
E
E
E
E
E
R
R
R
D
D
D
D
D
D
G
G
G
N
N
N
Y
Y
Y
Q
Q
Q
Y
Y
Y
R
R
R
D
D
D
K
K
K
V
V
V
P
P
P
E
E
E
E
E
E
F
F
F
K
K
K
L
L
L
E
E
E
I
I
I
I
I
I
I
I
I
M
M
M
T
T
T
K
K
K
R
R
R
R
R
R
R
R
R
K
K
K
F
F
F
V
V
V
V
V
V
I
I
I
Q
Q
Q
Q
Q
Q
Q
Q
Q
S
S
S
S
S
S
V
V
V
S
S
S
R
R
R
R
R
R
R
R
R
C
C
C
L
L
L
L
L
L
L
L
L
K
K
K
P
P
P
P
P
P
P
P
P
M
M
M
T
T
T
H
H
H
A
A
A
S
S
S
A
A
A
A
A
A
Q
Q
Q
R
R
R
R
R
R
G
G
G
G
G
G
I
I
I
R
R
R
R
R
R
N
N
N
P
P
P
P
P
P
G
G
G
G
G
G
D
D
D
E
E
E
Y
Y
Y
Y
Y
Y
L
L
M
N
N
N
K
K
K
V
V
V
V
V
V
V
V
V
I
I
I
I
I
I
R
R
R
K
K
K
K
K
K
K
K
K
H
H
N
W
W
W
D
D
D
D
D
D
D
D
D
G
G
G
G
G
G
E
E
E
A
A
A
S
S
S
I
I
I
I
I
I
D
D
D
D
D
D
R
R
R
V
V
V
F
F
F
F
F
F
K
K
K
V
V
V
V
V
I
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
F
F
F
F
F
F
E
E
E
E
E
E
E
E
E
M
M
M
G
G
G
A
A
A
A
A
A
N
N
N
E
E
E
L
L
L
F
F
F
P
P
P
P
P
P
P
P
P
R
R
R
A
A
A
W
W
W
S
S
S
S
S
S
G
G
G
F
F
F
D
D
D
D
D
D
H
H
H
S
S
S
S
S
S
R
R
R
N
N
N
N
N
N
E
E
E
A
A
A
A
A
A
I
I
I
G
G
G
G
G
G
K
K
K
T
T
T
P
P
P
V
V
V
V
V
V
V
V
V
W
W
W
F
F
F
W
W
W
V
V
V
T
T
T
I
I
I
D
D
D
D
D
D
T
T
T
S
S
S
S
S
S
N
N
N
M
M
M
E
E
E
V
V
V
V
V
V
E
E
E
E
E
E
V
V
V
V
V
V
V
V
V
R
R
R
R
R
R
A
A
A
T
T
T
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
F
F
F
A
A
A
H
H
H
F
F
F
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
P
P
P
P
P
P
D
D
D
S
S
S
S
S
S
S
S
S
P
P
P
R
R
R
R
R
R
V
V
V
E
E
E
E
E
E
M
M
M
M
M
M
G
G
G
R
R
R
D
D
D
G
G
G
G
G
G
Y
Y
Y
A
A
A
A
A
A
D
D
D
10 20 30 40 50
Strain
H/PF/2013 100
100
10098.6
99.8 99.3
99.5
98.4 98.4
H/PF/2013
BRA/2016
BRA/2016
MR766
MR766
90 100
140 150
190 200 HIS 584
ARG 583
THR 215
240 250
290 300
340 350
60 70
120
170
130
180
220 230
270 280
320 330
370 380
80
110
160
210
260
310
360
410 420 430 440
390
450
400
Figure 4. Multiple sequence alignment of helicase sequences of strains of H/PF/2013, BRA/2016 and MR766.
software (Molegro-a CLC Bio Company, Aarhus, Denmark) and UCSF Chimera software package [27]. An apo
system (NS3 helicase) and a resveratrol-bound system were subjected to 200 ns molecular dynamic simulations.
Molecular docking
Optimized conformations and binding affinities of resveratrol within the ATP-binding pocket of the ZIKV
NS3 helicase were achieved through molecular docking. Resveratrol was docked into the ATP-binding pocket
(competitive inhibitor of ATP) of the NS3 helicase (grid box of spacing of 0.375 A˚ and x, y, z dimensions of
32 × 26 × 30) via the AutoDock vina plugin of UCSF Chimera software [27–29]. Ten docked poses of the ligand
in the binding pocket of the enzyme were generated in PDBQT format by AutoDock Vina and the most favorable
geometric pose with the most negative binding energy (kcal.mol-1) was saved from the ViewDock feature. The
best complexes were subjected to molecular dynamic simulations. More detailed information regarding molecular
docking can be found in the referenced articles [30–32]. To verify that resveratrol was docked into the correct pocket,
Supplementary Figure 4 demonstrates the superimposition of ATP bound to the helicase (PDB: 5GJC) and the
docked complex of resveratrol to the helicase.
Molecular dynamic simulations
Molecular dynamic simulations were carried out using AMBER PMEMD dynamics engine with GPU acceler-
ation [33,34]. The helicase was parameterized using the AMBER force field, FF14SB [35,36]. The inhibitor was
hydrogenated and charged with Gasteiger charges, while the helicase protein was dehydrogenated preceding the
simulation. Atomic partial charges were created for resveratrol using antechamber which applies the general AM-
BER force field and restrained electrostatic potential methods [35,37,38]. The AMBER 14 LEAP module was used to
combine, neutralize and solvate all systems via addition of hydrogen atoms, sodium and chloride ions, followed by
suspension into an orthorhombic box of TIP3P water molecules to ensure all atoms were within 10 A˚ of the box
edges. The amino acid residues of the helicase were renumbered from one. The systems were initially minimized
(2500 steps) using a restraint potential of 10 kcal.mol-1 A˚-2 applied to the solutes, for 1000 steps of steepest descent
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followed by 1000 steps of conjugate gradient minimization. Thereafter, the systems were further fully minimized
(200 steps) via unrestrained conjugate gradient algorithm.
A constant-temperature, constant-volume ensemble simulation was carried out for 50 ps from 0 to 300 K, to
preserve a fixed volume and number of atoms in each system. A harmonic restraint of 10 kcal.mol-1 A˚-2 and
Langevin thermostat collision frequency of 1.0 ps-1 were applied to the solutes. All systems were then subjected to
equilibration (500 ps) with a constant operating temperature (300 K) and pressure (1 bar) using the Berendsen
barostat and number of atoms resembling an isobaric–isothermal ensemble. The shake algorithm was applied to
restrain hydrogen bonds during the simulations, whichwere conducted for 200 ns per system using a single-precision
floating-point (SPFP) precision model.
Per-residue decomposition analysis & binding free energy computation
To establish the binding free energy (!Gbind) of resveratrol to the ZIKV NS3 helicase enzyme, we employed
molecular mechanics integrated with the Poisson–Boltzmann or generalized Born and surface area continuum
solvation approach [39,40]. These methods have been elaborated in the referred papers [41,42].
The molecular dynamic simulation yielded a trajectory depicted by 50,000 snapshots, which were averaged to
generate !Gbind. The binding strengths between resveratrol and the helicase may be defined as:
!Gbind = Gcomplex − G receptor − G ligand (1)
!Gbind = Egas + G sol − TS (2)
Egas = E int + EvDW + E ele (3)
G sol = GGB + GSA (4)
GSA = γSASA (5)
where:
Eele Electrostatic potential energy from Coulomb forces
Egas Gas-phase energy (based on FF14SB force !eld terms)
Eint Internal energy
EvdW van der Waals energy
Gsol Solvation free energy
GGB Polar solvation energy
GSA Nonpolar solvation energy
S Total entropy of solute
SASA Solvent accessible surface area (water probe radius of 1.4 A˚)
T Total entropy of temperature
A per-residue free energy atomistic decomposition was adopted to estimate the contribution of each residue to the
total !Gbind at the binding site, for significant residues of the helicase using the AMBER14 molecular mechanics
integrated with generalized born surface area method. Further analyses were carried out on the resveratrol-bound
complex.
Absorption, distribution, metabolism & excretion assessment of resveratrol
Using the absorption, distribution, metabolism and excretion (ADME) online prediction tool, SWISS ADME, we
assessed the druglikeness of resveratrol. The SWISS ADME website allows the computation of physicochemical de-
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Figure 5. Resveratrol binding to Zika virus NS3 helicase stabilizes the enzyme. Snapshots at 10 ns intervals from 150 to 200 ns show the
spontaneous behavior of the RNA-binding loop (green) in the apo enzyme (gray), while the same loop (blue) in the bound enzyme (red)
becomes stable via formation of a 310-helix.
scriptors and provides a prediction of druglike nature, pharmacokinetic properties, medicinal chemistry friendliness
and ADME parameters small molecules to support drug discovery [43].
Results
Molecular dynamic simulations & systems stability
The trajectories of 200 ns molecular dynamic simulations of the apo and resveratrol-bound systems were monitored
and analyzed postdynamically to verify stability of the systems.
Atomic distribution of α-carbons of NS3 helicase
The deviation of α-carbons within the NS3 helicase during simulation of the systems was established by calculating
the root-mean-square deviation. In Figure 5, we show that resveratrol brought about different atomic changes in
the helicase during the simulation, when compared with the apo system. Both systems remained within a 1.5 A˚
range throughout the simulation.
The root-mean-square deviation pattern of the apo system indicates major fluctuations of the system between 34
and 40 ns and 164 and 167 ns, and convergence in the latter part of the simulation (after 175 ns). The fluctuations
of the resveratrol-helicase complex dropped between 180 and 200 ns, where the helicase became more compact
when compared with the apo helicase (Supplementary Figure 1). The P-loop in the apo also undergoes constant
structural variations (deviation = 1.783 A˚), whereas that of the bound enzyme is stable (deviation = 0.637 A˚).
Resveratrol also stabilized the helicase during the 34–40 ns and 164–167 ns period when the apo fluctuated. It is
noticed in Figure 5 that as the end of the simulation approached, the RNA-binding loop moved closer toward the
RNA-binding pocket. This may have impeding effects on the entry and binding of RNA in that pocket.
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Figure 6. Resveratrol binding to the NS3 helicase (red) induces compactness of the enzyme, as compared with the apo (gray).
Superimposition of the bound (red) and unbound (gray) helicase at 200 ns (Figure 6) demonstrates the impact
of resveratrol binding to the ZIKV NS3 helicase. The overall configuration of the helicase is more compact when
bound, as the outer loops and coils move inward, suggesting a looser apo conformation. As emphasized in Figure 6,
distances between loops on the top, left and right regions (domain III, II and I, respectively) of the enzyme decreased
in the bound complex when compared with the apo. The RNA-binding loop and extended coil surrounding the
inhibitor (enlarged in bottom right) move inward and the outer loop in domain II (enlarged in bottom left) move
upward conforming the enzyme to a more compact shape.
Intra & intermolecular interactions in ZIKV NS3 helicase
Fluctuating residues within the NS3 helicase
To provide a better understanding of the residues responsible for the fluctuating energy patterns in Figure 5, we
calculated the root-mean-square fluctuation of each residue of both systems.
The pattern in the fluctuation of residues in the apo system bear resemblance to the resveratrol-bound complex;
however, residues 1–43, 129–137, 201–208 and 389–414 in the apo fluctuate more than the bound complex. In
Figure 7, we demonstrate that domain I of the helicase (green) fluctuates more than domains II and III. Binding of
resveratrol to the helicase decreases movements of the P-loop and causes increase in movements of the RNA-binding
loop. Considering both systems, residues of the apo system are more energetic and therefore, the apo system is a lot
more flexible than the resveratrol-bound system, suggesting that the inhibitor reduces the energies of the residues
within the helicase.
Binding free energy calculations & binding site interaction decomposition analysis
The intensity of interactions between a ligand and receptor may be quantified by the binding free energy obtained
from molecular mechanics with Poisson–Boltzmann surface area calculations. Mean calculations of internal energy
changes of the resveratrol-helicase system, and resveratrol and the helicase alone, totaled over the 200 ns simulation
are presented in Table 1.
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Figure 7. Residues of the apo helicase (gray) !uctuate more than residues of the resveratrol-bound helicase (red).
Table 1. A representation of the binding free energy contributions to the resveratrol-bound system.
Energy components (kcal.mol-1)
!EvdW !Eelec !Ggas !Gsolv !Gbind
Helicase -3555.87 ± 29.16 -29681.50 ± 134.2 -33237.37 ± 133.18 -4769.99 ± 104.63 -38007.37 ± 63.52
Resveratrol -0.25 ± 0.66 65.32 ± 0.86 65.07 ± 1.08 -18.85 ± 0.3 46.22 ± 1.21
Complex -26.86 ± 2.53 -36.54 ± 4.69 -63.4 ± 4.64 33.05 ± 3.23 -30.35 ± 2.86
!Gbind: Binding free energy; !Eelec : Electrostatic energy; !Ggas : Free energy in gas phase; !Gsolv : Solvation energy; !EvdW : van der Waals force.
The estimated binding free energy between resveratrol and the helicase is -30.35 kcal.mol-1. This strong binding is
concurrent with experimental evidence that resveratrol binding to the helicase significantly reduces ATP hydrolysis
activity and is potent at an IC50 of 94.25 ± 5.02 µM [15]. The energies shown in Table 1 suggest that the most
favorable conditions for resveratrol binding are derived from !Ggas and !Ee lec.
The analysis was expanded into per-residue energy decomposition of resveratrol-binding residues of the helicase.
In Figure 8, we show the resveratrol-helicase interaction spectrum. The ligand interaction diagram in Figure 8A
clearly illustrates hydrophobic interactions between resveratrol and the helicase, particularly residues Leu20, His21,
Pro22, Ala24, Thr27, Arg28, Glu57 and Ala143. Hydrogen bonding is also clearly apparent between Gly23
and Gly25 with the O1 atom of resveratrol, and between Lys26 and the O3 atom of resveratrol. The graph in
Supplementary Figure 3 and the hydrogen bond surface surrounding resveratrol in Figure 8C coincide with these
results. The results from the graph in Figure 8B are concurrent with the findings in Table 1 that the electrostatic
energy contributes more toward total binding free energy than van der Waals forces. Residues His21, Lys26 and
Gly57 contributed mostly toward the electrostatic energy that was responsible for binding, and Lys26 and Thr27
contributed more toward van der Waals forces than other binding site residues.
Resveratrol ADME assessment
Using the online tool, SwissADME, the druglikeness of resveratrol was elucidated (Table 2). Resveratrol is likely
to permeate lipophilic membranes, as well as the blood–brain barrier. Clarification of the concept of LogP may
be found in Devnarain et al. (2017) [44]. Resveratrol is water soluble, which is favorable for oral bioavailability.
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Figure 8. Exploration of the interactions that exist between resveratrol and residues of the Zika virus NS3 helicase. (A) Resveratrol
within binding pocket of helicase zooming into the hydrophobic interactions and hydrogen bonds between ligand-binding residues and
resveratrol. (B) Per-residue decomposition analysis of ligand binding residues. (C) Hydrogen bonding in ligand binding pocket.
EEL: Electrostatic energy; vdW: van der Waals.
Table 2. Druglikeness of resveratrol.
Formula C14H12O3
Molecular weight 228.24 g.mol-1
Lipophilicity (LogP) 1.71
Water solubility (Log S) Soluble
Gastrointestinal absorption High
BBB permeant Yes
Lipinski’s rules Yes
Ghose, Veber, Egan, Muegge Yes
BBB: Blood–brain barrier.
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Lipinski’s rule of five is used to evaluate druglikeness of a chemical compound [45]. Resveratrol does not violate
any of Lipinski’s rules, and also adheres to other filters that define druglikeness, including Ghose, Veber, Egan
and Muegge. The BOILED-egg diagram of resveratrol generated by SwissADME is represented by Supplementary
Figure 2. The physicochemical and pharmacokinetic properties of resveratrol are favorable for drug discovery.
Discussion
The effects of resveratrol have been studied previously for its inhibition of nucleic acid synthesis, gene expression,
viral replication and protein synthesis in several viruses. Experimental studies have shown that resveratrol inhibits
ZIKV in vitro; however, the binding mechanism and binding interactions of resveratrol to the ZIKV NS3 helicase
were not elucidated. The 200 ns molecular dynamic simulations of the apo helicase and resveratrol-bound helicase
have allowed us to understand the shifts that occur in the enzyme upon binding and the affinity of the helicase for
resveratrol.
A ‘loose’ and expanded structure of the helicase is necessary to accommodate RNA in its binding pocket for
viral RNA replication. Resveratrol binding renders the helicase more compact than when unbound, limiting the
space within the RNA-binding pocket. The P-loop regulates ATP binding and hydrolysis during ZIKV replication.
Resveratrol stabilized the P-loop when compared with the apo and resulted in major shifts and conformational
changes in the RNA-binding loop. Since resveratrol binding to the helicase decreases ATP hydrolysis, we speculate
that resveratrol binding may also hinder RNA binding and replication due to movements of the RNA-binding loop
in front of the entrance of the RNA-binding pocket; however, further experimentation is required to substantiate
this theory. Strong binding interactions, including hydrophobic and hydrogen bonding, between resveratrol and
residues of the helicase also reduce fluctuations of the enzyme domains, thus explaining the high potency of
resveratrol inhibition on the ZIKVNS3 helicase. Conformational ensembles generated from themolecular dynamic
simulations in this study match with the experimental data.
Conclusion
To our understanding, this is the first study to have presented data describing the events that occur at a molecular
level when resveratrol binds to the ZIKV NS3 helicase enzyme. Since resveratrol is a competitive inhibitor of ATP
and stably binds to the ATPase pocket in the helicase, we can speculate that inhibition of ZIKV by resveratrol at
an organism level may render the enzyme ‘powerless’ and may even lead to resveratrol being a potent inhibitor
of multiple viruses including other flaviviruses such as DENV, West Nile virus and Japanese encephalitis virus.
Resveratrol is also a natural antioxidant; therefore, its use as a multipurpose antiviral implies safety, easy availability
and accessibility, and cost–effectiveness, particularly in rural communities.
This material refines the knowledge surrounding resveratrol inhibition of the ZIKV NS3 helicase and will aid
the search for anti-ZIKV drugs. Additional investigations are vital to substantiate the role of resveratrol in the
treatment of ZIKV. Further, analysis will also include the interactions between resveratrol and other members of
the flavivirus genus of viruses.
Summary points
• The Zika virus (ZIKV) continues to affect pregnant women and their infants without US FDA-approved vaccines or
treatments.
• There is still very much to learn about ZIKV before we can effectively treat it.
• Understanding the molecular dynamics behind potential organism level inhibition could help prevent future
resistance of ZIKV to drugs.
• Hence, we studied the molecular dynamics of the unbound and resveratrol-bound helicase for 200 ns.
• Molecular dynamic simulations and postdynamic analyses allowed us to pinpoint the precise residues and
interactions that are key in the binding of resveratrol to the helicase.
• The movements of loops surrounding RNA and inhibitor binding sites also regulate binding and
replication; therefore, we analyzed the shifts in loops surrounding the ATPase pocket and RNA-binding site.
• The druglikeness of resveratrol was also established using computational tools, which led to the conclusion that
resveratrol follows all of Lipinski’s rules and can pass the blood–brain barrier, making it suitable for the treatment
of ZIKV.
• This material demonstrates the structural dynamics of the ZIKV NS3 helicase upon resveratrol binding, which will
advance anti-ZIKV drug development.
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